Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Vaccine
    April 2024
  1. LEE JS, Choi H, Shin SH, Hwang MJ, et al
    Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
    Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  3. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  4. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  5. HUSETH-ZOSEL AL, Fuller H, Hicks A, Carson PJ, et al
    Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust.
    Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  6. BLAKE JM, Thompson J, HogenEsch H, Ekenstedt KJ, et al
    Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.
    Vaccine. 2024 Apr 10:S0264-410X(24)00398-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  7. THAI H, Audet EC, Koestner R
    Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
    Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  8. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  9. EL BUSHRA HE, Haroun AAA, Dauod Altaf M, Gardiwal H, et al
    Early use of oral cholera vaccines as a prime control measure during outbreaks: Necessary but not sufficient.
    Vaccine. 2024 Apr 8:S0264-410X(24)00332-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  10. KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
    A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
    Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  11. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  12. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  13. CHONG CY, Kam KQ, Zhang J, Bertoletti A, et al
    Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
    Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  14. BINTE HOSSAIN F, Muscatello D, Jayasinghe S, Jonnagaddala J, et al
    Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13.
    Vaccine. 2024 Apr 6:S0264-410X(24)00426-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  15. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  16. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  17. STEFANIZZI P, Moscara L, Palmieri C, Martinelli A, et al
    Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Vaccine. 2024 Apr 5:S0264-410X(24)00311-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  18. NYBRU GLEDITSCH R, Skogset Ofitserova T, Aubrey White R, Karoline Raberg Kjollesdal M, et al
    Vaccine coverage among children born to immigrant parents in Norway, 2000-2020.
    Vaccine. 2024 Apr 5:S0264-410X(24)00395-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  19. NAKANO T, Hasegawa M, Endo M, Matsuda K, et al
    Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants >/= 2 and < 43 months of Age: A phase III, multicenter
    Vaccine. 2024 Apr 5:S0264-410X(24)00394-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  20. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  21. ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
    Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
    Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  22. HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
    Identifying effective vaccine champions: Findings from a national survey of primary care professionals.
    Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  23. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  24. TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
    Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  25. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    >> Share

  26. LIU J, Qi Q, Liu Y, Ni P, et al
    A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak and strengthen local immunization programs.
    Vaccine. 2024;42:2155-2160.
    >> Share

  27. SU L, Zhou X, Peng W, Luo J, et al
    Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen.
    Vaccine. 2024;42:2448-2454.
    >> Share

  28. HUBER A, Kovacs E, Horvath A, Sahin-Toth J, et al
    Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary.
    Vaccine. 2024;42:2271-2277.
    >> Share

  29. KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
    Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
    Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
    >> Share

    March 2024
  30. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  31. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  32. PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
    Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development.
    Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  33. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  34. FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al
    Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus.
    Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  35. BRUUN N, Laursen MF, Carmelo R, Christensen E, et al
    Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
    Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  36. PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al
    Reduced pertussis disease severity in infants following the introduction of pertussis vaccination of pregnant women in Spain, 2015-2019.
    Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  37. WEYANT C, Hooda Y, Munira SJ, Lo NC, et al
    Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
    Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  38. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  39. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  40. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  41. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  42. PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al
    Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens.
    Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  43. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  44. STUREBORG R, Nichols J, Dhingra B, Yang J, et al
    Development and validation of VaxConcerns: A taxonomy of vaccine concerns and misinformation with Crowdsource-Viability.
    Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  45. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  46. COMES JDG, Doets K, Zegers T, Kessler M, et al
    Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
    Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  47. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  48. HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al
    Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series.
    Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  49. ZHANG Y, Wang Y, Li G, Zhao X, et al
    A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older.
    Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  50. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  51. ZHAO Z, Meng Q, Sun TZ, Zhu B, et al
    Mannose modified targeted immersion vaccine delivery system improves protective immunity against Infectious spleen and kidney necrosis virus in mandarin fish (Siniperca chuatsi).
    Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  52. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  53. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  54. BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al
    The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  55. CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al
    Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
    Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  56. ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al
    Subolesin knockdown in tick cells provides insights into vaccine protective mechanisms.
    Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  57. CHENG Y, Shen R, Liu F, Li Y, et al
    Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines.
    Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  58. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  59. GEHRT L, Englund H, Laake I, Nieminen H, et al
    Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
    Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  60. ANWARI P, Burnett E, Chavers TP, Samsor A, et al
    Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
    Vaccine. 2024;42:2059-2064.
    >> Share

  61. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    >> Share

  62. SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al
    The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
    Vaccine. 2024;42:1966-1972.
    >> Share

  63. KWON KW, Choi HG, Choi HH, Choi E, et al
    Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains.
    Vaccine. 2024;42:1941-1952.
    >> Share

  64. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  65. WU J, Jiang L, Shao Q, Liu J, et al
    Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
    Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  66. MEDENI V, Altiner OT, Medeni I
    Measles vaccination coverage and immunization status of nurses: An interventional study in Turkiye.
    Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  67. DANGOR Z, Benson N, Berkley JA, Bielicki J, et al
    Vaccine value profile for Klebsiella pneumoniae.
    Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  68. OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al
    High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
    Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  69. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  70. FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al
    Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  71. HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al
    Lymphatic distribution considerations for subunit vaccine design and development.
    Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  72. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  73. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  74. JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al
    Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France.
    Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  75. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  76. MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al
    Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
    Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  77. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  78. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  79. SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al
    Varicella outbreak at nursery school under routine immunization in Japan in 2017 and 2018 and vaccine effectiveness.
    Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  80. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  81. SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al
    UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration.
    Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  82. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  83. MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al
    Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 201
    Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  84. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  85. SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al
    An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
    Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  86. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  87. HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al
    Current vaccine strategies and novel approaches to combatting Francisella infection.
    Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  88. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  89. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  90. BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al
    Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations.
    Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  91. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  92. GHASEMIFAR S, Chabak O, Piri-Gharaghie T, Doosti A, et al
    PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model.
    Vaccine. 2024 Mar 7:S0264-410X(24)00209-3. doi: 10.1016/j.vaccine.2024.
    >> Share


  93. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    >> Share


  94. Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020, Pages 830-839].
    Vaccine. 2024;42:1850.
    >> Share

  95. DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al
    The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs.
    Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  96. SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al
    A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole.
    Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  97. GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al
    Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
    Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  98. MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al
    Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia.
    Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  99. ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al
    Probability of exposure to the wild measles virus in adult population - Estimation from seroepidemiology and historical data.
    Vaccine. 2024;42:1648-1655.
    >> Share

  100. HYAMS C, Lahuerta M, Theilacker C, King J, et al
    Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
    Vaccine. 2024;42:1599-1607.
    >> Share

  101. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  102. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  103. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  104. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  105. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  106. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  107. BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
    A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
    Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  108. DUAN X, Zhang L, Ding L, Zhang C, et al
    Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
    Vaccine. 2024 Mar 2:S0264-410X(24)00172-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  109. ZAMAN K, Schuind AE, Adjei S, Antony K, et al
    Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Vaccine. 2024 Mar 1:S0264-410X(24)00251-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  110. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    >> Share

    February 2024
  111. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  112. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  113. CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
    An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
    Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  114. LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
    Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents.
    Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  115. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  116. OMAR ALI S, Dessart C, Parikh R
    Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  117. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  118. ZHOU W, Guo X, Lu J, Lu X, et al
    Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.
    Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  119. JACKSON S, Kabir Z, Comiskey C
    Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
    Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  120. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  121. TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
    Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  122. GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
    Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
    Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  123. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    >> Share

  124. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  125. KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
    Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
    Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  126. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  127. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  128. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  129. BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
    Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
    Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  130. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  131. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  132. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  133. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  134. BOTTCHER J, Bauer BU, Ambros C, Alex M, et al
    The immune response to a Coxiella burnetii vaccine in sheep varies according to their natural pre-exposure.
    Vaccine. 2024 Feb 21:S0264-410X(24)00207-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  135. YIN Q, Zheng Y, Ying Z, Li J, et al
    Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase ? clinical trial.
    Vaccine. 2024 Feb 21:S0264-410X(24)00201-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  136. KABORE L, Pecenka C, Hausdorff WP
    Lassa fever vaccine use cases and demand: Perspectives from select West African experts.
    Vaccine. 2024 Feb 17:S0264-410X(24)00203-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  137. BRUEL S, Rakotomampionona Z, Gignon M, Agrinier N, et al
    The intentions of French health university students to recommend and to receive the HPV vaccine are mainly influenced by vaccine knowledge, confidence in vaccines and personal HPV vaccination.
    Vaccine. 2024 Feb 17:S0264-410X(24)00192-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  138. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  139. PIKE J, Lueken J, Zajac J, Tippins A, et al
    2022 Polio outbreak, Rockland County, NY: Cost evaluation of strategies to prevent future outbreaks of vaccine-preventable diseases.
    Vaccine. 2024 Feb 16:S0264-410X(24)00171-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  140. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  141. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  142. POLAND GA, Raina MacIntyre C
    Celebrating vaccines: The 2023 Nobel prize in medicine or physiology.
    Vaccine. 2024 Feb 15:S0264-410X(23)01258-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  143. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  144. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  145. TOBACK S, Marchese AM, Warren B, Ayman S, et al
    Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
    Vaccine. 2024 Feb 15:S0264-410X(24)00196-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  146. THIAUCOURT F, Exbrayat A, Loire E, Boissiere A, et al
    Deep sequencing and variant frequency analysis for the quality control of a live bacterial vaccine against contagious bovine pleuropneumonia, strain T1.
    Vaccine. 2024 Feb 15:S0264-410X(24)00177-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  147. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  148. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  149. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  150. DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
    Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
    Vaccine. 2024;42:1094-1107.
    >> Share

  151. PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
    What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
    Vaccine. 2024;42:1065-1070.
    >> Share

  152. ROWLEY F, Cottrell S, Howard C, Meredith N, et al
    Use of invitations and reminders are associated with higher levels of Herpes zoster (shingles) vaccination uptake. A cross-sectional survey of general practices in Wales, and ecological analysis of uptake data, 2022.
    Vaccine. 2024 Feb 14:S0264-410X(24)00193-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  153. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    Erratum to "BCGDeltaBCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice" [Vaccine 41(26) (2023) 3824-3835].
    Vaccine. 2024 Feb 14:S0264-410X(24)00176-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  154. DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
    U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.
    Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  155. BORYS D, Rupp R, Smulders R, Chichili GR, et al
    Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
    Vaccine. 2024 Feb 14:S0264-410X(24)00145-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  156. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  157. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  158. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  159. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  160. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  161. MCDERMID P, Blazek K, Mougin N, Thomson A, et al
    Attitudes and behaviors of maternal Tdap vaccination in Panama, Peru, and Colombia: An international cross-sectional study.
    Vaccine. 2024 Feb 13:S0264-410X(24)00143-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  162. LI Y, Sun X, Fu Y, You X, et al
    Literature review to identify evidence of secondary transmission of pentavalent human-bovine reassortant rotavirus vaccine (RV5) strains to unvaccinated subjects.
    Vaccine. 2024 Feb 13:S0264-410X(24)00107-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  163. BHARUCHA T, Gangadharan B, Clarke R, Fernandez LG, et al
    Repurposing rapid diagnostic tests to detect falsified vaccines in supply chains.
    Vaccine. 2024 Feb 13:S0264-410X(24)00019-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  164. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  165. MABALE MAA, Tejero LMS, Montes LA, Collante MTM, et al
    Implications of information heard about Dengvaxia on Filipinos' perception on vaccination.
    Vaccine. 2024 Feb 12:S0264-410X(24)00123-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  166. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  167. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  168. MANNING J, Manna S, Dunne EM, Bongcaron V, et al
    Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in mice.
    Vaccine. 2024 Feb 12:S0264-410X(24)00131-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  169. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  170. DE WALS P, Desjardins M
    Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine.
    Vaccine. 2024 Feb 12:S0264-410X(24)00163-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  171. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  172. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  173. MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
    COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
    Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  174. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  175. NGUYEN KH, Chen S, Zhao R, Vasudevan L, et al
    Vaccination patterns and up-to-date status of children 19-35 months, 2011-2021.
    Vaccine. 2024 Feb 9:S0264-410X(24)00122-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  176. FORTUNATO F, Musco A, Iannelli G, Meola M, et al
    Effectiveness of the combined MMRV Priorix-Tetra vaccine against varicella in a large Italian region: A case-control study.
    Vaccine. 2024 Feb 9:S0264-410X(24)00146-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  177. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  178. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  179. SERRANO-MAYORGA CC, Ibanez-Prada ED, Restrepo-Martinez JM, Garcia-Gallo E, et al
    The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia.
    Vaccine. 2024 Feb 8:S0264-410X(24)00109-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  180. AMINZADEH A, Hilgers L, Paul Platenburg P, Riou M, et al
    Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Vaccine. 2024 Feb 8:S0264-410X(24)00101-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  181. WELDEGEBRIEL GG, Okot C, Majingo N, Oumer NJ, et al
    Resurgent rotavirus diarrhoea outbreak five years after introduction of rotavirus vaccine in Botswana, 2018.
    Vaccine. 2024 Feb 7:S0264-410X(24)00108-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  182. CHEN M, Feng X, Liu J, Wang J, et al
    Prokaryote-derived phosphorylated Tau epitope vaccine is immunogenic and non-T-cell activated in the mice model.
    Vaccine. 2024 Feb 7:S0264-410X(23)01517-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  183. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  184. LAMBACH P, Orenstein W, Silal S, Sbarra AN, et al
    Report from the World Health Organization's immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13 September 2023.
    Vaccine. 2024 Feb 6:S0264-410X(24)00160-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  185. SOBLE A, Ko M, Gilchrist S, Malvolti S, et al
    A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches.
    Vaccine. 2024 Feb 6:S0264-410X(23)01493-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  186. KOHLI K, Jain B, Dee EC, Ho BL, et al
    Addressing cultural and political drivers of vaccine hesitancy: Considerations for the African and Asian contexts.
    Vaccine. 2024 Feb 6:S0264-410X(24)00159-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  187. SMITH TC, Gorski DH
    Infertility: A common target of antivaccine misinformation campaigns.
    Vaccine. 2024;42:924-929.
    >> Share

  188. PENG Y, Yan H, Zhang J, Peng R, et al
    Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold.
    Vaccine. 2024;42:732-737.
    >> Share

  189. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  190. KIM NE, Kim MJ, Park BJ, Kwon JW, et al
    A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses.
    Vaccine. 2024 Feb 5:S0264-410X(24)00114-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  191. HOUY N, Flaig J
    Value of information dynamics in Disease X vaccine clinical trials.
    Vaccine. 2024 Feb 3:S0264-410X(24)00075-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  192. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  193. HWANG YH, Byeon Y, Ahn SH, Kim MY, et al
    Live attenuated smallpox vaccine candidate (KVAC103) efficiently induces protective immune responses in mice.
    Vaccine. 2024 Feb 2:S0264-410X(24)00076-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  194. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
    Vaccine. 2024 Feb 2:S0264-410X(24)00068-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  195. LI D, Han M, Cao Y, Du J, et al
    Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine.
    Vaccine. 2024 Feb 2:S0264-410X(24)00062-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  196. WANG ZJ, Zhang RR, Wu M, Zhao H, et al
    Development of a live-attenuated chimeric vaccine against the emerging Usutu virus.
    Vaccine. 2024 Feb 2:S0264-410X(24)00098-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  197. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  198. SUMNER T, Clark RA, Mukandavire C, Portnoy A, et al
    Modelling the health and economic impacts ofM72/AS01(E) vaccination and BCG-revaccination: Estimates for South Africa.
    Vaccine. 2024 Feb 1:S0264-410X(24)00096-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  199. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  200. DE DEUS N, Chissaque A, Bauhofer A, Barata A, et al
    Safety of incidental exposure to the novel oral poliovirus vaccine type 2 in pregnancy: A longitudinal observational study in Mozambique, 2022-2023.
    Vaccine. 2024 Feb 1:S0264-410X(24)00095-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  201. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    >> Share

    January 2024
  202. SCHONBORN L, Pavord S, Chen VMY, Pai M, et al
    Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Jan 31:S0264-410X(24)00057-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  203. SLAVKOVSKY R, Callen E, Pecenka C, Mvundura M, et al
    Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Vaccine. 2024 Jan 31:S0264-410X(24)00118-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  204. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  205. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  206. KOFF WC, Anandkumar A, Poland GA
    AI and the future of vaccine development.
    Vaccine. 2024 Jan 30:S0264-410X(24)00071-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  207. POLAND GA, Black S
    Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.
    Vaccine. 2024 Jan 30:S0264-410X(24)00070-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  208. BURNS KE, Dube E, Nascimento HG, Meyer SB, et al
    Erratum to "Examining vaccine hesitancy among a diverse sample of Canadian adults" [Vaccine 42(2) (2024) 129-135].
    Vaccine. 2024 Jan 30:S0264-410X(24)00061-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  209. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  210. XIAOFEI L, Yudan LI, Qinghui C, Jiaming S, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
    Vaccine. 2024 Jan 30:S0264-410X(24)00080-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  211. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  212. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  213. VIDLUND J, Gelalcha BD, Gillespie BE, Agga GE, et al
    Efficacy of novel staphylococcal surface associated protein vaccines against Staphylococcus aureus and non-aureus staphylococcal mastitis in dairy cows.
    Vaccine. 2024 Jan 27:S0264-410X(24)00079-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  214. MURATA F, Maeda M, Ono R, Fukuda H, et al
    Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
    Vaccine. 2024 Jan 27:S0264-410X(24)00072-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  215. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  216. HALL E, Mahon BE, Peacock G
    The U.S. COVID-19 vaccination program: A look back and future directions.
    Vaccine. 2024 Jan 26:S0264-410X(24)00065-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  217. LEVIN A, Yeung KHT, Hutubessy R
    Systematic review of cost projections of new vaccine introduction.
    Vaccine. 2024 Jan 25:S0264-410X(24)00024-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  218. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  219. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    >> Share

  220. FERRERAS-COLINO E, Contreras M, Risalde MA, Sevilla IA, et al
    Heat-inactivated mycobacteria activate the toll-like receptor 2 and 4 pathways in the zebrafish model of tuberculosis.
    Vaccine. 2024;42:403-409.
    >> Share

  221. KHAN A, Hussain I, Rhoda DA, Umer M, et al
    Determinants of immunization in polio super high-risk union councils of Pakistan.
    Vaccine. 2024;42:583-590.
    >> Share

  222. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  223. RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
    Lessons learned: COVID-19 vaccinations and people with disabilities.
    Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  224. WANG CP, Lin YT, Du YZ, Zhang T, et al
    Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: A retrospective study.
    Vaccine. 2024 Jan 23:S0264-410X(24)00030-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  225. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  226. HARANAKA M, Young Song J, Huang KC, de Solom R, et al
    A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults?>/=?60 years of age in Japan, South Korea, and Taiwan.
    Vaccine. 2024 Jan 23:S0264-410X(24)00008-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  227. ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
    Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
    Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  228. HADLER SC, Shefer AM, Cavallaro KF, Ebama M, et al
    Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments - New tools and approaches.
    Vaccine. 2024 Jan 23:S0264-410X(24)00035-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  229. CLOTHIER HJ, Shetty AN, Mesfin Y, Mackie M, et al
    What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Vaccine. 2024 Jan 22:S0264-410X(24)00025-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  230. CAO H, Li H, Luan N, Zhang H, et al
    A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
    Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  231. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  232. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  233. CATALDI JR, Suresh K, Brewer SE, Perreira C, et al
    Boot Camp Translation using Community-Engaged messaging for adolescent Vaccination: A Cluster-Randomized trial.
    Vaccine. 2024 Jan 21:S0264-410X(24)00054-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  234. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  235. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  236. KUMWICHAR P, Chongsuvivatwong V, Vasoppakarn S, Atthakul N, et al
    Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
    Vaccine. 2024 Jan 20:S0264-410X(24)00026-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  237. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  238. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  239. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  240. MUNKWASE G
    Implications of vaccine non-specific effects on licensure of new vaccines.
    Vaccine. 2024 Jan 18:S0264-410X(24)00060-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  241. CHRISTOPH R, Giovanni A, Arne S, Sebastian V, et al
    Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis.
    Vaccine. 2024 Jan 18:S0264-410X(24)00022-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  242. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  243. FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al
    The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.
    Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  244. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  245. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  246. FAN J, Song Y, Cong S, Millman AJ, et al
    Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
    Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  247. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  248. TIAN X, Wang J, Chen H, Ding M, et al
    In vivo functional immunoprotection correlates for vaccines against invasive bacteria.
    Vaccine. 2024 Jan 16:S0264-410X(24)00018-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  249. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  250. KANG DW, Kim CR, Song JY, Park SK, et al
    Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Vaccine. 2024 Jan 14:S0264-410X(24)00031-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  251. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  252. BEARSON SMD, Monson MS, Bearson BL, Whelan SJ, et al
    Commercial vaccine provides cross-protection by reducing colonization of Salmonella enterica serovars Infantis and Hadar in turkeys.
    Vaccine. 2024 Jan 13:S0264-410X(23)01500-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  253. GUO W, Wang C, Song X, Xu H, et al
    Immunogenicity and protective efficacy of a trimeric full-length S protein subunit vaccine for porcine epidemic diarrhea virus.
    Vaccine. 2024 Jan 13:S0264-410X(24)00020-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  254. NAUTA J
    Estimand for non-inferiority influenza vaccine immunogenicity trials.
    Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  255. RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
    A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
    Vaccine. 2024;42:162-174.
    >> Share

  256. VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
    Vaccine. 2024;42:146-155.
    >> Share

  257. KURATA T, Kaida Y, Kanbayashi D, Motomura K, et al
    Achieving measles elimination and emerging modified measles: Longitudinal measles epidemiology from 1982 to 2021 in Osaka Prefecture, Japan.
    Vaccine. 2024;42:271-286.
    >> Share

  258. SMITH CL, Richardson B, Rubsamen M, Cameron MJ, et al
    Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation.
    Vaccine. 2024;42:229-238.
    >> Share

  259. THOMPSON KM, Kalkowska DA, Kidd SE, Burns CC, et al
    Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
    Vaccine. 2024 Jan 12:S0264-410X(23)01541-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  260. KNIJFF M, van Lier A, Boer M, de Vries M, et al
    Parental intention, attitudes, beliefs, trust and deliberation towards childhood vaccination in the Netherlands in 2022: Indications of change compared to 2013.
    Vaccine. 2024 Jan 11:S0264-410X(23)01539-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  261. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    Assessing the relationship between existing childhood, adolescent and adult immunization programmes and national COVID-19 vaccination capacities in 2021.
    Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  262. JOACHIM GE, Wagner AL, Naseem M, Boulton ML, et al
    Trends in childhood vaccination in Pakistan and associated factors; 2006-2018.
    Vaccine. 2024 Jan 10:S0264-410X(24)00015-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  263. SHARP M, Lozano P, Southworth A, Peters A, et al
    Mixed methods approach to understanding COVID-19 vaccine hesitancy among immigrants in the Chicago.
    Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  264. LIN HH, Wu YS, Chang MT, Shyur LF, et al
    Plant-derived galactolipids enhance specific antibody production and induce class-switch as vaccine adjuvant.
    Vaccine. 2024 Jan 9:S0264-410X(24)00002-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  265. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  266. MULLER MP, Navarro C, Wilson SE, Shulha HP, et al
    Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Vaccine. 2024 Jan 9:S0264-410X(23)01514-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  267. OKUMOTO A, Nomura Y, Okuda S, Shikano M, et al
    Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process.
    Vaccine. 2024 Jan 9:S0264-410X(23)01504-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  268. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  269. CARROLL JC, Herbert SMC, Nguyen TQ, Schork CJ, et al
    Vaccination equity and the role of community pharmacy in the United States: A qualitative study.
    Vaccine. 2024 Jan 8:S0264-410X(23)01509-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  270. ROZENBAUM MH, Huang L, Perdrizet J, Cane A, et al
    Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Vaccine. 2024 Jan 7:S0264-410X(23)01503-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  271. COSTA M, Mansilla F, Manuel Sala J, Saravia A, et al
    Fasciola hepatica infection modifies IgG1 specific immune response to foot-and-mouse disease virus induced by vaccination.
    Vaccine. 2024 Jan 6:S0264-410X(23)01513-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  272. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  273. DOBROVOLSKIENE N, Balevicius R, Mlynska A, Zilionyte K, et al
    Immunomodulatory properties of bacteriophage derived dsRNA of different size and their use as anticancer vaccine adjuvants.
    Vaccine. 2024 Jan 5:S0264-410X(23)01518-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  274. STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
    Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
    Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  275. REIS JN, Azevedo J, de Oliveira AML, Menezes APO, et al
    Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Vaccine. 2024 Jan 5:S0264-410X(23)01501-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  276. ENYINNAYA JC, Anderson AA, Kelp NC, Long M, et al
    The Social Ecology of Health Beliefs and Misinformation Framework: Examining the impact of misinformation on vaccine uptake through individual and sociological factors.
    Vaccine. 2024 Jan 5:S0264-410X(24)00001-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  277. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  278. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  279. ALVAREZ CA, Hall RG 2nd, Lin S, Perkins AR, et al
    Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population.
    Vaccine. 2024 Jan 3:S0264-410X(23)01532-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  280. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  281. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  282. YAEGASHI M, Matsui H, Yoshida A, Ban H, et al
    A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Vaccine. 2024 Jan 2:S0264-410X(23)01540-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  283. HUSSEIN I, Vanska S, Sivela J, Leino T, et al
    Factors associated with parental Human Papillomavirus (HPV) vaccination intention of daughter: A national survey in Finland.
    Vaccine. 2024 Jan 2:S0264-410X(23)01473-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  284. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  285. DE PINHO RB, Barbosa TN, Dall'Agno L, da Rocha Fonseca B, et al
    Mycobacterium bovis BCG expressing the proteins CP40 or CP09720 of Corynebacterium pseudotuberculosis promotes protection in mice after challenge.
    Vaccine. 2024;42:33-39.
    >> Share

  286. VASHI MD, Watkins M
    Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    >> Share

    December 2023
  287. ZOLA MATUVANGA T, Lariviere Y, Lemey G, Isekah Osang'ir B, et al
    Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo.
    Vaccine. 2023 Dec 31:S0264-410X(23)01530-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  288. ROMANO IG, Core SB, Lee NR, Mowry C, et al
    A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood.
    Vaccine. 2023 Dec 29:S0264-410X(23)01533-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  289. TO A, Wong TAS, Ball AH, Lieberman MM, et al
    Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.
    Vaccine. 2023 Dec 28:S0264-410X(23)01499-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  290. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  291. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  292. OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al
    Development of COVID-19 vaccine policy - United States, 2020-2023.
    Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  293. SURTEES TC, Granade CJ, Wells C, Banks M, et al
    CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.
    Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  294. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  295. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  296. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  297. MIRANDA MCR, Nunes CM, Santos LF, da Silva LB, et al
    Ordered mesoporous silicas for potential applications in solid vaccine formulations.
    Vaccine. 2023 Dec 24:S0264-410X(23)01478-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  298. SEESKIN ZH, Ganesh N, Maitra P, Herman P, et al
    Estimating county-level vaccination coverage using small area estimation with the National Immunization Survey-Child.
    Vaccine. 2023 Dec 23:S0264-410X(23)01492-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  299. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  300. MAHMOOD S, Skinner P, Warren CJ, Mayers J, et al
    In vivo challenge studies on vaccinated chickens indicate a virus genotype mismatched vaccine still offers significant protection against NDV.
    Vaccine. 2023 Dec 23:S0264-410X(23)01483-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  301. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  302. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  303. LANGLEY JM, Gantt S, Halperin SA, Ward B, et al
    An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2023 Dec 22:S0264-410X(23)01452-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  304. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  305. LEVITAN B, Hadler SC, Hurst W, Izurieta HS, et al
    The Brighton collaboration standardized module for vaccine benefit-risk assessment.
    Vaccine. 2023 Dec 21:S0264-410X(23)01109-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  306. JORDAN Z, Rowland E
    Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review.
    Vaccine. 2023 Dec 20:S0264-410X(23)01491-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  307. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  308. LINK-GELLES R, Britton A, Fleming-Dutra KE
    Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
    Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  309. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  310. STUMPF J, Anders L, Siepmann T, Schwobel J, et al
    9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  311. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  312. PILIOU S, Farman TA, Marini A, Manoharan S, et al
    Commensal Neisseria cinerea outer membrane vesicles as a platform for the delivery of meningococcal and gonococcal antigens to the immune system.
    Vaccine. 2023;41:7671-7681.
    >> Share

  313. DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
    Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  314. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  315. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  316. ZHAN XY, Chen Y, Zhang X, Shi Q, et al
    Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
    Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  317. BAJRACHARYA D, Jansen RJ
    Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
    Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  318. JIANG W, Lu C, Yan X, Tucker JD, et al
    Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  319. BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
    Examining vaccine hesitancy among a diverse sample of Canadian adults.
    Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  320. DONG C, Ma Y, Zhu W, Wang Y, et al
    Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
    Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  321. FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
    Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
    Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  322. CAO Z, Yu R, Yuan Q, Ji W, et al
    Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
    Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  323. SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al
    Monitoring and reporting the US COVID-19 vaccination effort.
    Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  324. LYU Y, Choong A, Chow EPF, Seib KL, et al
    Vaccine value profile for Neisseria gonorrhoeae.
    Vaccine. 2023 Dec 13:S0264-410X(23)00086-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  325. O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
    The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
    Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  326. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
    An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  327. YAMADA N, Nakatsuka K, Tezuka M, Murata F, et al
    Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study.
    Vaccine. 2023 Dec 11:S0264-410X(23)01442-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  328. YANG X, Shi N, Liu C, Zhang J, et al
    Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies.
    Vaccine. 2023 Dec 11:S0264-410X(23)01397-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  329. LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
    Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
    Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  330. LO VECCHIO A, Scarano SM, Palladino R, Del Bene M, et al
    Co-administration with Men-B vaccine increases Rotavirus vaccination coverage: A 5-year regionwide retrospective cohort study (STORM study).
    Vaccine. 2023 Dec 9:S0264-410X(23)01436-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  331. SKIRROW H, Foley K, Bedford H, Lewis C, et al
    Impact of pregnancy vaccine uptake and socio-demographic determinants on subsequent childhood Measles, Mumps and Rubella vaccine uptake: A UK birth cohort study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01431-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  332. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  333. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
    Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  334. BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al
    The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01420-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  335. JONGEN VW, Groot Bruinderink ML, Boyd A, Koole JCD, et al
    What determines mpox vaccination uptake? Assessing the effect of intent-to-vaccinate versus other determinants among men who have sex with men.
    Vaccine. 2023 Dec 9:S0264-410X(23)01449-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  336. SUI Y, Andersen H, Li J, Hoang T, et al
    SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
    Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  337. DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
    Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  338. MALAKER R, Hasanuzzaman M, Hooda Y, Rahman H, et al
    Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
    Vaccine. 2023 Dec 8:S0264-410X(23)01440-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  339. LI J, Ding J, Chen K, Xu X, et al
    Protective effects of a novel chimeric virus-like particle vaccine against virulent NDV and IBDV challenge.
    Vaccine. 2023 Dec 8:S0264-410X(23)01430-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  340. CHENG DR, Reimer H, Le D, Crawford NW, et al
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    >> Share

  341. REEF SE, Icenogle JP, Plotkin SA
    The path to eradication of rubella.
    Vaccine. 2023;41:7525-7531.
    >> Share

  342. LESCOP J, Pennes B, Epaulard O
    Mind the gap: Concordance between perceptions regarding vaccination as declared by patients and their evaluation by their general practitioner.
    Vaccine. 2023 Dec 7:S0264-410X(23)01433-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  343. YU Y, Zhang X, Lau MMC, Lau JTF, et al
    The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
    Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  344. GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
    Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
    Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  345. CHOKEPHAIBULKIT K, Puthanakit T, Chaithongwongwatthana S, Bhat N, et al
    Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
    Vaccine. 2023 Dec 6:S0264-410X(23)01386-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  346. HUANG L, Chen Z, Song Y, Tan J, et al
    Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01212-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  347. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  348. ENUL H, Uzar S, Satir E, Sarac F, et al
    Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirkoy strain sheep pox vaccine under field conditions.
    Vaccine. 2023 Dec 5:S0264-410X(23)01388-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  349. CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
    The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  350. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  351. SATO S, Katsuta T, Kawazoe Y, Takahashi M, et al
    Immune thrombocytopenic purpura and Guillain-Barre syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Vaccine. 2023 Dec 2:S0264-410X(23)01399-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  352. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
    Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  353. JENNINGS MC, Sauer M, Manchester C, Soeters HM, et al
    Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries.
    Vaccine. 2023 Dec 1:S0264-410X(23)01379-8. doi: 10.1016/j.vaccine.2023.
    >> Share

    November 2023
  354. BAQAR S, Bonavia A, Louis Bourgeois A, Campo JJ, et al
    The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
    Vaccine. 2023 Nov 29:S0264-410X(23)01391-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  355. BANERJEE S, Barry EM, Baqar S, Louis Bourgeois A, et al
    The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations.
    Vaccine. 2023 Nov 28:S0264-410X(23)01364-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  356. WANG Y, Hu Y, Ma Y, Li P, et al
    RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
    Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  357. NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
    Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
    Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  358. TANAKA T, Kakiuchi S, Tashiro M, Fujita A, et al
    Adherence to recommended vaccination policies for pre- and post-solid organ transplantation patients: A national questionnaire survey in Japan.
    Vaccine. 2023 Nov 24:S0264-410X(23)01377-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  359. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  360. DUCASA N, Benencio P, Mauro E, Anders M, et al
    Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  361. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
    Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  362. SOWE A, Namatovu F, Cham B, Gustafsson PE, et al
    Missed opportunities for vaccination at point of care and their impact on coverage and urban-rural coverage inequity in the Gambia.
    Vaccine. 2023 Nov 22:S0264-410X(23)01385-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  363. WANG B, McDonough J, Chen G, Ong JJ, et al
    Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  364. NEELY SR, Hao F
    Breakthrough COVID-19 infections and perceived vaccine effectiveness.
    Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  365. ECONOMIDOU EC, Soteriades ES
    Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  366. KAUR R, Gonzalez E, Pham M, Pichichero M, et al
    Naturally-induced serum antibody levels in children to pneumococcal polysaccharide 15B that correlate with protection from nasopharyngeal colonization but anti-serotype 15B antibody has low functional cross-reactivity with serotype 15C.
    Vaccine. 2023;41:7265-7273.
    >> Share

  367. NEUHANN JM, Stemler J, Carcas AJ, Frias-Iniesta J, et al
    Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults >/=75 years (EU-COVAT-1).
    Vaccine. 2023;41:7166-7175.
    >> Share

  368. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    >> Share

  369. LARIVIERE Y, Matuvanga TZ, Lemey G, Osang'ir BI, et al
    Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  370. LAW AW, Judy J, Atwell JE, Willis S, et al
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  371. NAUGLE D, Tibbels N, Dosso A, Benie W, et al
    "I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  372. MAN-LIK CHOI E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, et al
    Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in
    Vaccine. 2023 Nov 17:S0264-410X(23)01257-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  373. SHRESTHA AC, Field E, Rajmokan M, Lambert SB, et al
    Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia.
    Vaccine. 2023 Nov 16:S0264-410X(23)01327-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  374. CHANDPA HH, Panda AK, Meena CL, Meena J, et al
    Beyond the polysaccharide and glycoconjugate vaccines for Streptococcus pneumoniae: Does protein/peptide nanovaccines hold promises?
    Vaccine. 2023 Nov 16:S0264-410X(23)01332-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  375. YU Z, Keskinocak P, Orenstein WA, Toktay LB, et al
    A mixed integer programming model for vaccine pricing within a group purchasing organization.
    Vaccine. 2023 Nov 15:S0264-410X(23)01223-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  376. ANRAAD C, van Empelen P, Ruiter RAC, van Keulen H, et al
    Effects of an online tailored decision aid to promote informed decision making about maternal pertussis vaccination in the Netherlands: A randomized controlled trial.
    Vaccine. 2023 Nov 15:S0264-410X(23)01281-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  377. CHRISTENSEN S, Bouguermouh S, Ilangovan K, Pride MW, et al
    A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
    Vaccine. 2023 Nov 15:S0264-410X(23)01296-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  378. HAEDER SF
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  379. CHOI Y, Park S, Lee J, Kim Y, et al
    Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  380. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  381. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  382. CHOE S, Park GN, Kim KS, Shin J, et al
    Efficacy of an orally administered classical swine fever live marker vaccine (Flc-LOM-BE(rns) strain) in pigs.
    Vaccine. 2023 Nov 14:S0264-410X(23)01286-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  383. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  384. GUBERNOT D, Menis M, Whitaker B
    Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
    Vaccine. 2023;41:6922-6929.
    >> Share

  385. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  386. JIANG X, Wang J, Li C, Yeoh EK, et al
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  387. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
    "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  388. LIU YY, Xu YQ, Zhong Y, Wei F, et al
    Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01329-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  389. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  390. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  391. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  392. ANDERSON EC, Blair PS, Finn A, Ingram J, et al
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  393. WIDDERSHOVEN V, Reijs RP, Eskes A, Verhaegh-Haasnoot A, et al
    Maternal pertussis vaccination behavior: Psychosocial, attitudinal and organizational factors.
    Vaccine. 2023 Nov 9:S0264-410X(23)01325-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  394. TECHAKRIENGKRAI N, Aryuman S, Vanlarat K, Karnchanapraphas C, et al
    Impacts of shelter management on canine rabies immune status.
    Vaccine. 2023 Nov 9:S0264-410X(23)01330-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  395. YANG C, Zheng Z, Zheng P, Chen J, et al
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  396. TSAI SA, Lu CY, Chen TI, Huang SP, et al
    Adverse events from HPV vaccination in Taiwan.
    Vaccine. 2023 Nov 8:S0264-410X(23)01321-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  397. TAMIR TT, Kassie AT, Zegeye AF
    Prevalence and determinants of two or more doses of tetanus toxoid-containing vaccine immunization among pregnant women in sub-Saharan Africa: Evidence from recent demographic and health survey data.
    Vaccine. 2023 Nov 8:S0264-410X(23)01305-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  398. MVUNDURA M, Slavkovsky R, Debellut F, Naddumba T, et al
    Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Vaccine. 2023 Nov 8:S0264-410X(23)01306-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  399. GSELL PS, Giersing B, Gottlieb S, Wilder-Smith A, et al
    Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report.
    Vaccine. 2023 Nov 8:S0264-410X(23)01210-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  400. COOPER LV, Stuart JM, Okot C, Asiedu-Bekoe F, et al
    Corrigendum to "Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana" [Vaccine 37(37) (2019) 5657-5663].
    Vaccine. 2023 Nov 7:S0264-410X(23)01293-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  401. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  402. FLANDES X, Hansen CA, Palani S, Abbas K, et al
    Vaccine value profile for Chikungunya.
    Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  403. HAEDER SF
    Assessing vaccine hesitancy and support for vaccination requirements for pets and potential Spillovers from humans.
    Vaccine. 2023 Nov 5:S0264-410X(23)01263-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  404. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  405. JONES G, Perry M, Bailey R, Arumugam S, et al
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  406. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
    Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  407. KHALIL I, Anderson JD, Bagamian KH, Baqar S, et al
    Vaccine value profile for enterotoxigenic Escherichia coli (ETEC).
    Vaccine. 2023;41 Suppl 2:S95-S113.
    >> Share

  408. TROTTER CL, Alderson M, Dangor Z, Ip M, et al
    Vaccine value profile for Group B streptococcus.
    Vaccine. 2023;41 Suppl 2:S41-S52.
    >> Share

  409. KAYE PM, Matlashewski G, Mohan S, Le Rutte E, et al
    Vaccine value profile for leishmaniasis.
    Vaccine. 2023;41 Suppl 2:S153-S175.
    >> Share

  410. ARMAH G, Lopman BA, Vinje J, O'Ryan M, et al
    Vaccine value profile for norovirus.
    Vaccine. 2023;41 Suppl 2:S134-S152.
    >> Share

  411. MARTIN LB, Khanam F, Qadri F, Khalil I, et al
    Vaccine value profile for Salmonella enterica serovar Paratyphi A.
    Vaccine. 2023;41 Suppl 2:S114-S133.
    >> Share

  412. HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
    Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis.
    Vaccine. 2023;41 Suppl 2.
    >> Share

  413. HOLDER T, Coad M, Allan G, Hogarth PJ, et al
    Vaccination of calves with Bacillus Calmette-Guerin Danish strain 1331 results in a duration of immunity of at least 52 weeks.
    Vaccine. 2023 Nov 2:S0264-410X(23)01262-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  414. CHEN GL, Yu XY, Luo LP, Zhang F, et al
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  415. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
    Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  416. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  417. GREYSON D, Goh G
    Education components of school vaccine mandates: An environmental scan.
    Vaccine. 2023 Nov 1:S0264-410X(23)01155-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  418. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
    In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    October 2023
  419. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  420. RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
    A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  421. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  422. TANI N, Ikematsu H, Goto T, Kondo S, et al
    Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Vaccine. 2023;41:6672-6678.
    >> Share

  423. STEFANIZZI P, Di Lorenzo A, Martinelli A, Moscara L, et al
    Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
    Vaccine. 2023 Oct 26:S0264-410X(23)01158-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  424. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  425. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
    "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  426. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  427. BURNETT E, Riaz A, Anwari P, Myat TW, et al
    Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation.
    Vaccine. 2023 Oct 24:S0264-410X(23)01225-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  428. TRICOU V, Winkle PJ, Tharenos LM, Rauscher M, et al
    Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
    Vaccine. 2023 Oct 24:S0264-410X(23)01132-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  429. FLOR N, Garcia MI, Molineri A, Bottasso O, et al
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  430. KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
    Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  431. SHARIF H, Ghani H, Ahmad L, Bagol S, et al
    Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
    Vaccine. 2023 Oct 23:S0264-410X(23)01227-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  432. DI GIUSEPPE G, Pelullo CP, Napoli A, Napolitano F, et al
    Willingness to receive Herpes Zoster vaccination among adults and older people: A cross sectional study in Italy.
    Vaccine. 2023 Oct 23:S0264-410X(23)01247-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  433. LOONEY MM, Hatherill M, Musvosvi M, Flynn J, et al
    Conference report: WHO meeting report on mRNA-based tuberculosis vaccine development.
    Vaccine. 2023 Oct 21:S0264-410X(23)01209-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  434. BRESEE J, Koh M, Chadwick C, Jit M, et al
    The need and ongoing efforts to understand the full value of improved influenza vaccines.
    Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  435. TERADA M, Shimazu T, Saito J, Odawara M, et al
    Age, gender and socioeconomic disparities in human papillomavirus (HPV) awareness and knowledge among Japanese adults after a 7-year suspension of proactive recommendation for the HPV vaccine: A nationally representative cross-sectional survey.
    Vaccine. 2023 Oct 20:S0264-410X(23)01207-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  436. MORI Y, Uchida N, Wake A, Miyawaki K, et al
    Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  437. WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
    Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
    Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  438. PUTRI WCWS, Sawitri AAS, Yuliyatni PCD, Ariawan IMD, et al
    Cost-effectiveness analysis of Japanese Encephalitis (JE) vaccination program in Bali Province, Indonesia.
    Vaccine. 2023 Oct 20:S0264-410X(23)01177-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  439. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  440. VERMA N, Gupta P, Pandey AK, Awasthi S, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among sick and healthy children in northern India: A case-control study.
    Vaccine. 2023;41:6619-6624.
    >> Share

  441. HONGTU Q, BoLi L, Jianguo C, Shusheng P, et al
    Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.
    Vaccine. 2023 Oct 20:S0264-410X(23)01191-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  442. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  443. HART R, Feygin Y, Kluthe T, Quinn KG, et al
    Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
    Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  444. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  445. PUCHNER KP, Bottazzi ME, Periago V, Grobusch M, et al
    Vaccine value profile for Hookworm.
    Vaccine. 2023 Oct 18:S0264-410X(23)00540-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  446. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Corrigendum to "Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants" [Vaccine 41(11) (2023) 1892-1901].
    Vaccine. 2023 Oct 18:S0264-410X(23)01216-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  447. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  448. RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
    Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
    Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  449. ANGULO FJ, Zhang P, Halsby K, Kelly P, et al
    A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe.
    Vaccine. 2023 Oct 17:S0264-410X(23)01184-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  450. CHOPRA A, Rodriguez A, Prakash A, Raskar R, et al
    Using neural networks to calibrate agent based models enables improved regional evidence for vaccine strategy and policy.
    Vaccine. 2023 Oct 17:S0264-410X(23)01016-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  451. HAEDER SF
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  452. YANG H, Wang Z, Zhang Y, Xu M, et al
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  453. PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
    Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
    Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  454. WRIGHT J, Science M, Osman S, Arnold C, et al
    Uptake of pertussis immunization in pregnancy and determinants of vaccination in Toronto, Canada.
    Vaccine. 2023 Oct 14:S0264-410X(23)01192-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  455. MUKASA K, Sugawara T, Okutomi Y
    Susceptibility of nursery teachers to measles, rubella, varicella and mumps in Japan.
    Vaccine. 2023;41:6530-6534.
    >> Share

  456. ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
    Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
    Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  457. MOSCA S, Lin Q, Stokes R, Bharucha T, et al
    Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
    Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  458. VAN EWIJK CE, Smit C, Bavalia R, Ainslie K, et al
    Acceptance and timeliness of post-exposure vaccination against mpox in high-risk contacts, Amsterdam, the Netherlands, May-July 2022.
    Vaccine. 2023 Oct 12:S0264-410X(23)01183-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  459. SUKWA N, Mubanga C, Hatyoka LM, Chilyabanyama ON, et al
    Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX(R)) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
    Vaccine. 2023 Oct 12:S0264-410X(23)01138-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  460. RODRIGUEZ VJ, Kozlova S, LaBarrie DL, Liu Q, et al
    Parental anxiety and pediatric vaccine refusal in a US national sample of parents.
    Vaccine. 2023 Oct 11:S0264-410X(23)01187-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  461. NAND KN, Jordan TB, Yuan X, Basore DA, et al
    Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle.
    Vaccine. 2023 Oct 11:S0264-410X(23)01114-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  462. HAUSDORFF WP, Anderson JD 4th, Bagamian KH, Bourgeois AL, et al
    Vaccine value profile for Shigella.
    Vaccine. 2023 Oct 10:S0264-410X(22)01562-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  463. AYDIN I, May M, Pisano F, Mpofu-Maetzig N, et al
    Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study
    Vaccine. 2023 Oct 10:S0264-410X(23)01157-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  464. YAO X, Peng J, Ma Y, Fu M, et al
    Development of a vaccine hesitancy scale for childhood immunization in China.
    Vaccine. 2023 Oct 9:S0264-410X(23)01154-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  465. YU P, Liu Y, Tao X, He Y, et al
    Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains.
    Vaccine. 2023 Oct 9:S0264-410X(23)01161-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  466. PARK H, Jang MS, Choi JA, Kim W, et al
    Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
    Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  467. CHECCHI M, Mesher D, Panwar K, Anderson A, et al
    The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Vaccine. 2023 Oct 9:S0264-410X(23)01162-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  468. MO C, Li X, Wu Q, Fan Y, et al
    SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
    Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  469. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  470. FEBRIANI Y, Mansour T, Sadarangani M, Ulanova M, et al
    Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?
    Vaccine. 2023 Oct 8:S0264-410X(23)01160-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  471. BOPPANA SB, van Boven M, Britt WJ, Gantt S, et al
    Vaccine value profile for cytomegalovirus.
    Vaccine. 2023 Oct 6:S0264-410X(23)00670-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  472. PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al
    Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  473. LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
    Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
    Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  474. PAPACHRISTIDOU S, Lapea V, Charisi M, Kourkouni E, et al
    A multicenter study on the epidemiology of complicated parapneumonic effusion in the era of currently available pneumococcal conjugate vaccines.
    Vaccine. 2023 Oct 5:S0264-410X(23)01164-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  475. CAVIT L, Charania NA
    Exploring factors that influence vaccination uptake for children with refugee backgrounds: An interpretive description study of primary healthcare providers' perspectives.
    Vaccine. 2023 Oct 4:S0264-410X(23)01141-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  476. OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
    How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
    Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  477. BEERENS D, Poland GA
    Latest developments in vaccine research: Selected papers from the 16th annual vaccine congress.
    Vaccine. 2023 Oct 3:S0264-410X(23)01153-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  478. KANEVSKY I, Surendran N, McElwee K, Lei L, et al
    Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Vaccine. 2023 Oct 3:S0264-410X(23)01113-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  479. ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
    Individual variation in vaccine immune response can produce bimodal distributions of protection.
    Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    September 2023
  480. OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
    Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
    Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  481. OVSYANNIKOVA IG, Haralambieva IH, Schaid DJ, Warner ND, et al
    Genome-wide determinants of cellular immune responses to mumps vaccine.
    Vaccine. 2023 Sep 29:S0264-410X(23)01055-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  482. MIAO X, Zhang L, Zhou P, Yu R, et al
    Adenovirus-vectored PDCoV vaccines induce potent humoral and cellular immune responses in mice.
    Vaccine. 2023 Sep 29:S0264-410X(23)01139-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  483. DE COUVREUR LA, Cobo MJ, Kennedy PJ, Ellis JT, et al
    Bibliometric analysis of parasite vaccine research from 1990 to 2019.
    Vaccine. 2023 Sep 28:S0264-410X(23)01105-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  484. KOCHHAR S, Okomo U, Nkereuwem O, Shaum A, et al
    Establishing vaccine pregnancy registries and active surveillance studies in low-and middle-income countries: Experience from an observational cohort surveillance project in The Gambia.
    Vaccine. 2023 Sep 28:S0264-410X(23)01111-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  485. DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
    "The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
    Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  486. TSIRIGOTAKI M, Galanakis E
    Impact of vaccines on Staphylococcus aureus colonization: A systematic review and meta-analysis.
    Vaccine. 2023 Sep 28:S0264-410X(23)01104-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  487. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023 Sep 28:S0264-410X(23)00623-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  488. HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
    Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
    Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  489. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  490. SHEN X, Hao Y, Wang S, Li D, et al
    Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  491. CASSARINO N, Ahnger-Pier KK, Wurcel A
    Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
    Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  492. SANA S, Merkelbach I, Magnee T, Kollmann J, et al
    Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
    Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  493. GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
    Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
    Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  494. SALO H, Perala J, Hannila-Handelberg T, Sarvikivi E, et al
    Decline in varicella cases contacting primary health care after introduction of varicella vaccination in Finland - A population-based register study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01094-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  495. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023 Sep 22:S0264-410X(23)01053-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  496. NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
    Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  497. RAISER F, Davis M, Adelglass J, Cai MR, et al
    Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Vaccine. 2023;41:5965-5973.
    >> Share

  498. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  499. FU Y, Wu K, Wang Z, Yang H, et al
    Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  500. KIM DR, You YA, Ahn HS, Park EL, et al
    Statistical considerations on real time and extended controlled temperature conditions (ECTC) stability data analysis of vaccines.
    Vaccine. 2023 Sep 21:S0264-410X(23)00944-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  501. WILKINSON B, Patel KS, Smith K, Walker R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
    Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  502. DEPEW CE, McSorley SJ
    The role of tissue resident memory CD4 T cells in Salmonella infection: Implications for future vaccines.
    Vaccine. 2023 Sep 20:S0264-410X(23)01066-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  503. ALHARBI HS
    Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
    Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  504. SCHMITZ KS, Comvalius AD, Nieuwkoop NJ, Geers D, et al
    A measles virus-based vaccine induces robust chikungunya virus-specific CD4(+) T-cell responses in a phase II clinical trial.
    Vaccine. 2023 Sep 17:S0264-410X(23)01092-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  505. HAN C, Zhao ZZ, Chan P, Li F, et al
    A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  506. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  507. WANG Y, Ji W, Li D, Sun T, et al
    Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection.
    Vaccine. 2023 Sep 15:S0264-410X(23)01049-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  508. SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
    Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
    Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  509. IRALA S, Hamid S, Penayo E, Michel F, et al
    COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.
    Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  510. SALAT J, Hunady M, Svoboda P, Strelcova L, et al
    Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs.
    Vaccine. 2023 Sep 14:S0264-410X(23)01089-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  511. LUGELO A, Hampson K, McElhinney LM, Lankester F, et al
    Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera.
    Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  512. REID MC, Mittler JE, Murphy JT, Stansfield SE, et al
    Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study.
    Vaccine. 2023 Sep 13:S0264-410X(23)01027-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  513. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023 Sep 12:S0264-410X(23)00946-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  514. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023 Sep 11:S0264-410X(23)01051-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  515. REUSCHENBACH M, Doorbar J, Del Pino M, Joura EA, et al
    Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer.
    Vaccine. 2023 Sep 11:S0264-410X(23)00990-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  516. SU F, Xue Y, Ye S, Yu B, et al
    Integrative transcriptomic and metabolomic analysis in mice reveals the mechanism by which ginseng stem-leaf saponins enhance mucosal immunity induced by a porcine epidemic diarrhea virus vaccination.
    Vaccine. 2023 Sep 11:S0264-410X(23)01085-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  517. SURYAWANSHI YR
    An overview of protein-based SARS-CoV-2 vaccines.
    Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  518. ROY VL, Majumder PP
    Genomic associations with antibody response to an oral cholera vaccine.
    Vaccine. 2023 Sep 10:S0264-410X(23)01084-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  519. FULLER HR, Huseth-Zosel A, Vleet BV, Hajdar M, et al
    Vaccine attitudes and acceptance among older adults in North Dakota: Understanding demographic characteristic variability.
    Vaccine. 2023 Sep 9:S0264-410X(23)01059-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  520. POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
    Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
    Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  521. MCCARTY JM, Bedell L, Mendy J, Coates EE, et al
    Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
    Vaccine. 2023 Sep 8:S0264-410X(23)01052-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  522. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  523. PANDEY MK, Rajukumar K, Senthilkumar D, Kombiah S, et al
    Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate.
    Vaccine. 2023 Sep 7:S0264-410X(23)01047-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  524. MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
    Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Vaccine. 2023;41:5742-5751.
    >> Share

  525. LI P, Jia WY, Zhang X, Wang DB, et al
    Effect of enterovirus 71 vaccine on epidemiological characteristics of hand, foot and mouth disease: An 8-year retrospective intermittent time series analysis.
    Vaccine. 2023 Sep 6:S0264-410X(23)01061-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  526. CHILDS K, Harvey Y, Waters R, Woma T, et al
    Development of a quadrivalent foot-and-mouth disease vaccine candidate for use in East Africa.
    Vaccine. 2023 Sep 5:S0264-410X(23)01054-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  527. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  528. YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
    When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
    Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  529. TIEU HV, Karuna S, Huang Y, Sobieszczyk ME, et al
    Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Vaccine. 2023 Sep 5:S0264-410X(23)00877-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  530. PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
    Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  531. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023 Sep 4:S0264-410X(23)01018-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  532. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023 Sep 4:S0264-410X(23)01040-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  533. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  534. CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
    Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
    Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  535. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  536. ZHOU G, Ma Q, Li Q, Wang S, et al
    The disruption of LPS in Salmonella Typhimurium provides partial protection against Salmonella Choleraesuis as a live attenuated vaccine.
    Vaccine. 2023 Sep 2:S0264-410X(23)01044-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  537. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
    Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  538. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  539. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023 Sep 1:S0264-410X(23)00954-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  540. SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
    Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness.
    Vaccine. 2023 Sep 1:S0264-410X(23)00989-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  541. PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
    Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
    Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  542. PALMER M, Katanoda K, Saito E, Acuti Martellucci C, et al
    Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" [Vaccine 40(41) (2022) 5971-5996].
    Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.
    >> Share

    August 2023
  543. FLOOD T, McLaughlin M, Hughes CM, Wilson IM, et al
    Applying the COM-B behaviour model to understand factors which impact school immunisation nurses' attitudes towards designing and delivering a HPV educational intervention in post-primary schools for 15-17 year old students in Northern Ireland, UK.
    Vaccine. 2023;41:5630-5639.
    >> Share

  544. GRILLS LA, Wagner AL
    The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
    Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  545. SAKALA IG, Honda-Okubo Y, Petrovsky N
    Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
    Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  546. DUDLEY HM, O'Mara M, Auma A, Gong J, et al
    Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
    Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  547. REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
    Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
    Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  548. KRISHNA SUSARLA S, Jahagirdar R, Ghosh Uttam K, Srikanth Bhatt S, et al
    Immunogenicity and safety of Mebella vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.
    Vaccine. 2023 Aug 31:S0264-410X(23)01021-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  549. SNIDER CJ, Zaman K, Wilkinson AL, Binte Aziz A, et al
    Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
    Vaccine. 2023 Aug 29:S0264-410X(23)01009-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  550. PUNCHHI G, Negus R, Saif H, Pritchard S, et al
    Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT.
    Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  551. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023 Aug 29:S0264-410X(23)01019-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  552. YI EJ, Kim YI, Song JH, Ko HJ, et al
    Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.
    Vaccine. 2023 Aug 28:S0264-410X(23)00961-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  553. HACKER E, Baker B, Lake T, Ross C, et al
    Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.
    Vaccine. 2023 Aug 27:S0264-410X(23)00959-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  554. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
    Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  555. NYGARD S, Nygard M, Orumaa M, Hansen BT, et al
    Erratum to "Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals" [Vaccine 41(37) (2023) 5469-5476].
    Vaccine. 2023 Aug 26:S0264-410X(23)01010-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  556. UGAI S, Ugai T, Kanayama T, Kamiya H, et al
    Mumps vaccine hesitancy: Current evidence and an evidence-based campaign in Japan.
    Vaccine. 2023 Aug 26:S0264-410X(23)00976-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  557. YANG J, Li B, Yang D, Wu J, et al
    The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  558. MOTTA M, Motta G, Stecula D
    Sick as a dog? The prevalence, politicization, and health policy consequences of canine vaccine hesitancy (CVH).
    Vaccine. 2023 Aug 26:S0264-410X(23)01015-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  559. JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
    The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
    Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  560. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  561. CHEUVART B, Callegaro A, Rosillon D, Meyer N, et al
    Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing.
    Vaccine. 2023 Aug 25:S0264-410X(23)00888-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  562. CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
    Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
    Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  563. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  564. GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
    Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
    Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  565. MOHAMMED IS, Widome R, Searle KM
    COVID-19 vaccine decision-making among Black women: A qualitative study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  566. WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
    The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
    Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  567. STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
    Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
    Vaccine. 2023;41:5351-5359.
    >> Share

  568. TIAN J, Zheng B, Yang L, Guan Y, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study.
    Vaccine. 2023 Aug 23:S0264-410X(23)00973-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  569. HALDER P, Maiti S, Banerjee S, Das S, et al
    Bacterial ghost cell based bivalent candidate vaccine against Salmonella Typhi and Salmonella Paratyphi A: A prophylactic study in BALB/c mice.
    Vaccine. 2023 Aug 23:S0264-410X(23)00992-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  570. SHAPIRO JR, Andreani G, Dube C, Berube M, et al
    Development and characterization of a plant-derived norovirus-like particle vaccine.
    Vaccine. 2023 Aug 23:S0264-410X(23)00968-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  571. HOMAIRA N, Strachan R, Quinn H, Beggs S, et al
    Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91].
    Vaccine. 2023 Aug 23:S0264-410X(23)00870-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  572. KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al
    Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
    Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  573. MAKI Y, Edo N, Mizuguchi M, Ikeda M, et al
    Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen(R)) vaccination on antibody titers; a japanese cross-sectional study.
    Vaccine. 2023 Aug 22:S0264-410X(23)00962-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  574. YAO T, Guo Y, Xu X, Zhang X, et al
    Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
    Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  575. SU Y, Guo Z, Gu X, Sun S, et al
    Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
    Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  576. CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
    Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
    Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  577. ENUJIOKE SC, Shedd-Steele R, Daggy J, Burney HN, et al
    County-level correlates of completed HPV vaccination in Indiana.
    Vaccine. 2023 Aug 18:S0264-410X(23)00875-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  578. KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
    Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  579. MORRISON K, Cullen L, James AB, Chua V, et al
    Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  580. PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
    Lessons learned from the COVID-19 pandemic for improved influenza control.
    Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  581. DALE JB, Aranha MP, Penfound TA, Salehi S, et al
    Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine.
    Vaccine. 2023 Aug 16:S0264-410X(23)00958-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  582. ZUR M, Shelef L, Glassberg E, Fink N, et al
    Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
    Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  583. FILARDO TD, Prasad N, Waddell CJ, Persad N, et al
    Mpox vaccine acceptability among people experiencing homelessness in San Francisco - October-November 2022.
    Vaccine. 2023 Aug 15:S0264-410X(23)00914-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  584. REIFFERSCHEID L, Kiely MS, Lin MSN, Libon J, et al
    Effectiveness of hospital-based strategies for improving childhood immunization coverage: A systematic review.
    Vaccine. 2023;41:5233-5244.
    >> Share

  585. TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
    DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  586. WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
    Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  587. FRANCONERI L, Antona D, Cauchemez S, Levy-Bruhl D, et al
    Two-dose measles vaccine effectiveness remains high over time: A French observational study, 2017-2019.
    Vaccine. 2023 Aug 14:S0264-410X(23)00950-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  588. YIN MZ, Gu YY, Shu JT, Zhang B, et al
    Cost-effectiveness of cytomegalovirus vaccination for females in China: A decision-analytical Markov study.
    Vaccine. 2023 Aug 12:S0264-410X(23)00943-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  589. BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
    Parental acceptability of vaccinating young children against influenza and COVID-19.
    Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  590. MALIRAT V, Caldevilla C, Cardillo S, Espinoza AM, et al
    Broad immunogenic spectrum of monovalent and trivalent foot-and-mouth disease virus vaccines containing O(1) campos, A24 cruzeiro and A Argentina 2001 strains against circulating viral lineages in cattle and pigs.
    Vaccine. 2023 Aug 11:S0264-410X(23)00939-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  591. SUFFEL AM, Walker JL, Williamson E, McDonald HI, et al
    Timeliness of childhood vaccination in England: A population-based cohort study.
    Vaccine. 2023 Aug 11:S0264-410X(23)00926-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  592. BUMATAY S, Dickinson C, Larsen R, Stock I, et al
    A comparison of electronic health records and the Oregon state immunization registry for human papilloma virus vaccine delivery (2005-2022).
    Vaccine. 2023 Aug 10:S0264-410X(23)00949-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  593. EIFFERT SR, Sturmer T, Thorpe CT, Traub R, et al
    Vaccine patterns among patients diagnosed with Guillain-Barre Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020.
    Vaccine. 2023 Aug 10:S0264-410X(23)00947-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  594. CARDONA RSB, Weckx LY, de Moraes-Pinto MI, Ramos BCF, et al
    Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate: A cross-sectional serological study.
    Vaccine. 2023 Aug 10:S0264-410X(23)00940-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  595. HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
    An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
    Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  596. BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
    Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
    Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  597. WARIRI O, Utazi CE, Okomo U, Metcalf CJE, et al
    Mapping the timeliness of routine childhood vaccination in The Gambia: A spatial modelling study.
    Vaccine. 2023 Aug 8:S0264-410X(23)00928-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  598. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  599. KOCHHAR S, Izurieta HS, Chandler RE, Hacker A, et al
    Benefit-risk assessment of vaccines.
    Vaccine. 2023 Aug 8:S0264-410X(23)00872-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  600. PITTS PJ, Poland GA
    Trust and science: Public health's home field advantage in addressing vaccine hesitancy and improving immunization rates.
    Vaccine. 2023 Aug 6:S0264-410X(23)00927-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  601. VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
    Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
    Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  602. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  603. SIMMS AJ, King KD, Tsui N, Edwards SA, et al
    COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
    Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  604. IZULLA P, Wagai JN, Akelo V, Ombeva A, et al
    Vaccine safety surveillance in Kenya using GAIA standards: A feasibility assessment of existing national and subnational research and program systems.
    Vaccine. 2023 Aug 5:S0264-410X(23)00906-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  605. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  606. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  607. XU S, Yu H, Cheng X, Wu J, et al
    Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  608. GRANT LR, Slack MPE, Theilacker C, Vojicic J, et al
    Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Vaccine. 2023 Aug 4:S0264-410X(23)00925-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  609. AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
    Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  610. SINGER D, Salem A, Stempniewicz N, Ma S, et al
    The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Vaccine. 2023 Aug 2:S0264-410X(23)00837-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  611. CARTER A, Msemburi W, Sim SY, Gaythorpe KAM, et al
    Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030.
    Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  612. MO J, Spackman E, Swayne DE
    Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
    Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    July 2023
  613. AMAI M, Nojima M, Yuki Y, Kiyono H, et al
    A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials".
    Vaccine. 2023 Jul 31:S0264-410X(23)00918-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  614. GUNALE B, Farinola N, Yeolekar L, Shrivastava S, et al
    A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Vaccine. 2023 Jul 31:S0264-410X(23)00876-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  615. HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
    An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  616. WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
    A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  617. VAN WALSTIJN C, Verweij S, Care R, Rigsby P, et al
    Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines.
    Vaccine. 2023 Jul 30:S0264-410X(23)00885-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  618. LIU B, Stepien S, Qian J, Gidding H, et al
    Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
    Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  619. AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
    Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
    Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  620. DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al
    Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada.
    Vaccine. 2023 Jul 29:S0264-410X(23)00880-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  621. GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
    COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
    Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  622. LENTSCH V, Aslani S, Echtermann T, Preet S, et al
    "EvoVax" - A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs.
    Vaccine. 2023 Jul 28:S0264-410X(23)00890-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  623. KIM SY, Lee KM, Kim KH
    Differences between DNA vaccine and single-cycle viral vaccine in the ability of cross-protection against viral hemorrhagic septicemia virus (VHSV) and infectious hematopoietic necrosis virus (IHNV).
    Vaccine. 2023 Jul 28:S0264-410X(23)00889-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  624. PADENIYA TN, Hui BB, Wood JG, Seib KL, et al
    The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting.
    Vaccine. 2023 Jul 28:S0264-410X(23)00879-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  625. HAMAD SAIED M, van Straalen JW, de Roock S, de Joode-Smink GCJ, et al
    Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
    Vaccine. 2023 Jul 27:S0264-410X(23)00883-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  626. LAVENDER B, Hooker C, Frampton C, Williams M, et al
    Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
    Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  627. JIANG XY, Gong MQ, Zhang HJ, Peng AQ, et al
    The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial.
    Vaccine. 2023 Jul 27:S0264-410X(23)00878-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  628. NYGARD S, Nygard M, Orumaa M, Hansen BT, et al
    Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Vaccine. 2023 Jul 27:S0264-410X(23)00852-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  629. ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
    BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  630. KABIR A, Randall D, Newall AT, Moore HC, et al
    Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00873-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  631. KIM DH, Lee J, Youk S, Jeong JH, et al
    Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
    Vaccine. 2023;41:4787-4797.
    >> Share

  632. MARTINI M, Orsini D
    The ghost of polio haunts us once again. The appeal of the scientific community is clear: "Vaccinate your kids today!".
    Vaccine. 2023 Jul 24:S0264-410X(23)00850-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  633. TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
    Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
    Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  634. GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
    Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
    Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  635. ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
    Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
    Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  636. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  637. ORAMI T, Aho C, Ford RL, Pomat WS, et al
    Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
    Vaccine. 2023 Jul 19:S0264-410X(23)00838-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  638. CANTARERO D, Ocana D, Onieva-Garcia MA, Rodriguez-Garcia J, et al
    Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
    Vaccine. 2023 Jul 19:S0264-410X(23)00828-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  639. JESUDASON T, Rodarte A, Tordrup D, Carias C, et al
    Systematic review of rotavirus vaccination cost-effectiveness in high income settings utilising dynamic transmission modelling techniques.
    Vaccine. 2023 Jul 19:S0264-410X(23)00749-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  640. CLIMACO MC, de Figueiredo LA, Lucas RC, Pinheiro GRG, et al
    Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis.
    Vaccine. 2023 Jul 19:S0264-410X(23)00832-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  641. PISL V, Vevera J
    COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
    Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  642. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  643. VIETRI J, Sato R, Averin A, Weycker D, et al
    Pneumococcal vaccine uptake among Medicare Beneficiaries aged >/=65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019.
    Vaccine. 2023 Jul 18:S0264-410X(23)00855-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  644. ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
    Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
    Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  645. DAS SK, Khan J
    Timeliness in the uptake of hepatitis B birth dose among Indian children under age five: A population-based study.
    Vaccine. 2023 Jul 17:S0264-410X(23)00827-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  646. BATOOL R, Yousafzai MT, Qureshi S, Muhammad S, et al
    Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
    Vaccine. 2023 Jul 16:S0264-410X(23)00806-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  647. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  648. SCHAEFER GO, Emanuel EJ, Atuire CA, Leland RJ, et al
    Equitable global allocation of monkeypox vaccines.
    Vaccine. 2023 Jul 15:S0264-410X(23)00835-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  649. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  650. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  651. MYERS MG
    Beginning to address vaccine reluctance and refusal.
    Vaccine. 2023 Jul 14:S0264-410X(23)00851-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  652. GIERSING B, Karron R, Tufet-Bayona M, Trotter C, et al
    Vaccine Value profiles.
    Vaccine. 2023 Jul 14:S0264-410X(23)00786-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  653. TALOTTA R
    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  654. GLESER D, Spinner K, Klement E
    Effectiveness of the strain 919 bovine ephemeral fever virus vaccine in the face of a real-world outbreak: A field study in Israeli dairy herds.
    Vaccine. 2023 Jul 12:S0264-410X(23)00747-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  655. ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
    Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
    Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  656. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  657. YAMAGUCHI K, Shimizu H, Takahashi K, Nagatomo T, et al
    Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
    Vaccine. 2023;41:4497-4507.
    >> Share

  658. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  659. MIELLET WR, Pluister G, Sikking M, Tappel M, et al
    Surveillance of Neisseria meningitidis carriage four years after menACWY vaccine implementation in the Netherlands reveals decline in vaccine-type and rise in genogroup e circulation.
    Vaccine. 2023 Jul 7:S0264-410X(23)00781-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  660. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  661. FLEMING JA, Baral R, Higgins D, Khan S, et al
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  662. ZHANG X, Shen P, Liu J, Ji X, et al
    Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
    Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  663. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  664. LE H, de Klerk N, Blyth CC, Gidding H, et al
    Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
    Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  665. ROSHCHINA Y, Rozhkova K, Roshchin S
    Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  666. PATEL UC, Schultz T, Schmidt J
    Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
    Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  667. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  668. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  669. GRUZDEV N, Pitcovski J, Katz C, Ruimi N, et al
    Development of toxin-antitoxin self-destructive bacteria, aimed for salmonella vaccination.
    Vaccine. 2023 Jul 1:S0264-410X(23)00777-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  670. IZUMI F, Miyamoto S, Masatani T, Sasaki M, et al
    Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.
    Vaccine. 2023 Jul 1:S0264-410X(23)00779-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  671. KELLY M, Mandlik A, Charles RC, Verma S, et al
    Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.
    Vaccine. 2023 Jul 1:S0264-410X(23)00738-7. doi: 10.1016/j.vaccine.2023.
    >> Share

    June 2023
  672. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  673. SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  674. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  675. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
    Vaccine. 2023;41:4212-4219.
    >> Share

  676. VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
    Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    Vaccine. 2023;41:4319-4326.
    >> Share

  677. ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
    One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
    Vaccine. 2023;41:4199-4205.
    >> Share

  678. LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
    Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  679. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  680. CARRERA JM, Aktepe TE, Earnest L, Christiansen D, et al
    Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00757-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  681. YUKI Y, Harada N, Sawada SI, Uchida Y, et al
    Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.
    Vaccine. 2023 Jun 27:S0264-410X(23)00754-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  682. DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
    Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
    Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  683. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  684. GONZALES BE, Mercado EH, Castillo-Tokumori F, Montero AE, et al
    Pneumococcal serotypes and antibiotic resistance in healthy carriage children after introduction of PCV13 in Lima, Peru.
    Vaccine. 2023;41:4106-4113.
    >> Share

  685. CARNEIRO GB, Castro JT, Davi M, Miyaji EN, et al
    Immune responses and protection against Streptococcus pneumoniae elicited by recombinant Bordetella pertussis adenylate cyclase (CyaA) carrying fragments of pneumococcal surface protein A, PspA.
    Vaccine. 2023;41:4170-4182.
    >> Share

  686. BAUER BU, Schwecht KM, Jahnke R, Matthiesen S, et al
    Humoral and cellular immune responses in sheep following administration of different doses of an inactivated phase I vaccine against Coxiella burnetii.
    Vaccine. 2023 Jun 23:S0264-410X(23)00746-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  687. DU J, Wang T, Xu L, Wang C, et al
    Clostridium perfringens epsilon prototoxin mutant rpETX(Y30A/Y71A/H106P/Y196A) as a vaccine candidate against enterotoxemia.
    Vaccine. 2023 Jun 23:S0264-410X(23)00719-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  688. HOWARD MC
    Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
    Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  689. BOLIO A, Goldstein I, Rauh L, Ratzan S, et al
    Statement: Multisectoral actions to build trust at the local and community level to promote vaccine acceptance.
    Vaccine. 2023 Jun 23:S0264-410X(23)00693-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  690. CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
    Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  691. HAIST V, Bellebeau-Barbier F, Montange C, Lemaitre L, et al
    Comparison of the local safety of two multi-component feline vaccines, adjuvanted (1 mL) versus non-adjuvanted at reduced volume (0.5 mL), using computed tomography imaging.
    Vaccine. 2023 Jun 23:S0264-410X(23)00720-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  692. TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
    Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  693. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  694. SALEH SN, McDonald SA, Basit MA, Kumar S, et al
    Public perception of COVID-19 vaccines through analysis of Twitter content and users.
    Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  695. DE MELO ARAUJO AC, da Silva Aragao J, de Souza WV, Rodrigues LC, et al
    The impact of implementing the 10-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among children.
    Vaccine. 2023 Jun 21:S0264-410X(23)00724-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  696. FUKUSHIMA S, Kiyohara T, Nakano T, Tada Y, et al
    Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults.
    Vaccine. 2023 Jun 21:S0264-410X(23)00723-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  697. JIANG B, Luo Y, Yan N, Shen Z, et al
    An X-ray inactivated vaccine against Pseudomonas aeruginosa Keratitis in mice.
    Vaccine. 2023 Jun 21:S0264-410X(23)00627-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  698. KIM J, Han K, Chung SJ, Kim C, et al
    Psychometric validation of the Korean versions of the Vaccine Hesitancy Scale and Vaccination Attitudes Examination Scale.
    Vaccine. 2023 Jun 21:S0264-410X(23)00721-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  699. PERRILLO R, Garrido LF, Ma TW, Rahimi R, et al
    Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy.
    Vaccine. 2023 Jun 21:S0264-410X(23)00716-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  700. AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
    A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
    Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  701. LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
    How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
    Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  702. CHEN X, Lin Y, Yue S, Yang Y, et al
    PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
    Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  703. KREMER P, Haruna F, Tuffour Sarpong R, Agamah D, et al
    An impact assessment of the use of aerial logistics to improve access to vaccines in the Western-North Region of Ghana.
    Vaccine. 2023 Jun 19:S0264-410X(23)00701-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  704. SUZUKI H, Fujita H, Iwai K, Kuroki H, et al
    Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
    Vaccine. 2023 Jun 19:S0264-410X(23)00625-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  705. EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
    Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  706. AILLOUD J, Branchereau M, Fall E, Juneau C, et al
    How can we improve the acceptability of vaccination against Human Papillomavirus (HPV) in France? An original qualitative study with focus groups comprising parents and school staff, interviewed separately.
    Vaccine. 2023 Jun 19:S0264-410X(23)00656-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  707. TATON M, Willems F, Widomski C, Martin C, et al
    Impact of pregnancy on polyfunctional IgG and memory B cell responses to Tdap immunization.
    Vaccine. 2023;41:4009-4018.
    >> Share

  708. TAFURI S, Cuscianna E, Bianchi FP
    Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis.
    Vaccine. 2023;41:4057-4063.
    >> Share

  709. HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  710. UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
    Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
    Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  711. TZENG R, Huang FY, Lee J
    Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
    Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  712. ORANGZEB S, Watle SV, Caugant DA
    Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020.
    Vaccine. 2023 Jun 17:S0264-410X(23)00699-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  713. HAMEL BL, Patel J, Still J, Joshi A, et al
    A diagnostic quandary: Rotavirus vaccine associated diarrhea.
    Vaccine. 2023 Jun 17:S0264-410X(23)00715-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  714. MASOUD D, Pierz A, Rauh L, Cruz AK, et al
    Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
    Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  715. DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
    Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
    Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  716. SINGH A, Boggiano C, Eller MA, Maciel M Jr, et al
    Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
    Vaccine. 2023 Jun 16:S0264-410X(23)00694-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  717. DUNN DT, Gilson R, McCormack S, McCoy LE, et al
    Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
    Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  718. BISWAS RK, Afiaz A, Huq S, Farzana M, et al
    Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
    Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  719. PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
    Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
    Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  720. MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
    Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  721. KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
    Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
    Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  722. PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  723. NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
    Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  724. SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
    Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  725. CIEMINS EL, Gillen A, Tallam M
    RSV: A vaccine is coming, time to educate providers.
    Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  726. MUWONGE R, Basu P
    Re: Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection: Reply to the commentary written by Christine Velicer, Alain Luxembourg, Ya-Ting Chen, Melvin Kohn, and Alfred Saah, Merck
    Vaccine. 2023 Jun 14:S0264-410X(23)00696-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  727. WOO EJ, Gee J, Marquez P, Baggs J, et al
    Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  728. YOUNG S, Goldin S, Dumolard L, Shendale S, et al
    National vaccination policies for health workers - A cross-sectional global overview.
    Vaccine. 2023 Jun 13:S0264-410X(23)00518-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  729. CINCONZE E, Rosillon D, Rappuoli R, Vadivelu K, et al
    Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.
    Vaccine. 2023 Jun 13:S0264-410X(23)00552-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  730. SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
    Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
    Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  731. SMITH WJ, Thompson R, Egan PM, Zhang Y, et al
    Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines.
    Vaccine. 2023 Jun 13:S0264-410X(23)00620-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  732. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    BCG∆BCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice.
    Vaccine. 2023;41:3824-3835.
    >> Share

  733. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  734. WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
    Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  735. SATO R
    Revisiting the measurement of vaccine hesitancy: Comparison between routine immunization and supplementary immunization activity in Nigeria.
    Vaccine. 2023 Jun 12:S0264-410X(23)00691-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  736. AL-RASHEED M, Ball C, Parthiban S, Ganapathy K, et al
    Evaluation of protection and immunity induced by infectious bronchitis vaccines administered by oculonasal, spray or gel routes in commercial broiler chicks.
    Vaccine. 2023 Jun 12:S0264-410X(23)00642-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  737. TINGGAARD M, Slotved HC, Jorgensen CS, Kronborg G, et al
    Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV.
    Vaccine. 2023 Jun 12:S0264-410X(23)00686-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  738. MA D, Tian S, Qin Q, Yu Y, et al
    Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
    Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  739. ACKERSON B, Sy LS, Slezak J, Qian L, et al
    Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine.
    Vaccine. 2023 Jun 10:S0264-410X(23)00661-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  740. NAKAO R, Hirayama S, Yamaguchi T, Senpuku H, et al
    A bivalent outer membrane vesicle-based intranasal vaccine to prevent infection of periodontopathic bacteria.
    Vaccine. 2023 Jun 9:S0264-410X(23)00619-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  741. MADRAN B, Kayi I, Beser A, Ergonul O, et al
    Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
    Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  742. UI M, Hirama T, Akiba M, Honda M, et al
    Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  743. MARTINEZ MR, Gao J, Wan H, Kang H, et al
    Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
    Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  744. DE GIER B, van Asten L, Boere TM, van Roon A, et al
    Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
    Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  745. NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
    Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
    Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  746. KALKOWSKA DA, Badizadegan K, Thompson KM
    Outbreak management strategies for cocirculation of multiple poliovirus types.
    Vaccine. 2023;41:3718-3727.
    >> Share

  747. MWENDA V, Jalang'o R, Miano C, Bor JP, et al
    Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
    Vaccine. 2023 Jun 7:S0264-410X(23)00546-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  748. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  749. KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
    Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
    Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  750. MITCHELL SL, Schulkin J, Power ML
    Vaccine hesitancy in pregnant Women: A narrative review.
    Vaccine. 2023 Jun 6:S0264-410X(23)00608-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  751. KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
    Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  752. PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
    From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
    Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  753. KIM WJ, Roberts CC, Song JY, Yoon JG, et al
    Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
    Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  754. ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
    Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  755. YANAI T, Yoshida S, Takeuchi M, Kawakami K, et al
    Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Vaccine. 2023 Jun 5:S0264-410X(23)00626-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  756. MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
    Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  757. WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
    COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
    Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  758. KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
    Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  759. VOHRA P, Bremner A, Nicholls B, Chintoan-Uta C, et al
    Evaluation of N-glycan-decorated live attenuated Escherichia coli and outer membrane vesicles as vaccines against Campylobacter jejuni colonisation in chickens.
    Vaccine. 2023 Jun 3:S0264-410X(23)00595-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  760. ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
    Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  761. FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
    Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
    Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  762. RAINA MACINTYRE C, Lim S, Gurdasani D, Miranda M, et al
    Early detection of emerging infectious diseases - implications for vaccine development.
    Vaccine. 2023 Jun 2:S0264-410X(23)00630-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  763. MVUNDURA M, Ng J, Reynolds K, Theng Ng Y, et al
    Vaccine wastage in Ghana, Mozambique, and Pakistan: An assessment of wastage rates for four vaccines and the context, causes, drivers, and knowledge, attitudes and practices for vaccine wastage.
    Vaccine. 2023 Jun 1:S0264-410X(23)00582-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  764. SANDERS C, Matthews RL, Esfahani SHZ, Khan N, et al
    Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.
    Vaccine. 2023 Jun 1:S0264-410X(23)00618-7. doi: 10.1016/j.vaccine.2023.
    >> Share

    May 2023
  765. CHORIN O, Markovich MP, Avramovich E, Rahmani S, et al
    Oral and fecal polio vaccine excretion following bOPV vaccination among Israeli infants.
    Vaccine. 2023 May 31:S0264-410X(23)00585-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  766. OLIVERA MESA D, Winskill P, Ghani AC, Hauck K, et al
    The societal cost of vaccine refusal: A modelling study using measles vaccination as a case study.
    Vaccine. 2023 May 30:S0264-410X(23)00589-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  767. SCHLEY K, Borchert K, Seidel K, Jacob C, et al
    Did the change of the vaccination schedule effect pneumococcal conjugate vaccination compliance and adherence of premature and mature born infants in Germany? Answers from a claims database analysis.
    Vaccine. 2023 May 30:S0264-410X(23)00594-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  768. WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
    Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
    Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  769. ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
    Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  770. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  771. PAYNTER J, Howe AS, Best E, Petousis-Harris H, et al
    A retrospective cohort study investigating the comparative effectiveness of pneumococcal vaccines against hospitalisation with otitis media and pneumonia in New Zealand.
    Vaccine. 2023 May 25:S0264-410X(23)00591-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  772. MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
    COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
    Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  773. HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
    Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
    Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  774. CURTIS MG, Davoudpour S, Rodriguez-Ortiz AE, Felt D, et al
    Predictors of Mpox vaccine uptake among sexual and gender minority young adults living in Illinois: Unvaccinated vs. double vs. single dose vaccine recipients.
    Vaccine. 2023 May 24:S0264-410X(23)00593-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  775. RAO S, Abeyratne E, Freitas JR, Yang C, et al
    A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice.
    Vaccine. 2023 May 23:S0264-410X(23)00571-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  776. MOHAMMED AM, Musa A, Etapelong SG, Bolori MT, et al
    Expanding polio surveillance reach beyond vaccination reach in Borno State, Nigeria: The contribution of community informants from insecure areas engaged to conduct polio surveillance in security compromised areas, 2018-2019.
    Vaccine. 2023 May 23:S0264-410X(23)00547-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  777. CHOUDHARY P, Boamah B, Hon Ng S, White A, et al
    Solidified saturated fats coating subunit vaccines greatly extended vaccine booster release and contributed to a Th1/Th2 mixed immune response in mice.
    Vaccine. 2023 May 23:S0264-410X(23)00550-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  778. NUGENT C, Abul Y, White EM, Shehadeh F, et al
    Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Vaccine. 2023;41:3403-3409.
    >> Share

  779. WANG R, Fan X, Jiang Y, Li G, et al
    Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates.
    Vaccine. 2023 May 22:S0264-410X(23)00385-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  780. EGER J, Kaplan LC, Sternberg H
    How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
    Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  781. ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
    Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
    Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  782. GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
    Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
    Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  783. GUO BQ, Li HB, Yang LQ
    Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  784. BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
    A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
    Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  785. JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
    Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  786. EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
    Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  787. MALO B, Labbe F, Meyer SB, Filice E, et al
    "I Want People to Be Able to Make an Informed Choice": How Quebec naturopaths discuss vaccination in their practice.
    Vaccine. 2023 May 18:S0264-410X(23)00553-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  788. SHAW CA, August A, Bart S, Booth PJ, et al
    A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.
    Vaccine. 2023 May 18:S0264-410X(23)00488-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  789. BOING AF, Boing AC, Barberia L, Borges ME, et al
    Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  790. MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al
    A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
    Vaccine. 2023;41:3387-3398.
    >> Share

  791. WANLAPAKORN N, Pruetarat N, Sarawanangkoor N, Phanphanit K, et al
    Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age.
    Vaccine. 2023 May 16:S0264-410X(23)00541-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  792. ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
    Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  793. LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
    COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
    Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  794. SUN W
    Monkeypox, smallpox, FDA, and accelerated approval of vaccines - A regulatory perspective.
    Vaccine. 2023 May 15:S0264-410X(23)00526-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  795. SHATO T, Humble S, Anandarajah A, Barnette A, et al
    Influences of sociodemographic characteristics and parental HPV vaccination hesitancy on HPV vaccination coverage in five US states.
    Vaccine. 2023 May 15:S0264-410X(23)00517-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  796. BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
    Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
    Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  797. OHM M, van Straalen JW, Zijlstra M, de Joode-Smink G, et al
    Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study.
    Vaccine. 2023 May 15:S0264-410X(23)00480-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  798. GARCIA-FOGEDA I, Besbassi H, Lariviere Y, Ogunjimi B, et al
    Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: A systematic review.
    Vaccine. 2023 May 15:S0264-410X(23)00422-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  799. SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
    Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  800. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    A national survey of parents' views on childhood vaccinations in Ireland.
    Vaccine. 2023 May 13:S0264-410X(23)00522-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  801. GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
    Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
    Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  802. VESIKARI T, Langley JM, Spaans JN, Petrov I, et al
    The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.
    Vaccine. 2023 May 11:S0264-410X(23)00528-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  803. CHOI Y, Lee GS, Li S, Lee JW, et al
    Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
    Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  804. PIERRE E, Pladys A, Bayat-Makoei S, Tattevin P, et al
    Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year.
    Vaccine. 2023 May 11:S0264-410X(23)00521-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  805. KEHAGIA E, Papakyriakopoulou P, Valsami G
    Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  806. MIDDLETON BF, Danchin M, Cunliffe NA, Jones MA, et al
    Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination.
    Vaccine. 2023 May 11:S0264-410X(23)00525-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  807. ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
    Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
    Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  808. VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
    Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  809. GOVINDAN V, Ganaie FA, Ramakrishnan SM, Ravindran S, et al
    Estimation of baseline IgG antibody levels to 23 pneumococcal vaccine-type capsular polysaccharides in healthy vaccine naive Indian adults.
    Vaccine. 2023 May 10:S0264-410X(23)00497-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  810. RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
    Building global vaccine manufacturing capacity: Spotlight on Africa.
    Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  811. WILSON RJ, Leigh L, Bah H, Larson HJ, et al
    HPV vaccination acceptance and perceptions related to fertility and population control in the Gambia: An anthropological analysis.
    Vaccine. 2023 May 10:S0264-410X(23)00508-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  812. LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
    Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  813. SMITH K, Hegazy K, Cai MR, McKnight I, et al
    Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  814. BERRY A, Kapelus D, Singh P, Groome M, et al
    ABO blood types, but not Secretor or Lewis blood types, influence strength of antibody response to Hepatitis B vaccine in Black South African children.
    Vaccine. 2023 May 9:S0264-410X(23)00465-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  815. HIEBERT J, Saboui M, Frost JR, Zubach V, et al
    Mumps resurgence in a highly vaccinated population: Insights gained from surveillance in Canada, 2002-2020.
    Vaccine. 2023 May 9:S0264-410X(23)00513-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  816. CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
    Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
    Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  817. OLUSANYA OA, Tomar A, Thomas J, Alonge K, et al
    Application of the theoretical domains framework to identify factors influencing catch-up HPV vaccinations among male college students in the United States: A review of evidence and recommendations.
    Vaccine. 2023 May 8:S0264-410X(23)00509-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  818. SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
    Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
    Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  819. BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
    Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  820. KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
    Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  821. FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
    Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
    Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  822. GOLDBLATT D, Andrews NJ, Sheppard CL, Rose S, et al
    Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
    Vaccine. 2023;41:3019-3023.
    >> Share

  823. KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
    Informing the design of a whole of life immunisation register for Australia.
    Vaccine. 2023;41:3011-3018.
    >> Share

  824. LEWIS CY, Mishra K, Sun Y, Sechrist SJ, et al
    Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Vaccine. 2023 May 5:S0264-410X(23)00491-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  825. CZIBENER C, Rey Serantes DA, Romani AM, Bruno L, et al
    Bm Delta-pgm, a vaccine for the control of Brucella melitensis with cross-species protective properties.
    Vaccine. 2023 May 5:S0264-410X(23)00511-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  826. RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
    Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
    Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  827. KINGSLEY T, Phelan D, Poland GA
    Corrigendum to "A review of 2023 adult immunization schedule updates" [Vaccine 41(16) (2023) 2631-2633].
    Vaccine. 2023 May 3:S0264-410X(23)00462-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  828. TALBIRD SE, Anderson SA, Nossov M, Beattie N, et al
    Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.
    Vaccine. 2023 May 3:S0264-410X(23)00414-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  829. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
    Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  830. BERAN J, Lattanzi M, Costantini M, Pammolli A, et al
    Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
    Vaccine. 2023 May 2:S0264-410X(23)00485-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  831. VOSS SS, Norgaard SK, Valentiner-Branth P
    Identification of subgroups in the Danish population for targeted human papillomavirus vaccination efforts.
    Vaccine. 2023 May 2:S0264-410X(23)00484-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  832. FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
    Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
    Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  833. SIDDIQUE M, Iftikhar S, Dharma VK, Shah MT, et al
    Using geographic information system to track children and optimize immunization coverage and equity in Karachi, Pakistan.
    Vaccine. 2023;41:2922-2931.
    >> Share

  834. VEREEN RJ, Aden JK, Drumm CM
    Newborn medication adherence and childhood under-immunization in military beneficiaries.
    Vaccine. 2023;41:2887-2892.
    >> Share

  835. LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
    Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
    Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  836. MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
    Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
    Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  837. KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
    COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
    Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  838. HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
    COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
    Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
    >> Share

    April 2023
  839. CHU K, Li Y, Yu D, Song Y, et al
    Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
    Vaccine. 2023 Apr 29:S0264-410X(23)00259-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  840. MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
    NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  841. HALSEY N, Evans S, Santosham M, Hacker A, et al
    Considerations for unblinding individual study participants during vaccine trials.
    Vaccine. 2023 Apr 28:S0264-410X(23)00425-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  842. COSTA JP, Jesus S, Colaco M, Duarte A, et al
    Endotoxin contamination of nanoparticle formulations: A concern in vaccine adjuvant mechanistic studies.
    Vaccine. 2023 Apr 28:S0264-410X(23)00487-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  843. IMMINK MM, van der Maas NAT, de Melker HE, Ferreira JA, et al
    Socio-psychological determinants of second trimester maternal pertussis vaccination acceptance in the Netherlands.
    Vaccine. 2023 Apr 28:S0264-410X(23)00482-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  844. BLACK S, Evans S
    Serious adverse events following mRNA vaccination in randomized trials in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00432-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  845. VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
    A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  846. DE LA TORRE ARRIETA J, Briceno D, de Castro IG, Roser B, et al
    A thermostable tetanus/diphtheria (Td) vaccine in the StablevaX pre-filled delivery system.
    Vaccine. 2023 Apr 28:S0264-410X(23)00431-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  847. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  848. KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
    COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
    Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  849. GREENBERG V, Vazquez-Benitez G, Kharbanda EO, Daley MF, et al
    Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes.
    Vaccine. 2023 Apr 26:S0264-410X(23)00457-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  850. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Cardiac events following JYNNEOS vaccination for prevention of Mpox.
    Vaccine. 2023 Apr 26:S0264-410X(23)00466-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  851. ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
    Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
    Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  852. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  853. SMITH MJ, Emanuel EJ
    Learning from five bad arguments against mandatory vaccination.
    Vaccine. 2023 Apr 25:S0264-410X(23)00461-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  854. KIM SJ, Kwon SL, Lee JY, Oh J, et al
    Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
    Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  855. JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
    COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  856. CAI B, Peyrani P, Beeslaar J, Burman C, et al
    Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
    Vaccine. 2023;41:2729-2733.
    >> Share

  857. WALTER D, Ophir Y, Ye H
    Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
    Vaccine. 2023;41:2868-2877.
    >> Share

  858. CHARLTON CL, Bailey AM, Thompson LA, Kanji JN, et al
    What's in a number? The value of titers as routine proof of immunity for medical students.
    Vaccine. 2023;41:2734-2738.
    >> Share

  859. KLOSE SM, De Souza DP, Disint JF, Andrews DM, et al
    Reversion of mutations in a live mycoplasma vaccine alters its metabolism.
    Vaccine. 2023 Apr 24:S0264-410X(23)00459-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  860. ROPER RL, Garzino-Demo A, Del Rio C, Brechot C, et al
    Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.
    Vaccine. 2023 Apr 21:S0264-410X(23)00393-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  861. MA L, Brecher M, Soufal A, Gaiotto T, et al
    Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
    Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  862. CLARKE L, Brighton T, Chunilal SD, Lee CSM, et al
    Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem.
    Vaccine. 2023 Apr 19:S0264-410X(23)00379-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  863. TERRINONI M, Nordqvist SL, Lofstrand M, Nilsson F, et al
    A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.
    Vaccine. 2023 Apr 19:S0264-410X(23)00387-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  864. GIRNDT M, Houser P, Manllo-Karim R, Ervin JE, et al
    Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Vaccine. 2023 Apr 19:S0264-410X(23)00420-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  865. BAO Y, He L, Miao B, Zhong Z, et al
    BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  866. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  867. PILLSBURY A, Phillips A, Deng L, Quinn H, et al
    Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  868. MIDDELDORP M, Steens A, Lagerweij G, van Sorge NM, et al
    The burden of invasive meningococcal disease in the Netherlands, 2011-2020.
    Vaccine. 2023;41:2664-2670.
    >> Share

  869. HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
    COVID-19 vaccine distribution: A high reliability organization approach.
    Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  870. GORDON SF, Lam J, Vasquez JT, Cercone R, et al
    A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
    Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  871. TCHOUALEU DD, Fleming M, Traicoff DA
    A systematic review of pre-service training on vaccination and immunization.
    Vaccine. 2023 Apr 15:S0264-410X(23)00369-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  872. KANG B, Goldlust S, Lee EC, Hughes J, et al
    Spatial distribution and determinants of childhood vaccination refusal in the United States.
    Vaccine. 2023 Apr 15:S0264-410X(23)00402-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  873. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
    COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  874. FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
    Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  875. KUAN-MAHECHA MA, Rahman S, Martinez-Rivera P, Lamb MM, et al
    Differences in parental vaccine confidence and attitudes by health system in Guatemala and their impact on immunization timeliness.
    Vaccine. 2023 Apr 13:S0264-410X(23)00371-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  876. ANDRAUD M, Herve S, Gorin S, Barbier N, et al
    Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
    Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  877. KATTSTROM M, Uggla B, Tina E, Kimby E, et al
    Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
    Vaccine. 2023 Apr 13:S0264-410X(23)00399-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  878. FORTUNA LBDP, Miranda FM, Antunes IMF, Silva AB, et al
    Prevalence, capsular types, antimicrobial resistance and risk factors associated with pneumococcal carriage among children after long-term 10-valent pneumococcal conjugate vaccine use in Brazil.
    Vaccine. 2023 Apr 13:S0264-410X(23)00415-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  879. LI J, Shi LW, Yu BW, Huang LR, et al
    Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
    Vaccine. 2023 Apr 13:S0264-410X(23)00392-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  880. KHANAM F, Babu G, Rahman N, Liu X, et al
    Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Vaccine. 2023 Apr 13:S0264-410X(23)00397-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  881. ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
    Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  882. YOUNG G, Zahralban-Steele M, Dean HJ
    Impact of prior flavivirus vaccination on immunogenicity and efficacy of an inactivated Zika vaccine in Indian rhesus macaques.
    Vaccine. 2023 Apr 11:S0264-410X(23)00398-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  883. KIM GL, Pyo SW, Yi H, Kim SH, et al
    Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model.
    Vaccine. 2023 Apr 11:S0264-410X(23)00386-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  884. UEMURA K, Ono S, Michihata N, Yamana H, et al
    Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
    Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  885. RATHORE APS, St John AL
    Promises and challenges of mucosal COVID-19 vaccines.
    Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  886. KAWADE A, Dayma G, Apte A, Telang N, et al
    Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix(TM) and Prevenar13(TM))) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-lab
    Vaccine. 2023 Apr 10:S0264-410X(23)00388-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  887. PERKINS-OINES S, Dias N, Krafsur G, Abdelsalam K, et al
    The effect of neonatal vaccination for bovine respiratory disease in the face of a dual challenge with bovine viral diarrhea virus and Mannheimia hemolytica.
    Vaccine. 2023 Apr 10:S0264-410X(23)00391-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  888. CHANG CC, Algaissi A, Lai CC, Chang CK, et al
    Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.
    Vaccine. 2023 Apr 10:S0264-410X(23)00390-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  889. DOLD C, Zhu H, Silva-Reyes L, Blackwell L, et al
    Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines.
    Vaccine. 2023 Apr 8:S0264-410X(23)00395-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  890. HARRIS C, Cottrell S, Perry M, Meaden R, et al
    A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
    Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  891. HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
    Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
    Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  892. HAMAD SAIED M, van Straalen JW, de Roock S, de Joode-Smink GCJ, et al
    Safety of Measles-Mumps-Rubella booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study.
    Vaccine. 2023 Apr 7:S0264-410X(23)00381-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  893. JAGNE I, von Mollendorf C, Wee-Hee A, Ortika B, et al
    A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age.
    Vaccine. 2023 Apr 7:S0264-410X(23)00370-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  894. VARGAS-ZAMBRANO JC, Clark LR, Johnson DR, Monfredo C, et al
    Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis.
    Vaccine. 2023 Apr 7:S0264-410X(23)00342-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  895. LIU J, Guo S, Jin Z, Zhao K, et al
    Adjuvanted quaternized chitosan composite aluminum nanoparticles-based vaccine formulation promotes immune responses in chickens.
    Vaccine. 2023 Apr 7:S0264-410X(23)00374-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  896. LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
    Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
    Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  897. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    >> Share

  898. HEMPEL K, McDonald W, Osgood ND, Fisman D, et al
    Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study.
    Vaccine. 2023;41:2430-2438.
    >> Share

  899. AFSAR A, Mallya A, Mohammed AAG, Anand S, et al
    Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Vaccine. 2023;41 Suppl 1:A79-A84.
    >> Share

  900. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    >> Share

  901. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    >> Share

  902. VOORMAN A, O'Reilly K, Lyons H, Goel AK, et al
    Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Vaccine. 2023;41 Suppl 1:A105-A112.
    >> Share

  903. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    >> Share

  904. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    >> Share

  905. PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
    Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
    Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  906. WANG SM, Keegan EA, Bryan KM, Kazma J, et al
    Human papillomavirus vaccination receipt and provider counseling rates among high-risk patients.
    Vaccine. 2023 Apr 5:S0264-410X(23)00378-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  907. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
    Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  908. MACHIDA M, Inoue S
    Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study.
    Vaccine. 2023 Apr 4:S0264-410X(23)00355-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  909. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  910. PRADA E, Langbecker A, Catalan-Matamoros D
    Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
    Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  911. FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
    The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  912. TOSHKOV D
    What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
    Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  913. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  914. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  915. ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
    Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
    Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  916. PRASAD N, Stoecker C, Xing W, Cho BH, et al
    Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
    Vaccine. 2023 Apr 1:S0264-410X(23)00338-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  917. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  918. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    >> Share

    March 2023
  919. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  920. DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
    Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
    Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  921. HU Y, Wang Y, Shao T, Tang W, et al
    Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
    Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  922. STEIN-ZAMIR C, Shoob H, Abramson D
    Measles clinical presentation, hospitalization and vaccination status among children in a community-wide outbreak.
    Vaccine. 2023 Mar 29:S0264-410X(23)00337-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  923. FUKUDA H, Maeda M, Murata F
    Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
    Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  924. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  925. SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
    Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  926. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  927. PANNUS P, Depickere S, Kemlin D, Georges D, et al
    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
    Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  928. GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
    Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
    Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  929. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  930. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  931. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  932. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  933. DE SANTIS R, Faggioni G, Amoroso A, Ciammaruconi A, et al
    Durability of neutralizing antibodies against yellow fever virus after vaccination in healthy adults.
    Vaccine. 2023 Mar 24:S0264-410X(23)00284-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  934. THWAITES CL, Thanh TT, Ny NTH, Nguyet LA, et al
    Seroprotection against tetanus in southern Vietnam.
    Vaccine. 2023;41:2208-2213.
    >> Share

  935. FREEMAN RE, Leary CS, Graham JM, Albers AN, et al
    Geographic proximity to immunization providers and vaccine series completion among children ages 0-24 months.
    Vaccine. 2023 Mar 22:S0264-410X(23)00297-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  936. VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
    Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
    Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  937. PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
    Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  938. SATO R
    Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
    Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  939. MCCARTY JM, Cassie D, Bedell L
    Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States.
    Vaccine. 2023 Mar 21:S0264-410X(23)00260-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  940. XU S, Duan H, An Y, Jin X, et al
    Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE.
    Vaccine. 2023 Mar 21:S0264-410X(23)00319-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  941. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  942. MURPHY A, Kirby A, De Blasio F
    The economic impact of the introduction of universal rotavirus vaccination on rotavirus gastroenteritis related hospitalisations in children in Ireland.
    Vaccine. 2023 Mar 20:S0264-410X(23)00257-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  943. ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
    Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
    Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  944. WILSON GJ, Rodriguez B, Li SS, Allen M, et al
    Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Vaccine. 2023 Mar 17:S0264-410X(23)00262-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  945. SHAHID S, Ahmed S, Qazi MF, Ali R, et al
    Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.
    Vaccine. 2023 Mar 16:S0264-410X(23)00254-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  946. NAKANO T
    Changes in vaccination administration in Japan.
    Vaccine. 2023 Mar 16:S0264-410X(23)00282-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  947. PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
    Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
    Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  948. RIDDLE MS, Louis Bourgeois A, Clifford A, Jeon S, et al
    Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.
    Vaccine. 2023 Mar 15:S0264-410X(23)00250-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  949. LIN JH, Huang YT, Yu JC, Chan KA, et al
    Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
    Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  950. LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
    Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
    Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  951. KELLY D, O'Donnell K, Marron L, Dwyer R, et al
    Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
    Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  952. WONODI C, Moss W
    Editorial from guest editors for vaccine supplement: Vaccine-derived poliovirus type 2 outbreaks after the cessation of use of oral poliovirus vaccine type 2_ 2016-2021 journal supplement.
    Vaccine. 2023 Mar 11:S0264-410X(23)00244-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  953. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
    Vaccine. 2023;41:1892-1901.
    >> Share

  954. KIM E, He J, Kaufhold RM, McGuinness D, et al
    Evaluation of cross-protection between S. Pneumoniae serotypes 35B and 29 in a mouse model.
    Vaccine. 2023;41:1774-1777.
    >> Share

  955. LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
    Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2023;41:1902-1910.
    >> Share

  956. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  957. ALLEMAN MM, Jorba J, Riziki Y, Henderson E, et al
    Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Vaccine. 2023 Mar 10:S0264-410X(23)00177-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  958. CLAY PA, Thompson TD, Markowitz LE, Ekwueme DU, et al
    Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  959. SEAL AJ, Mohamed HA, Stokes-Walter R, Mohamed S, et al
    Use of an adapted participatory learning and action cycle to increase knowledge and uptake of child vaccination in internally displaced persons camps (IVACS): A cluster-randomised controlled trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00142-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  960. SYLVIE YANG R, Yang Y, Gowetski DB, Tsybovsky Y, et al
    Characterization of Flu MOSAIC nanoparticle vaccine candidate using high performance size-exclusion chromatography to support vaccine process development.
    Vaccine. 2023 Mar 9:S0264-410X(23)00248-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  961. RIVAS DRZ, Ticona JPA, Doss-Gollin S
    Lessons from the Bolivian vaccine mandate.
    Vaccine. 2023 Mar 9:S0264-410X(23)00251-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  962. SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
    Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  963. PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
    Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  964. IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
    Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
    Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  965. CHOWDHURY F, Aziz AB, Ahmmed F, Ahmed T, et al
    The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial.
    Vaccine. 2023 Mar 8:S0264-410X(23)00197-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  966. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Corrigendum to "Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa" [Vaccine 41(1) (2023) 61-67].
    Vaccine. 2023 Mar 8:S0264-410X(23)00168-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  967. GILBERT M, Ablona A, Chang HJ, Grennan T, et al
    Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia.
    Vaccine. 2023 Mar 7:S0264-410X(23)00229-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  968. BACON A, Teixeira M, Costa V, Bone P, et al
    Generation of a thermostable, oral Zika vaccine that protects against virus challenge in non-human primates.
    Vaccine. 2023 Mar 7:S0264-410X(23)00198-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  969. BOONE AC, Kulkarni RR, Cortes AL, Villalobos T, et al
    In ovo HVT vaccination enhances cellular responses at hatch and addition of poly I:C offers minimal adjuvant effects.
    Vaccine. 2023 Mar 7:S0264-410X(23)00238-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  970. YELVERTON V, Hair NL, Ghosh SH, Mfinanga SG, et al
    Corrigendum to "Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania" [Vaccine 40(37) (2022) 5483-5493].
    Vaccine. 2023 Mar 6:S0264-410X(23)00218-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  971. HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
    Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
    Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  972. PRYSLIAK T, Menghwar H, Perez-Casal J
    Complement-mediated killing of Mycoplasma bovis does not play a role in the protection of animals against an experimental challenge.
    Vaccine. 2023;41:1743-1752.
    >> Share

  973. GELORMINI M, Gripenberg M, Marke D, Murray M, et al
    Coverage survey and lessons learned from a pre-emptive cholera vaccination campaign in urban and rural communities affected by landslides and floods in Freetown Sierra Leone.
    Vaccine. 2023 Mar 3:S0264-410X(23)00037-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  974. WU L, Yang S, Huang Z, Liu J, et al
    Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Vaccine. 2023 Mar 3:S0264-410X(23)00226-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  975. BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
    A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Vaccine. 2023;41:1694-1702.
    >> Share

  976. GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
    From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
    Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  977. ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
    Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  978. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Willingness to vaccinate children against COVID-19 declined during the pandemic.
    Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  979. XIE S, Monteiro K, Gjelsvik A
    The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
    Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  980. NEWALL AT, Beutels P, Kis Z, Towse A, et al
    Placing a value on increased flexible vaccine manufacturing capacity for future pandemics.
    Vaccine. 2023 Mar 2:S0264-410X(23)00219-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  981. NARII N, Kitamura T, Komukai S, Zha L, et al
    Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00240-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  982. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
    COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  983. BEAUJEAN M, Uijen RF, Langereis JD, Boccara D, et al
    The immunological effects of intradermal particle-based vaccine delivery using a novel microinjection needle studied in a human skin explant model.
    Vaccine. 2023 Mar 2:S0264-410X(23)00175-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  984. HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
    The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  985. NA L, Banks S, Wang PP
    Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
    Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
    >> Share

    February 2023
  986. DARWAR R, Biya O, Greene SA, Jorba J, et al
    Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
    Vaccine. 2023 Feb 28:S0264-410X(23)00214-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  987. AL ALAWI S, Al Zaabi O, Heffernan ME, Arulappan J, et al
    Knowledge, attitudes and acceptance toward Human papillomavirus (HPV) vaccination: Perspectives of Muslim women and men.
    Vaccine. 2023 Feb 27:S0264-410X(23)00217-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  988. ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
    Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  989. MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
    Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  990. TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
    Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  991. O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
    Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  992. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Erratum to "Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey" [Vaccine 41(1) (2023) 101-108.
    Vaccine. 2023 Feb 25:S0264-410X(23)00107-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  993. CHANG AM, Chen CC, Lee JW, Hou DL, et al
    Effects of a novel recombinant Gonadotropin-Releasing Hormone-1 vaccine on the reproductive function of mixed-breed dogs (Canis familiaris) in Taiwan.
    Vaccine. 2023 Feb 25:S0264-410X(23)00215-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  994. BAKHSHIZADEH GASHTI A, Chahal PS, Gaillet B, Garnier A, et al
    Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate.
    Vaccine. 2023 Feb 24:S0264-410X(23)00201-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  995. ZHANG Y, Na D, Zhang W, Liu X, et al
    Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform.
    Vaccine. 2023;41:1573-1583.
    >> Share

  996. FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
    A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  997. FANTINATO FFST, Wachira VK, Porto VBG, Peixoto HM, et al
    Factors associated with yellow fever vaccine failure: A systematic literature review.
    Vaccine. 2023 Feb 23:S0264-410X(23)00133-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  998. HOSSEINNEZHAD-LAZARJANI E, Doosti A, Sharifzadeh A
    Novel csuC-DNA nanovaccine based on chitosan candidate vaccine against infection with Acinetobacter baumannii.
    Vaccine. 2023 Feb 23:S0264-410X(23)00181-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  999. BENFIELD T, Ramet M, Valentini P, Seppa I, et al
    Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
    Vaccine. 2023 Feb 23:S0264-410X(23)00176-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1000. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1001. CANNON K, Cardona JF, Yacisin K, Thompson A, et al
    Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1002. KASSTAN B, Chantler T, Marcus B, Mounier-Jack S, et al
    Linked poliovirus incidents in the UK, USA and Israel: Silent transmission or missed warnings of vaccine inequity?
    Vaccine. 2023 Feb 22:S0264-410X(23)00178-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1003. KOUIAVSKAIA D, Mirochnitchenko O, Troy S, Chumakov K, et al
    Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines.
    Vaccine. 2023 Feb 22:S0264-410X(23)00052-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1004. ZHANG H, Chen L, Huang Z, Li D, et al
    The effects of parent's health literacy and health beliefs on vaccine hesitancy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1005. SABATO B, Augusto PSA, Lima Goncalves Pereira R, Coutinho Batista Esteves F, et al
    Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model.
    Vaccine. 2023 Feb 21:S0264-410X(23)00166-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1006. HAMBURG M, Poland GA
    The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
    Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1007. MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1008. MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
    Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
    Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1009. LU L, Ma W, Johnson CH, Khan SA, et al
    In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
    Vaccine. 2023 Feb 20:S0264-410X(23)00183-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1010. DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
    Vaccinomics: A scoping review.
    Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1011. USTYUGOVA IV, Pougatcheva S, Farrell T, Strugnell T, et al
    AF03 adjuvant improves anti-hemagglutinin and anti-neuraminidase immune responses induced by licensed seasonal quadrivalent influenza vaccines in mice.
    Vaccine. 2023 Feb 18:S0264-410X(23)00169-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1012. GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
    Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
    Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1013. YI W, Wang H, Qin H, Wang Q, et al
    Construction and efficacy of a new live chimeric C-strain vaccine with DIVA characteristics against classical swine fever.
    Vaccine. 2023 Feb 18:S0264-410X(23)00179-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1014. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1015. SHERMAN SM, Lingley-Heath N, Lai J, Sim J, et al
    Parental acceptance of and preferences for administration of routine varicella vaccination in the UK: A study to inform policy.
    Vaccine. 2023;41:1438-1446.
    >> Share

  1016. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1017. PARODI A, Martini M
    History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
    Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1018. MORAIS A, Morais J, Felix M, Neto Z, et al
    Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1019. DA SILVA AB, Cardoso-Marques NT, Dolores IM, Teixeira LM, et al
    Carriage prevalence, serotype distribution, antimicrobial resistance, pspA typing and pilus islets of Streptococcus pneumoniae isolated from adults living in a Brazilian urban slum.
    Vaccine. 2023;41:1431-1437.
    >> Share

  1020. MEYER C, Goffe L, Antonopoulou V, Graham F, et al
    Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
    Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1021. ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
    The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
    Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  1022. PILIC A, Reda S, Jo CL, Burchett H, et al
    Use of existing systematic reviews for the development of evidence-based vaccination recommendations: Guidance from the SYSVAC expert panel.
    Vaccine. 2023 Feb 16:S0264-410X(23)00162-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1023. BENEDICT KPOZEHOUEN E, Arrudsivah B, Raina Macintyre C
    Knowledge, attitudes and practices of health care workers in a cardiology department on influenza vaccination.
    Vaccine. 2023 Feb 15:S0264-410X(23)00112-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1024. KLOUWENS MJ, Trentelman JJA, Barriales D, Ersoz JI, et al
    The Ixodes ricinus salivary gland proteome during feeding and B. Afzelii infection: New avenues for an anti-tick vaccine.
    Vaccine. 2023 Feb 14:S0264-410X(23)00129-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1025. WAHAB MT, Tan RKJ, Cook AR, Prem K, et al
    Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
    Vaccine. 2023 Feb 14:S0264-410X(23)00160-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1026. VOJICIC J, Grajales AG, Cane A
    Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vaccine. 2023 Feb 14:S0264-410X(23)00130-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1027. SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
    Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
    Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1028. WANKHEDE D, Grover S, Hofman P
    Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1029. AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
    Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
    Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1030. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1031. BARNES K, Faasse K, Colagiuri B
    The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
    Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1032. GETCHELL M, Mantaring EJ, Yee K, Pronyk P, et al
    Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review.
    Vaccine. 2023 Feb 11:S0264-410X(23)00132-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1033. O'LEARY ST, Spina CI, Spielvogle H, Robinson JD, et al
    Development of PIVOT with MI: A motivational Interviewing-Based vaccine communication training for pediatric clinicians.
    Vaccine. 2023 Feb 10:S0264-410X(23)00136-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1034. FACCHIN G, Bella A, Del Manso M, Rota MC, et al
    Decline in reported measles cases in Italy in the COVID-19 era, January 2020 - July 2022: The need to prevent a resurgence upon lifting non-pharmaceutical pandemic measures.
    Vaccine. 2023;41:1286-1289.
    >> Share

  1035. SELL H, Raj Paudel Y, Voaklander D, MacDonald SE, et al
    School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study.
    Vaccine. 2023;41:1333-1341.
    >> Share

  1036. DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
    Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
    Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1037. HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
    Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1038. FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
    Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1039. SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
    Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
    Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1040. BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
    Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1041. OK BAIK Y, Lee Y, Lee C, Kyung Kim S, et al
    A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV(R) in healthy 6 Months-45 years aged participants.
    Vaccine. 2023 Feb 9:S0264-410X(22)01524-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1042. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
    Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1043. WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
    Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1044. PERETTI A, Scorpio DG, Kong WP, Pang YS, et al
    A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques.
    Vaccine. 2023 Feb 8:S0264-410X(23)00128-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1045. BUGHIN J, Cincera M, Peters K, Reykowska D, et al
    Make it or break it: On-time vaccination intent at the time of Covid-19.
    Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1046. DENG HM, Romero N, Allard N, Rowe S, et al
    Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009-2017).
    Vaccine. 2023 Feb 7:S0264-410X(23)00076-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1047. ERDEM R, De Coster I, Withanage K, Mercer LD, et al
    Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
    Vaccine. 2023 Feb 4:S0264-410X(23)00078-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1048. FELL DB, Torok E, Sprague AE, Regan AK, et al
    Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
    Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1049. HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
    Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
    Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1050. SEESEN M, Jearanaiwitayakul T, Limthongkul J, Midoeng P, et al
    A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells.
    Vaccine. 2023 Feb 3:S0264-410X(23)00096-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1051. PARK I, Unger ER, Kemp TJ, Pinto LA, et al
    The second HPV serology meeting: Progress and challenges in standardization of human papillomavirus serology assays.
    Vaccine. 2023;41:1177-1181.
    >> Share

  1052. LI R, Liu H, Fairley CK, Ong JJ, et al
    mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1053. MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
    Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
    Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1054. ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
    Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  1055. HAMADA H, Futamura M, Ito H, Yamamoto R, et al
    Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1056. JOHNSON R, Djaafara B, Haw D, Doohan P, et al
    The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
    >> Share

    January 2023
  1057. UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
    Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1058. PATRICIA WODI A, Marquez P, Mba-Jonas A, Barash F, et al
    Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS).
    Vaccine. 2023 Jan 31:S0264-410X(22)01563-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1059. STONE AE, Rambaran S, Trinh IV, Estrada M, et al
    Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients.
    Vaccine. 2023 Jan 31:S0264-410X(23)00055-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1060. HUANG CY, Chi H, Chang L, Chiu NC, et al
    Typical time courses and appearance of skin reactions at the site of Bacillus Calmette-Guerin vaccination for infants inoculated at 5-8 months of age.
    Vaccine. 2023 Jan 30:S0264-410X(23)00083-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1061. KABIR SULAIMAN S, Isma'il Tsiga-Ahmed F, Sale Musa M, Kabir Sulaiman A, et al
    Prevalence, determinants, and reasons for malaria vaccine hesitancy among caregivers of under-five children in Nigeria: Results from a nationwide cross-sectional survey.
    Vaccine. 2023 Jan 30:S0264-410X(23)00089-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1062. RAABE V, Lai L, Morales J, Xu Y, et al
    Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVDeltaG-ZEBOV-GP).
    Vaccine. 2023 Jan 30:S0264-410X(23)00090-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1063. SESHADRI S, Martin SW, Hills SL, Collins LC Jr, et al
    Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019.
    Vaccine. 2023 Jan 30:S0264-410X(23)00093-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1064. GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
    Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
    Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1065. HARBIN A, Laventhal N, Navin M
    Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
    Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1066. PARODI JB, Indavere A, Bobadilla Jacob P, Toledo GC, et al
    Impact of COVID-19 vaccination in post-COVID cardiac complications.
    Vaccine. 2023 Jan 27:S0264-410X(23)00084-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  1067. MATTA MG, Pulido L, Herrera-Paz JJ, Picco JM, et al
    Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina.
    Vaccine. 2023 Jan 27:S0264-410X(23)00088-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1068. BARAL R, Levin A, Odero C, Pecenka C, et al
    Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Vaccine. 2023 Jan 27:S0264-410X(23)00064-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1069. PIRAS-DOUCE F, Broudic K, Chautard E, Raynal F, et al
    Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Vaccine. 2023 Jan 24:S0264-410X(22)01464-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1070. SUZUKI F, Maeyama JI, Kubota A, Nishimune A, et al
    Effect of cigarette smoke on mucosal vaccine response with activation of plasmacytoid dendritic cells: The outcomes of in vivo and in vitro experiments.
    Vaccine. 2023 Jan 24:S0264-410X(23)00030-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1071. TENG Y, Hanibuchi T, Machida M, Nakaya T, et al
    Psychological determinants of COVID-19 vaccine acceptance: A comparison between immigrants and the host population in Japan.
    Vaccine. 2023 Jan 23:S0264-410X(23)00056-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  1072. ZOLOTAROVA T, Dussault C, Park H, Varsaneux O, et al
    Education increases COVID-19 vaccine uptake among people in Canadian federal prisons in a prospective randomized controlled trial: The EDUCATE study.
    Vaccine. 2023 Jan 23:S0264-410X(23)00061-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1073. MYERS TR, Marquez PL, Gee JM, Hause AM, et al
    The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC's COVID-19 pandemic response.
    Vaccine. 2023 Jan 23:S0264-410X(22)01545-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1074. JOSHI K, Rumpler E, Kennedy-Shaffer L, Bosan R, et al
    Comparative performance of between-population vaccine allocation strategies with applications for emerging pandemics.
    Vaccine. 2023 Jan 23:S0264-410X(22)01579-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1075. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1076. KRAUSE NM, Beets B, Howell EL, Tosteson H, et al
    Collateral damage from debunking mRNA vaccine misinformation.
    Vaccine. 2023;41:922-929.
    >> Share

  1077. RENNERT W, Hindiyeh M, Allahham M, Mercer LD, et al
    Introducing ROTAVAC(R) to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.
    Vaccine. 2023;41:945-954.
    >> Share

  1078. KUZEL TG, Fu J, Anderson M, Stec M, et al
    Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naive and previously-infected individuals.
    Vaccine. 2023;41:879-882.
    >> Share

  1079. FAIZULOEV E, Gracheva A, Korchevaya E, Smirnova D, et al
    Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.
    Vaccine. 2023;41:892-902.
    >> Share

  1080. GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
    COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
    Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1081. MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
    Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  1082. VATCHARAVONGVAN P, Boonyanitchayakul N, Khampachuea P, Sinturong I, et al
    Health Belief Model and parents' acceptance of the Pfizer-BioNTech and Sinopharm COVID-19 vaccine for children aged 5-18 years Old: A national survey.
    Vaccine. 2023 Jan 23:S0264-410X(23)00050-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1083. GRASSLY NC, Andrews N, Cooper G, Stephens L, et al
    Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial.
    Vaccine. 2023 Jan 21:S0264-410X(23)00057-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1084. KRAMER C, Song M, Sufrin CB, Eber GB, et al
    COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons.
    Vaccine. 2023 Jan 21:S0264-410X(23)00060-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1085. DARBY B, Alexander V, Murphy J
    SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
    Vaccine. 2023 Jan 20:S0264-410X(23)00062-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1086. BIANCHI FP, Stefanizzi P, Martinelli A, Brescia N, et al
    COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis.
    Vaccine. 2023 Jan 20:S0264-410X(23)00058-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1087. DUDLEY MZ, Schuh HB, Shaw J, Rimal RN, et al
    COVID-19 vaccination among different types of US Healthcare Personnel.
    Vaccine. 2023 Jan 20:S0264-410X(23)00051-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1088. TRICOU V, Eyre S, Ramjee M, Collini P, et al
    A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Vaccine. 2023 Jan 19:S0264-410X(23)00007-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1089. MARSHALL S, Fleming A, Sahm LJ, Moore AC, et al
    Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory.
    Vaccine. 2023 Jan 18:S0264-410X(23)00036-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  1090. GHORBANI A, Ngunjiri JM, Edward C Abundo M, Pantin-Jackwood M, et al
    Development of in Ovo-Compatible NS1-truncated live attenuated influenza vaccines by modulation of hemagglutinin cleavage and polymerase Acidic X Frameshifting sites.
    Vaccine. 2023 Jan 18:S0264-410X(23)00029-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1091. ZABALZA-BARANGUA A, Poveda-Urkixo I, Mena-Bueno S, Ramirez GA, et al
    Vaccine properties of Brucella melitensis 16MDeltawzm and reactivation of placental infection in pregnant sheep.
    Vaccine. 2023 Jan 16:S0264-410X(23)00028-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1092. MOINI A, Rabiei M, Pirjani R, Abiri A, et al
    COVID‑19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran.
    Vaccine. 2023 Jan 16:S0264-410X(23)00032-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1093. YANG H, Li Z, Zhang R, Guo S, et al
    Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac(R)) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Vaccine. 2023 Jan 13:S0264-410X(23)00031-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  1094. KALRA S, Kalra D, Grafova I, Rubin JS, et al
    Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
    Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1095. BEDSTON S, Lowthian E, Jarvis CI, Akbari A, et al
    COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study.
    Vaccine. 2023 Jan 13:S0264-410X(23)00034-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  1096. KLUWER B, Margrethe Rydland K, Nybru Gleditsch R, Mamelund SE, et al
    Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21.
    Vaccine. 2023 Jan 11:S0264-410X(23)00013-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  1097. DU J, Liu B, Wang T, Zhu Z, et al
    A non-toxic recombinant bivalent chimeric protein rETX(m3)CSA(m4/TMD) as a potential vaccine candidate against enterotoxemia and braxy.
    Vaccine. 2023 Jan 10:S0264-410X(22)01419-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1098. ELLISON TJ, Talbott GC, Henderson DR
    Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.
    Vaccine. 2023;41:304-314.
    >> Share

  1099. MOELLER-ARENDT M, van de Witte S, Nauta J, de Voogd H, et al
    Enhanced passive safety surveillance of Influvac(R) and Influvac(R) Tetra: Results from seven consecutive seasons.
    Vaccine. 2023;41:606-613.
    >> Share

  1100. TAKAHASHI H, Morita M, Kamiya H, Fukusumi M, et al
    Genomic characterization of Japanese meningococcal strains isolated over a 17-year period between 2003 and 2020 in Japan.
    Vaccine. 2023;41:416-426.
    >> Share

  1101. DESCHANVRES C, Levieux K, Launay E, Huby AC, et al
    Non-immunization associated with increased risk of sudden unexpected death in infancy: A national case-control study.
    Vaccine. 2023;41:391-396.
    >> Share

  1102. WAGNER AL, Moniz MH, Stout MJ, Townsel C, et al
    Experiences, risk perceptions, and COVID-19 vaccination outcomes among hospital workers.
    Vaccine. 2023 Jan 9:S0264-410X(23)00012-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1103. NAVIN MC, Scherer AM, Bradley E, Attwell K, et al
    School staff as vaccine advocates: Perspectives on vaccine mandates and the student registration process.
    Vaccine. 2023 Jan 9:S0264-410X(23)00014-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1104. MENON I, Kang SM, Braz Gomes K, Uddin MN, et al
    Laser-assisted intradermal delivery of a microparticle vaccine for respiratory syncytial virus induces a robust immune response.
    Vaccine. 2023 Jan 9:S0264-410X(23)00002-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  1105. KEVIN YIN J, Harris RC, Loiacono MM, Chit A, et al
    Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al.
    Vaccine. 2023 Jan 9:S0264-410X(22)01559-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1106. CHAWANPAIBOON S, Anuwutnawin S, Kanjanapongporn A, Pooliam J, et al
    Breastfeeding women's attitudes towards and acceptance and rejection of COVID-19 vaccination: Implementation research.
    Vaccine. 2023 Jan 9:S0264-410X(23)00015-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1107. OZAKI T, Nishimura N, Gotoh K, Takemoto K, et al
    Anti-varicella-zoster virus antibody titers and seroprotection status from before the first dose of varicella vaccination to before entering elementary school in one region in Japan.
    Vaccine. 2023 Jan 9:S0264-410X(23)00010-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  1108. WHITEHEAD HS, French CE, Caldwell DM, Letley L, et al
    A systematic review of communication interventions for countering vaccine misinformation.
    Vaccine. 2023 Jan 9:S0264-410X(22)01593-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1109. TULLOCH JSP, Lawrenson K, Gordon AL, Ghebrehewet S, et al
    COVID-19 vaccine hesitancy in care home staff: A survey of Liverpool care homes.
    Vaccine. 2023 Jan 9:S0264-410X(23)00009-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  1110. MORO PL, Zhang B, Ennulat C, Harris M, et al
    Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Vaccine. 2023 Jan 9:S0264-410X(23)00016-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1111. EBRAHIMI N, Mazdak M, Shaygannejad V, Mirmosayyeb O, et al
    CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Vaccine. 2023 Jan 6:S0264-410X(23)00004-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  1112. JANG Y, Cho H, Chun J, Park K, et al
    Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
    Vaccine. 2023 Jan 6:S0264-410X(22)01602-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1113. LUPINACCI R, Rupp R, Wittawatmongkol O, Jones J, et al
    A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Vaccine. 2023 Jan 6:S0264-410X(22)01575-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1114. LONG Z, He J, Shuai Q, Zhang K, et al
    Influenza vaccination-induced H3 stalk-reactive memory B-cell clone expansion.
    Vaccine. 2023 Jan 6:S0264-410X(22)01603-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1115. CUTLAND CL, Peyrani P, Webber C, Newton R, et al
    A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
    Vaccine. 2023 Jan 6:S0264-410X(22)01461-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1116. XIE L, Ren J, Min S, Zhu X, et al
    Knowledge, attitude, and perception regarding HPV-related diseases and vaccination among the general public in Guizhou Province of China.
    Vaccine. 2023 Jan 5:S0264-410X(22)01538-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1117. TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
    Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  1118. TORALES J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, et al
    An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Vaccine. 2023;41:109-118.
    >> Share

  1119. HOMAIRA N, Strachan R, Quinn H, Beggs S, et al
    Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.
    Vaccine. 2023;41:85-91.
    >> Share

  1120. MAERTZDORF KM, Rietman ML, Lambooij MS, Verschuren WMM, et al
    Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population.
    Vaccine. 2023 Jan 4:S0264-410X(23)00001-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  1121. VALENCIA-HERNANDEZ AM, Zillinger T, Ge Z, Tan PS, et al
    Complexing CpG adjuvants with cationic liposomes enhances vaccine-induced formation of liver T(RM) cells.
    Vaccine. 2023 Jan 4:S0264-410X(22)01572-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1122. IMMINK MM, Kemmeren JM, Broeders L, Bekker MN, et al
    Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands.
    Vaccine. 2023 Jan 3:S0264-410X(22)01596-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1123. BAGGA S, Krishnan A, Dar L
    Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
    Vaccine. 2023 Jan 3:S0264-410X(22)01594-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1124. REGO RT, Kenney B, Ngugi AK, Espira L, et al
    COVID-19 vaccination refusal trends in Kenya over 2021.
    Vaccine. 2023 Jan 3:S0264-410X(22)01601-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1125. OVERBO J, Aziz A, Zaman K, Clemens J, et al
    Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01599-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1126. SONGOL A, Amiri-Farahani L, Haghani S, Pezaro S, et al
    Comparing the effect of parental education via both lecture and film upon vaccination uptake for children under one year of age: A cluster randomized clinical trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01522-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1127. SHOOK NJ, Oosterhoff B, Sevi B
    A longitudinal assessment of variability in COVID-19 vaccine hesitancy and psychosocial correlates in a national United States sample.
    Vaccine. 2023 Jan 2:S0264-410X(22)01600-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1128. FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
    Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
    Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
    >> Share

    December 2022
  1129. MOETLHOA B, Tjale M, Pretorius A, Hayeshi R, et al
    Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13.
    Vaccine. 2022 Dec 31:S0264-410X(22)01591-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1130. AZUMA M, Oishi K, Akeda Y, Morino S, et al
    Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naive adults aged >/= 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
    Vaccine. 2022 Dec 31:S0264-410X(22)01595-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1131. KIM TV, Pham TND, Le DH, Dao DVB, et al
    Significant gaps in hepatitis B vaccination in adults in Viet Nam: Important targets toward hepatitis B elimination by 2030.
    Vaccine. 2022 Dec 30:S0264-410X(22)01577-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1132. BURROWS H, Antillon M, Gauld JS, Kim JH, et al
    Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Vaccine. 2022 Dec 29:S0264-410X(22)01557-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1133. ZUBKOVA I, Zhao Y, Cui Q, Kachko A, et al
    Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Vaccine. 2022 Dec 29:S0264-410X(22)01590-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1134. WANG H, Cao L, Logue CM, Barbieri NL, et al
    Evaluation of immunogenicity and efficacy of the enterobactin conjugate vaccine in protecting chickens from colibacillosis.
    Vaccine. 2022 Dec 28:S0264-410X(22)01592-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1135. TOTTEY S, Shoji Y, Mark Jones R, Musiychuk K, et al
    Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.
    Vaccine. 2022 Dec 28:S0264-410X(22)01573-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1136. GAMBLE A, Hastings TJ, Westrick SC, Smith M, et al
    COVID-19 booster vaccination in rural community pharmacies.
    Vaccine. 2022 Dec 26:S0264-410X(22)01576-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1137. XIE Z, Hamadi HY, Mainous AG, Hong YR, et al
    Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity.
    Vaccine. 2022 Dec 23:S0264-410X(22)01568-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1138. ANDREJKO KL, Myers JF, Openshaw J, Fukui N, et al
    Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
    Vaccine. 2022 Dec 23:S0264-410X(22)01578-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1139. CURRY S, Kaufhold RM, Monslow MA, Zhang Y, et al
    Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models.
    Vaccine. 2022 Dec 22:S0264-410X(22)01531-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1140. SAIAG E, Alcalay Y, Marudi O, Orr-Urtreger A, et al
    Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older.
    Vaccine. 2022 Dec 21:S0264-410X(22)01560-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1141. WAND O, Breslavsky A, Bar-Shai A, Levy C, et al
    One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine.
    Vaccine. 2022 Dec 21:S0264-410X(22)01567-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1142. TYAGI P, Ganguly M, Manney S, Wadkar K, et al
    Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates.
    Vaccine. 2022 Dec 21:S0264-410X(22)01543-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1143. SIENA E, Schiavetti F, Borgogni E, Taccone M, et al
    Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.
    Vaccine. 2022 Dec 21:S0264-410X(22)01519-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1144. XU S, Huang R, Sy LS, Hong V, et al
    A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination.
    Vaccine. 2022 Dec 20:S0264-410X(22)01561-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1145. RANE MS, Robertson MM, Kulkarni SG, Frogel D, et al
    Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Vaccine. 2022 Dec 20:S0264-410X(22)01564-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1146. WILLIAMS KV, Moehling Geffel K, Alcorn JF, Patricia Nowalk M, et al
    Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
    Vaccine. 2022 Dec 19:S0264-410X(22)01566-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1147. DUDLEY MZ, Barnett EE, Paulenich A, Omer SB, et al
    Characterization of parental intention to vaccinate elementary school aged children in the state of California.
    Vaccine. 2022 Dec 19:S0264-410X(22)01544-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1148. BOISSON A, Morgan CE, Stover A, Ngimbi P, et al
    Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool.
    Vaccine. 2022 Dec 16:S0264-410X(22)01542-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1149. YIH WK, Daley MF, Duffy J, Fireman B, et al
    A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
    Vaccine. 2022 Dec 16:S0264-410X(22)01541-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1150. MIDDLETON BF, Danchin M, Fathima P, Bines JE, et al
    Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006 - 2021.
    Vaccine. 2022 Dec 16:S0264-410X(22)01525-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1151. SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al
    Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1152. PAPAZACHARIOU A, Tsioutis C, Lytras T, Malikides O, et al
    The impact of seasonal influenza vaccination uptake on COVID-19 vaccination attitudes in a rural area in Greece.
    Vaccine. 2022 Dec 15:S0264-410X(22)01539-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1153. VAUX S, Fonteneau L, Pefau M, Venier AG, et al
    Vaccination against influenza, measles, pertussis and varicella in workers in healthcare facilities in France: A national cross-sectional study in 2019.
    Vaccine. 2022 Dec 15:S0264-410X(22)01537-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1154. OLAYINKA F, Sauer M, Menning L, Summers D, et al
    Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2).
    Vaccine. 2022 Dec 15:S0264-410X(22)01451-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1155. MAERTENS K, Orije MRP, Huoi C, Boisnard F, et al
    Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP approximately T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy.
    Vaccine. 2022 Dec 15:S0264-410X(22)01535-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1156. CHEN L, Levine MZ, Zhou S, Bai T, et al
    Mild and asymptomatic influenza B virus infection among unvaccinated pregnant persons: Implication for effectiveness of non-pharmaceutical intervention and vaccination to prevent influenza.
    Vaccine. 2022 Dec 14:S0264-410X(22)01468-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1157. OHNO M, Sagata M, Sekiya T, Nomura N, et al
    Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.
    Vaccine. 2022 Dec 14:S0264-410X(22)01534-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1158. IBROCI E, Liu X, Lieb W, Jessel R, et al
    Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort.
    Vaccine. 2022 Dec 14:S0264-410X(22)01226-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1159. PALMU AAM, Nieminen H, Lahdenkari M, Palmu AA, et al
    A retrospective nationwide register-based study to evaluate the non-specific effects of first MMR vaccination among children in Finland.
    Vaccine. 2022 Dec 14:S0264-410X(22)01536-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1160. BISANZIO D, Davis AE, Talbird SE, Van Effelterre T, et al
    Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study.
    Vaccine. 2022 Dec 14:S0264-410X(22)01449-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1161. GATWOOD J, Brookhart A, Kinney O, Hagemann T, et al
    Impact of patient and provider nudges on addressing herpes zoster vaccine series completion.
    Vaccine. 2022 Dec 14:S0264-410X(22)01530-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1162. SUN L, Zhao N, Li H, Wang B, et al
    Construction of a Lactobacillus plantarum-based claudin-3 targeting delivery system for the development of vaccines against Eimeria tenella.
    Vaccine. 2022 Dec 14:S0264-410X(22)01528-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1163. SAINI SJ, Carle AC, Forsyth AR, Chi DL, et al
    Association between caregiver opposition to topical fluoride and COVID-19 vaccines.
    Vaccine. 2022 Dec 14:S0264-410X(22)01532-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1164. MARIA FP, Maria BA, Dario RO, Paula AP, et al
    Effectiveness of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies.
    Vaccine. 2022 Dec 13:S0264-410X(22)01521-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1165. BILI A, Dobson S, Quinones J, Phongsamart W, et al
    A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
    Vaccine. 2022 Dec 13:S0264-410X(22)01344-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1166. GUO J, Zhang H, Zhang H, Lai X, et al
    Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Vaccine. 2022 Dec 13:S0264-410X(22)01515-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1167. SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al
    Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
    Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1168. HALL PA, Meng G, Boudreau C, Hudson A, et al
    Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
    Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1169. CHO BH, Athar HM, Bates LG, Yarnoff BO, et al
    Patient flow time data of COVID-19 vaccination clinics in 23 sites, United States, April and May 2021.
    Vaccine. 2022 Dec 12:S0264-410X(22)01527-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1170. CHIBA S, Hatta M, Pattinson D, Yasuhara A, et al
    Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
    Vaccine. 2022 Dec 12:S0264-410X(22)01518-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1171. CUDDIHY MT, Berger WL, Cummings PL, Keith R, et al
    An organizational assessment of 101 Community-Based Adult Services centers to identify and address gaps in influenza vaccination among Medicare-Medicaid beneficiaries.
    Vaccine. 2022 Dec 10:S0264-410X(22)01490-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1172. PEPIN S, Samson SI, Alvarez FP, Dupuy M, et al
    Corrigendum to "Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres" [Vaccin
    Vaccine. 2022 Dec 9:S0264-410X(22)01483-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1173. FERNANDES NEHAB M, Goncalves Camacho K, Teixeira Reis A, Junqueira-Marinho MF, et al
    Willingness of Brazilian caregivers in having their children and adolescents vaccinated against Covid-19.
    Vaccine. 2022 Dec 9:S0264-410X(22)01520-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1174. WALLACE AS, Ryman TK, Privor-Dumm L, Morgan C, et al
    Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030.
    Vaccine. 2022 Dec 8:S0264-410X(22)01452-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1175. CHEN S, Gao S, Li J, Li J, et al
    Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China.
    Vaccine. 2022 Dec 8:S0264-410X(22)01498-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1176. CERNUSCHI T, Hall S, Malvolti S, Bloem P, et al
    Improving access to human papillomavirus vaccines: A case study in the IA2030 core principle of partnership.
    Vaccine. 2022 Dec 7:S0264-410X(22)01453-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1177. HEININGER U, Buttery J, Kochhar S
    Harmonized case definitions for endpoints in vaccine efficacy trials are needed.
    Vaccine. 2022 Dec 7:S0264-410X(22)01494-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1178. NAGEL J, Jonsson G, Nilsson JA, Manuswin C, et al
    Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis.
    Vaccine. 2022 Dec 7:S0264-410X(22)01499-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1179. ANDERSON-CHAVARRIA M, Turner J
    Searching for the 'Trigger': An ethnographic analysis of parental beliefs regarding autism causation and vaccination in Puerto Rico.
    Vaccine. 2022 Dec 7:S0264-410X(22)01488-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1180. LATKIN C, Dayton L, Miller J, Eschliman E, et al
    Trusted information sources in the early months of the COVID-19 pandemic predict vaccination uptake over one year later.
    Vaccine. 2022 Dec 6:S0264-410X(22)01510-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1181. NGUYEN KH, Zhao R, Mullins C, Corlin L, et al
    Trends in vaccination schedules and up-to-date status of children 19-35 months, United States, 2015-2020.
    Vaccine. 2022 Dec 5:S0264-410X(22)01422-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1182. PROSPERI C, Thangaraj JWV, Hasan AZ, Kumar MS, et al
    Added value of the measles-rubella supplementary immunization activity in reaching unvaccinated and under-vaccinated children, a cross-sectional study in five Indian districts, 2018-20.
    Vaccine. 2022 Dec 5:S0264-410X(22)01396-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1183. SERISIER A, Beale S, Boukari Y, Hoskins S, et al
    A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales.
    Vaccine. 2022 Dec 5:S0264-410X(22)01497-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1184. UTTEKAR S, MacDonald N, Orenstein WA, Danchin M, et al
    Empowering Health Workers to Build Public Trust in Vaccination: Experience from the International Pediatric Association's Online Vaccine Trust Course, 2020-2021.
    Vaccine. 2022 Dec 2:S0264-410X(22)01485-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1185. FENG T, Wang X, Li J, Wang C, et al
    Common issues and improvement solution of vaccine hesitancy in children with underlying neurological conditions: Experience from one National Children's Medical Center in China.
    Vaccine. 2022 Dec 2:S0264-410X(22)01486-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1186. HOES J, King AJ, Berkhof J, de Melker HE, et al
    High vaccine effectiveness persists for ten years after HPV16/18 vaccination among young Dutch women.
    Vaccine. 2022 Dec 2:S0264-410X(22)01471-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1187. IWAI-SAITO K, Sato K, Kondo K
    Associations of influenza and pneumococcal vaccinations with burdens of older family caregivers: The Japan Gerontological Evaluation study (JAGES) cross-sectional study.
    Vaccine. 2022 Dec 2:S0264-410X(22)01460-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1188. MACAJ M, Perdochova L, Jakubikova J
    Streptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008-2019).
    Vaccine. 2022 Dec 2:S0264-410X(22)01423-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  1189. CASPERSEN IH, Juvet LK, Feiring B, Laake I, et al
    Menstrual disturbances in 12- to 15-year-old girls after one dose of COVID-19 Comirnaty vaccine: Population-based cohort study in Norway.
    Vaccine. 2022 Dec 2:S0264-410X(22)01492-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1190. STOLIAROFF-PEPIN A, Peine C, Herath T, Lachmann J, et al
    Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
    Vaccine. 2022 Dec 2:S0264-410X(22)01489-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1191. AL-KASSAB-CORDOVA A, Silva-Perez C, Mendez-Guerra C, Sangster-Carrasco L, et al
    Inequalities in infant vaccination coverage during the COVID-19 pandemic: A population-based study in Peru.
    Vaccine. 2022 Dec 2:S0264-410X(22)01491-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1192. INGRAM C, Roe M, Downey V, Phipps L, et al
    Exploring key informants' perceptions of Covid-19 vaccine hesitancy in a disadvantaged urban community in Ireland: Emergence of a '4Cs' model.
    Vaccine. 2022 Dec 2:S0264-410X(22)01496-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1193. BENDER FL, Rief W, Wilhelm M
    Really just a little prick? A meta-analysis on adverse events in placebo control groups of seasonal influenza vaccination RCTs.
    Vaccine. 2022 Dec 1:S0264-410X(22)01431-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1194. WONG HL, Tworkoski E, Ke Zhou C, Hu M, et al
    Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.
    Vaccine. 2022 Dec 1:S0264-410X(22)01493-1. doi: 10.1016/j.vaccine.2022.
    >> Share

    November 2022
  1195. HSIAO A, Struckmann V, Stephani V, Mmbando D, et al
    Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Vaccine. 2022 Nov 29:S0264-410X(22)01430-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1196. TURNER OVERTON E, Schmidt D, Vidojkovic S, Menius E, et al
    A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN(R) vaccine in healthy adults.
    Vaccine. 2022 Nov 29:S0264-410X(22)01333-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1197. SULLIVAN KM, Farraye FA, Winthrop KL, Willer DO, et al
    Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Vaccine. 2022 Nov 29:S0264-410X(22)01329-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1198. TANG S, Liu X, Jia Y, Chen H, et al
    Education level modifies parental hesitancy about COVID-19 vaccinations for their children.
    Vaccine. 2022 Nov 29:S0264-410X(22)01484-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1199. SUN Y, Huang SK, Arlikatti S, Lindell MK, et al
    What attributes influence rural household's willingness to get vaccinated for COVID-19? Perspectives from six Chinese townships.
    Vaccine. 2022 Nov 29:S0264-410X(22)01487-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1200. POOLEY HB, Panag G, Plain KM, de Silva K, et al
    IP10 is a predictor of successful vaccine protection against paratuberculosis infection in sheep.
    Vaccine. 2022 Nov 28:S0264-410X(22)01418-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1201. UIJEN RF, van Beek LF, van Opzeeland F, Simonetti E, et al
    Intradermal administration of the pneumococcal conjugate vaccine in mice results in lower antibody responses as compared to intramuscular administration.
    Vaccine. 2022 Nov 26:S0264-410X(22)01456-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1202. CHRISTOU-ERGOS M, Wiley KE, Leask J
    Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Vaccine. 2022 Nov 26:S0264-410X(22)01447-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1203. JOSHI S, Anantharaman D, Muwonge R, Bhatla N, et al
    Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.
    Vaccine. 2022 Nov 26:S0264-410X(22)01457-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1204. STOCKER A, Hoffmann J, Mause L, Neufeind J, et al
    What impact does the attitude toward COVID-19 vaccination have on physicians as vaccine providers? A cross sectional study from the German outpatient sector.
    Vaccine. 2022 Nov 25:S0264-410X(22)01466-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1205. ZARZECZNA N, Bertlich T, Veckalov B, Rutjens BT, et al
    Spirituality is associated with Covid-19 vaccination scepticism.
    Vaccine. 2022 Nov 25:S0264-410X(22)01463-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1206. RADER B, Chiang ME, Kriner DL, Weintraub RL, et al
    Persistent drop in confidence following US recommended pause of Ad26.COV2.S vaccine administration.
    Vaccine. 2022 Nov 25:S0264-410X(22)01448-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1207. MICHELLE DRIEDGER S, Capurro G, Tustin J, Jardine CG, et al
    "I won't be a guinea pig": Rethinking public health communication and vaccine hesitancy in the context of COVID-19.
    Vaccine. 2022 Nov 25:S0264-410X(22)01469-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1208. LIP A, Pateman M, Fullerton MM, Chen HM, et al
    Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping review.
    Vaccine. 2022 Nov 24:S0264-410X(22)01225-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1209. BUDIGAN NI H, de Broucker G, Patenaude BN, Dudley MZ, et al
    Economic impact of vaccine safety incident in Ukraine: The economic case for safety system investment.
    Vaccine. 2022 Nov 24:S0264-410X(22)01374-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1210. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
    Vaccine. 2022 Nov 24:S0264-410X(22)01467-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1211. HUMBLE RM, Scott SD, Dube E, Olson J, et al
    The impact of the COVID-19 pandemic on parents' perceptions and acceptance of routine childhood vaccination in Canada: A national longitudinal study.
    Vaccine. 2022 Nov 24:S0264-410X(22)01465-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1212. TANAKA H, Mukai J, Kushibiki K, Mizushima S, et al
    Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
    Vaccine. 2022 Nov 24:S0264-410X(22)01462-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1213. TSURANE K, Umehara N, Nakayama T, Okada K, et al
    Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society.
    Vaccine. 2022;40:7122-7129.
    >> Share

  1214. CAETANO C, Morgado ML, Patricio P, Leite A, et al
    Measuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal.
    Vaccine. 2022;40:7115-7121.
    >> Share

  1215. MARCHETTI F, Lamiani G, Bona M, Amerighi C, et al
    Developing communication tools on rotavirus vaccination to support family paediatricians in Italy.
    Vaccine. 2022;40:7108-7114.
    >> Share

  1216. KAUFMANN J, DeVoe JE, Angier H, Moreno L, et al
    Association of parent influenza vaccination and early childhood vaccinations using linked electronic health record data.
    Vaccine. 2022;40:7097-7107.
    >> Share

  1217. HASSAN YAM, Daud Ali M, Al-Eid RR, Al-Ghuraya FA, et al
    A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Vaccine. 2022;40:7087-7096.
    >> Share

  1218. FRANCO C, Herazo-Padilla N, Castaneda JA
    A queueing Network approach for capacity planning and patient Scheduling: A case study for the COVID-19 vaccination process in Colombia.
    Vaccine. 2022;40:7073-7086.
    >> Share

  1219. ZHOU W, Tang B, Bai Y, Shao Y, et al
    The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Vaccine. 2022;40:7141-7150.
    >> Share

  1220. WILLAME C, Dodd C, Duran CE, Elbers R, et al
    Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.
    Vaccine. 2022 Nov 22:S0264-410X(22)01429-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1221. OZDARENDELI A, Sezer Z, Pavel STI, Inal A, et al
    Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
    Vaccine. 2022 Nov 22:S0264-410X(22)01380-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1222. MATHEWS KO, Norris JM, Phalen D, Malikides N, et al
    Factors associated with Q fever vaccination in Australian wildlife rehabilitators.
    Vaccine. 2022 Nov 21:S0264-410X(22)01364-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  1223. TRAN QM, Soda J, Siraj A, Moore S, et al
    Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling.
    Vaccine. 2022 Nov 21:S0264-410X(22)01426-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1224. SEEGER JD, Amend KL, Turnbull BR, Zhou L, et al
    Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States.
    Vaccine. 2022 Nov 21:S0264-410X(22)01307-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1225. ELICABE RJ, Distel MN, Jofre BL, Leporati M, et al
    Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Vaccine. 2022 Nov 21:S0264-410X(22)01416-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1226. UTAZI CE, Aheto JMK, Wigley A, Tejedor-Garavito N, et al
    Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria.
    Vaccine. 2022 Nov 19:S0264-410X(22)01420-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1227. FEKETE M, Horvath A, Santa B, Tomisa G, et al
    COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary.
    Vaccine. 2022 Nov 18:S0264-410X(22)01415-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1228. ZHANG Z, Shi J, Zhang X, Guo X, et al
    Willingness of parents of 9-to-18-year-old females in China to vaccinate their daughters with HPV vaccine.
    Vaccine. 2022 Nov 18:S0264-410X(22)01404-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  1229. NOVAK A, Hindriks E, Hoek A, Veraart C, et al
    Cellular and humoral immune responsiveness to inactivated Leptospira interrogans in dogs vaccinated with a tetravalent Leptospira vaccine.
    Vaccine. 2022 Nov 18:S0264-410X(22)01417-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1230. NIQUEUX E, Flodrops M, Allee C, Lebras MO, et al
    Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks.
    Vaccine. 2022 Nov 18:S0264-410X(22)01398-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1231. AMPOFO AG, Mackenzie L, Boyes AW
    HPV vaccination: Intention to participate among female senior high school students in Ghana.
    Vaccine. 2022 Nov 18:S0264-410X(22)01383-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  1232. MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al
    SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
    Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1233. KAHN AL, Steffen CA, Henaff L, MacDonald NE, et al
    COVID-19 vaccine policy development in a sample of 44 countries - Key findings from a December 2021 survey of National Immunization Technical Advisory Groups (NITAGs).
    Vaccine. 2022 Nov 17:S0264-410X(22)01427-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1234. KIM J, Kim ED, Shin HS, Han SJ, et al
    Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops.
    Vaccine. 2022 Nov 16:S0264-410X(22)01192-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1235. KALKOWSKA DA, Wassilak SGF, Pallansch MA, Burns CC, et al
    Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Vaccine. 2022 Nov 16:S0264-410X(22)01336-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  1236. POURIAYEVALI MH, Teimoori A, Esmaeili S, Abdoli A, et al
    Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856-2868].
    Vaccine. 2022;40:7009.
    >> Share

  1237. PANICKAN S, Bhatia S, Bhat S, Bhandari N, et al
    Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens.
    Vaccine. 2022;40:6998-7008.
    >> Share

  1238. ALFANO V, Ercolano S
    Your vaccine attitude determines your altitude. What are the determinants of attitudes toward vaccination?
    Vaccine. 2022;40:6987-6997.
    >> Share

  1239. TURBYFILL C, Adams K, Tenforde MW, Murray NL, et al
    Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Vaccine. 2022;40:6979-6986.
    >> Share

  1240. KULKARNI AV, Jaggaiahgari S, Iyengar S, Simhadri V, et al
    Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.
    Vaccine. 2022;40:6971-6978.
    >> Share

  1241. MOORE KL, Tan L
    Preferential recommendations for vaccines: Time for a structured, transparent process.
    Vaccine. 2022;40:6893-6894.
    >> Share

  1242. HE H, Zhu Y, Jin M, Zhou Y, et al
    The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study.
    Vaccine. 2022;40:6956-6962.
    >> Share

  1243. ATTWELL K, Rizzi M, Paul KT
    Consolidating a research agenda for vaccine mandates.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01384.
    >> Share

  1244. HANSEN J, Yee A, Lewis N, Li S, et al
    Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01395.
    >> Share

  1245. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01301.
    >> Share

  1246. FIX J, Vielot NA, Lund JL, Weber DJ, et al
    Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01347.
    >> Share

  1247. ZIMMERMAN T, Shiroma K, Fleischmann KR, Xie B, et al
    Misinformation and COVID-19 vaccine hesitancy.
    Vaccine. 2022 Nov 14:S0264-410X(22)01402-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  1248. VANWORMER JJ, Alicea G, Weichelt BP, Berg RL, et al
    COVID-19 vaccine coverage disparities in rural and farm children.
    Vaccine. 2022 Nov 14:S0264-410X(22)01403-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  1249. FABIANI M, Mateo-Urdiales A, Sacco C, Rota MC, et al
    Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Vaccine. 2022 Nov 14:S0264-410X(22)01399-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1250. JACKSON ML, Phillips CH, Wellwood S, Kiniry E, et al
    Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01397.
    >> Share

  1251. KPOZEHOUEN EB, Tan T, Macintyre CR
    Uptake of influenza, pneumococcal and herpes zoster vaccines among people with heart failure and atrial fibrillation.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01377.
    >> Share

  1252. QI W, Qingfeng L, Jing Z, Maolin Z, et al
    A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model.
    Vaccine. 2022 Nov 11. pii: S0264-410X(22)01327.
    >> Share

  1253. LUKEHART SA, Molini B, Gomez A, Godornes C, et al
    Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum.
    Vaccine. 2022 Nov 11. pii: S0264-410X(22)01372.
    >> Share

  1254. DE FIGUEIREDO A, Simas C, Larson HJ
    COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: A multi-country cross-sectional study.
    Vaccine. 2022 Nov 10:S0264-410X(22)01310-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  1255. YU Z, Keskinocak P, Sokol J, Chen YH, et al
    Flexible analytic model to inform multi-stakeholder pediatric vaccine scheduling decisions.
    Vaccine. 2022 Nov 9. pii: S0264-410X(22)01198.
    >> Share

  1256. BAI Q, Wang Z, An Y, Tian J, et al
    Chitosan-functionalized graphene oxide as adjuvant in HEV P239 vaccine.
    Vaccine. 2022 Nov 9. pii: S0264-410X(22)01375.
    >> Share

  1257. YU X, Suo L, Li W, Chen W, et al
    Molecular surveillance of rubella virus in Beijing, China during 2010-2021: Progress and challenges in rubella elimination.
    Vaccine. 2022;40:6857-6863.
    >> Share

  1258. REN H, Li H, Cao L, Wang Z, et al
    Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice.
    Vaccine. 2022;40:6830-6838.
    >> Share

  1259. ECHEVERRIA-LONDONO S, Hartner AM, Li X, Roth J, et al
    Exploring the subnational inequality and heterogeneity of the impact of routine measles immunisation in Africa.
    Vaccine. 2022;40:6806-6817.
    >> Share

  1260. MARTINI M, Orsini D
    The fight against poliomyelitis through the history: past, present and hopes for the future. Albert Sabin's missing Nobel and his "gift to all the world's children".
    Vaccine. 2022;40:6802-6805.
    >> Share

  1261. TRENTELMAN JJA, de Vogel FA, Colstrup E, Sima R, et al
    Identification of novel conserved Ixodes vaccine candidates; a promising role for non-secreted salivary gland proteins.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01292.
    >> Share

  1262. MARSHALL T, Addison M, Crawford NW, Buttery JP, et al
    Aiming too high: Shoulder injury related to vaccine administration (SIRVA): A case series.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01368.
    >> Share

  1263. HASHIMOTO M, Aoe S, Kawazu Y, Seki NM, et al
    Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01379.
    >> Share

  1264. MOLL K, Lufkin B, Fingar KR, Ke Zhou C, et al
    Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Vaccine. 2022 Nov 8:S0264-410X(22)01373-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  1265. LOPEZ-DORIGA RUIZ P, Gunnes N, Michael Gran J, Karlstad O, et al
    Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01367.
    >> Share

  1266. KIRTLAND KA, Raghunathan T, Patel Murthy B, Li J, et al
    Estimating vaccination coverage for routinely recommended vaccines among children aged 24months and adolescents aged 13 through 17years using data from immunization information systems in the United States.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01341.
    >> Share

  1267. OSOWICKI J, Morgan HJ, Harris A, Clothier HJ, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01366.
    >> Share

  1268. HAO XB, Anand M, Wang TR, Rao AR, et al
    Reducing COVID vaccine hesitancy by inducing a comparative mindset.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01359.
    >> Share

  1269. BEALE S, Burns R, Braithwaite I, Byrne T, et al
    Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01362.
    >> Share

  1270. SKAWRAN S, Schiesser H, Maurer A, Sartoretti T, et al
    Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01376.
    >> Share

  1271. WU YY, Zhang W
    Demographic disparities in COVID-19 vaccine hesitancy among U.S. adults: Analysis of household pulse survey data from Jul 21 to Oct 11 in 2021.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01381.
    >> Share

  1272. TAKEUCHI Y, Iwagami M, Ono S, Michihata N, et al
    A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01370.
    >> Share

  1273. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey.
    Vaccine. 2022 Nov 7:S0264-410X(22)01371-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  1274. GHIANI M, Hagemann C, Friedrich J, Maywald U, et al
    Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01346.
    >> Share

  1275. LEUNG J, Gray EB, Anderson TC, Sharkey SM, et al
    Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01328.
    >> Share

  1276. THOMMES E, Coudeville L, Muhammad R, Martin M, et al
    Public health impact and cost-effectiveness of implementing a 'pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01343.
    >> Share

  1277. KRASSELT J, Robin D, Fadda M, Geutjes A, et al
    Tick-Talk: Parental online discourse about TBE vaccination.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01326.
    >> Share

  1278. PRIYAMVADA L, Carson WC, Ortega E, Navarra T, et al
    Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo.
    Vaccine. 2022 Nov 4. pii: S0264-410X(22)01360.
    >> Share

  1279. MORSTEAD T, Zheng J, Sin NL, DeLongis A, et al
    Perceived threat and coping responses during the COVID-19 pandemic: Prospective associations with vaccine hesitancy.
    Vaccine. 2022 Nov 4. pii: S0264-410X(22)01363.
    >> Share

  1280. RICKS T, Trent MJ, MacIntyre CR
    Predictors of herpes zoster vaccination among Australian adults aged 65 and over.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01332.
    >> Share

  1281. WATESKA AR, Patricia Nowalk M, Lin CJ, Harrison LH, et al
    Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01340.
    >> Share

  1282. MALDEN DE, Gee J, Glenn S, Li Z, et al
    Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01361.
    >> Share

  1283. KURATA T, Miyama T, Kanbayashi D, Kaida Y, et al
    Increasing seroprevalence but waning herd immunity against measles after elimination: Longitudinal seroepidemiology of measles in Osaka Prefecture, Japan, 2003-2020.
    Vaccine. 2022;40:6581-6588.
    >> Share

  1284. HAYMAN B, Kumar Suri R, Downham M
    Sustainable vaccine manufacturing in low- and middle-Income countries.
    Vaccine. 2022 Nov 2. pii: S0264-410X(22)01305.
    >> Share

  1285. FISHER DG, Gnazzo V, Holthausen DJ, Lopez CB, et al
    Non-standard viral genome-derived RNA activates TLR3 and type I IFN signaling to induce cDC1-dependent CD8+ T-cell responses during vaccination in mice.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01312.
    >> Share

  1286. CAREY KA, Newman LM, Spicknall IH
    Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01291.
    >> Share

  1287. MORRILL JC, Peters CJ, Bettinger GE, Palermo PM, et al
    Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01339.
    >> Share

  1288. TOMPKINS LK, Baggs J, Myers TR, Gee JM, et al
    Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01342.
    >> Share

  1289. CHANG CT, Lim XJ, Chew CC, Rajan P, et al
    Preferences and willingness of accepting COVID-19 vaccine booster: Results from a middle-income country.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01334.
    >> Share

  1290. LUCINDE RK, Karia B, Ouma N, Amadi D, et al
    The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.
    Vaccine. 2022 Nov 1:S0264-410X(22)01345-7. doi: 10.1016/j.vaccine.2022.
    >> Share

    October 2022
  1291. KUNASEKARAN M, Moa A, Hooshmand E, Trent M, et al
    Effectiveness estimates for enhanced trivalent influenza vaccines in an aged care summer outbreak.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00766.
    >> Share

  1292. KUNASEKARAN M, Poulos CJ, Chughtai AA, Heslop DJ, et al
    Factors associated with repeated influenza vaccine uptake among aged care staff in an Australian sample from 2017 to 2019.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00981.
    >> Share

  1293. TONG C, Liu H, Wang J, Sun Y, et al
    Safety, efficacy, and DIVA feasibility on a novel live attenuated CSFV marker vaccine candidate.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01293.
    >> Share

  1294. THULUVA S, Paradkar V, Gunneri S, Yerroju V, et al
    Safety, tolerability and immunogenicity of Biological E's CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01308.
    >> Share

  1295. LIMAYE RJ, Paul A, Gur-Arie R, Zavala E, et al
    A socio-ecological exploration to identify factors influencing the COVID-19 vaccine decision-making process among pregnant and lactating women: Findings from Kenya.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01331.
    >> Share

  1296. CAPURRO G, Maier R, Tustin J, Jardine CG, et al
    "They're trying to bribe you and taking away your freedoms": COVID-19 vaccine hesitancy in communities with traditionally low vaccination rates.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01338.
    >> Share

  1297. SIANI A, Tranter A
    Is vaccine confidence an unexpected victim of the COVID-19 pandemic?
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01337.
    >> Share

  1298. MARIE REINHART A, Tian Y, Lilly AE
    The role of trust in COVID-19 vaccine hesitancy and acceptance among Black and White Americans.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01330.
    >> Share

  1299. CRUZ MC, Nascimento-Carvalho CM
    The early evolution of COVID-19 incidence and mortality among people aged under 80 years or 80 years and above after COVID-19 vaccine implementation in the state of Bahia, Brazil.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01335.
    >> Share

  1300. GILLES C, Rozenberg S, Buxant F, Manigart Y, et al
    HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01288.
    >> Share

  1301. XIE L, Li Y
    Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development.
    Vaccine. 2022 Oct 29. pii: S0264-410X(22)01311.
    >> Share

  1302. HEYERDAHL LW, Dielen S, Dodion H, Van Riet C, et al
    Strategic silences, eroded trust: The impact of divergent COVID-19 vaccine sentiments on healthcare workers' relations with peers and patients.
    Vaccine. 2022 Oct 27. pii: S0264-410X(22)01306.
    >> Share

  1303. BAMOUH Z, Hamdi J, Elkarhat Z, Fellahi S, et al
    Attenuation and genetic characteristics of a Moroccan strain of Camel pox virus.
    Vaccine. 2022;40:6471-6480.
    >> Share

  1304. SCHIFF J, Schmidt AR, Pham PK, Perez JB, et al
    Parental attitudes in the pediatric emergency department about the COVID-19 vaccine.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01309.
    >> Share

  1305. MALTEZOU HC, Ledda C, Gagneux-Brunon A, Botelho-Nevers E, et al
    Mandatory COVID-19 vaccination for healthcare personnel in the era of new SARS-CoV-2 variants.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01313.
    >> Share

  1306. MALTEZOU HC, Gamaletsou MN, Koukou DM, Giannouchos TV, et al
    Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01304.
    >> Share

  1307. TADDIO A, McMurtry CM, Logeman C, Gudzak V, et al
    Prevalence of pain and fear as barriers to vaccination in children - Systematic review and meta-analysis.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01287.
    >> Share

  1308. PHOKSAWAT W, Nithichanon A, Lerdsamran H, Wongratanacheewin S, et al
    Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01265.
    >> Share

  1309. SHU Y, Yu Y, Ji Y, Zhang L, et al
    Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01281.
    >> Share

  1310. SERRA L, Webber C, Burman C, Bueti P, et al
    Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01197.
    >> Share

  1311. RABE APJ, Costello P, Were JJ, Farrer A, et al
    The burden of selected vaccine-preventable diseases on the secondary care health system in England: Results from a five-year administrative healthcare dataset.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01263.
    >> Share

  1312. MADEWELL ZJ, Chacon-Fuentes R, Badilla-Vargas X, Ramirez C, et al
    Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01284.
    >> Share

  1313. NAYAR R, Pattath B, Mantha N, Debnath S, et al
    Routine childhood vaccination in India from 2005-2006 to 2015-2016: Temporal trends and geographic variation.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01285.
    >> Share

  1314. ARASA J, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A, et al
    Impact of rotavirus vaccination on seizure hospitalizations in children: A systematic review.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01228.
    >> Share

  1315. ARRIETA A, Garcia-Prado A, Sarmiento JP, Paz Castro C, et al
    Identifying early adopters of COVID-19 vaccines in Latin America.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01294.
    >> Share

  1316. SUN R, Budhwani H
    Negative sentiments toward novel coronavirus (COVID-19) vaccines.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01297.
    >> Share

  1317. BLANCO S, Spinsanti L, Javier Aguilar J, Diaz A, et al
    Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01283.
    >> Share

  1318. SANTIBANEZ TA, Black CL, Vogt TM, Chatham-Stephens K, et al
    Where are children ages 5-17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01282.
    >> Share

  1319. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    >> Share

  1320. DUCLOS P, MacDonald NE, Dochez C, Thacker N, et al
    Report of the 2nd workshop of the International Collaboration on advanced vaccinology training.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01222.
    >> Share

  1321. ZHONG VW, Li X, Ran J, Hu G, et al
    Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01262.
    >> Share

  1322. HOSHI SL, Shono A, Seposo X, Okubo R, et al
    Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01259.
    >> Share

  1323. LAI L, Rouphael N, Xu Y, Kabbani S, et al
    An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01146.
    >> Share

  1324. HALL PA, Meng G, Sakib MN, Quah ACK, et al
    Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test of the risk compensation hypothesis in a representative sample during the COVID-19 pandemic.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289.
    >> Share

  1325. FUJI N, Pichichero M, Kaur R
    Pathogenesis of Streptococcus pneumoniae serotype 3 during natural colonization and infections among children and its IgG correlate of protection in a mouse model.
    Vaccine. 2022;40:6412-6421.
    >> Share

  1326. RUAN J, Dong W, Liu Y, Zhang Y, et al
    Establishment of a model to assess mumps virus neurovirulence in neonatal Wistar rats.
    Vaccine. 2022;40:6397-6403.
    >> Share

  1327. GOLLAMUDI J, Sartain SE, Navaei AH, Aneja S, et al
    Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:6431-6444.
    >> Share

  1328. SAPUAN S, Andrews N, Hallis B, Hole L, et al
    An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-containing vaccines or received no pertussis-containin
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01243.
    >> Share

  1329. PENG M, Joo J, Alvarado-Martinez Z, Tabashsum Z, et al
    Intracellular autolytic whole cell Salmonella vaccine prevents colonization of pathogenic Salmonella Typhimurium in chicken.
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01261.
    >> Share

  1330. URUENA A, Ruiz JI, Lew DA, David J, et al
    Opinions, attitudes, and barriers to pediatric vaccination in Argentina.
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01256.
    >> Share

  1331. LIAO SH, Chang WJ, Hsu CY, Ming-Fang Yen A, et al
    Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01258.
    >> Share

  1332. AKSOY N, Ozturk N, Ulusoy S, Omur MF, et al
    Knowledge and attitude of students studying at health department towards HPV and HPV vaccination.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01264.
    >> Share

  1333. TAKAHASHI Y, Ishitsuka K, Sampei M, Okawa S, et al
    COVID-19 vaccine literacy and vaccine hesitancy among pregnant women and mothers of young children in Japan.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01227.
    >> Share

  1334. RHODES S, Smith N, Evans T, White R, et al
    Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01260.
    >> Share

  1335. CREISHER PS, Campbell AD, Perry JL, Roznik K, et al
    Influenza subtype-specific maternal antibodies protect offspring against infection but inhibit vaccine-induced immunity and protection in mice.
    Vaccine. 2022 Oct 14. pii: S0264-410X(22)01241.
    >> Share

  1336. HUDSON A, Hall PA, Hitchman SC, Meng G, et al
    Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
    >> Share

  1337. AROCHO ROSARIO CM, Miller RJ, Klafke GM, Coates C, et al
    Interaction between anti-tick vaccine and a macrocyclic lactone improves acaricidal efficacy against Rhipicephalus (Boophilus) microplus (Canestrini) (Acari: Ixodidae) in experimentally infested cattle.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01230.
    >> Share

  1338. SAADE EA, Abul Y, McConeghy K, Edward Davidson H, et al
    High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01215.
    >> Share

  1339. MO Y, Li Y, Liu G, Chen J, et al
    A phase II, single-center, randomized, double-blind, parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)00948.
    >> Share

  1340. LIU S, Yang G, Li M, Sun F, et al
    Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)01102.
    >> Share

  1341. WHALEY M, Axon DR
    Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting.
    Vaccine. 2022 Oct 10. pii: S0264-410X(22)01229.
    >> Share

  1342. BUDDY CREECH C, Jimenez-Truque N, Kown N, Sokolow K, et al
    Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01196.
    >> Share

  1343. VOGELSANG EM, Polonijo AN
    Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01183.
    >> Share

  1344. CHONG CY, Tan NW, Yung CF, Li J, et al
    Effectiveness of maternal pertussis vaccination in Singapore: A test-negative case-control study.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01219.
    >> Share

  1345. RUGHINIS C, Vulpe SN, Flaherty MG, Vasile S, et al
    Shades of doubt: Measuring and classifying vaccination confidence in Europe.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01147.
    >> Share

  1346. CHEN JY, Hsieh SM, Hwang SJ, Liu CS, et al
    Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01200.
    >> Share

  1347. RUSTANDI RR, Hamm M, Onimus M, Yuan Y, et al
    Monitoring bromide loss in bromoacetyl-derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB(R) by capillary electrophoresis and NMR spectroscopy.
    Vaccine. 2022;40:6012-6016.
    >> Share

  1348. KATZ S, Townsend-Payne K, Louth J, Lee-Jones L, et al
    Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
    Vaccine. 2022;40:6042-6047.
    >> Share

  1349. MARLOWE E, Pranikoff S, Borsheim B, Salafian K, et al
    Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01194.
    >> Share

  1350. KRAAY ANM, Steele MK, Baker JM, Hall EW, et al
    Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01193.
    >> Share

  1351. WOLF AS, Mitsi E, Jones S, Jochems SP, et al
    Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01190.
    >> Share

  1352. BYRNE A, Thompson LA, Filipp SL, Ryan K, et al
    COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01221.
    >> Share

  1353. SIMON JK, Kennedy SB, Mahon BE, Dubey SA, et al
    Immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine (ERVEBO(R)) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01145.
    >> Share

  1354. PAGUIO JA, Ojikutu BO, Alfonso PG, Yao JS, et al
    Association of culturally competent care with influenza vaccination coverage in the United States.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01065.
    >> Share

  1355. CHUGHTAI AA, Mohammed S, Al Ariqi L, McCarron M, et al
    Development of a road map to scale up the uptake and utilization of influenza vaccine in 22 countries of Eastern Mediterranean Region.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01159.
    >> Share

  1356. VAN EWIJK CE, Hazelhorst EI, Hahne SJM, Knol MJ, et al
    COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    Vaccine. 2022 Oct 4. pii: S0264-410X(22)01213.
    >> Share

  1357. AL-SHAIKH A, Mahmoud RI, Boukerdenna H, Muthu N, et al
    Counselling of non-communicable diseases' patients for COVID-19 vaccine uptake in Jordan: Evaluating the intervention.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01214.
    >> Share

  1358. FERREIRA LS, de Almeida GB, Borges ME, Simon LM, et al
    Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01216.
    >> Share

  1359. CHAO CR, Xu L, Cannizzaro N, Bronstein D, et al
    Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01195.
    >> Share

  1360. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    >> Share

    September 2022
  1361. MANJATE F, Quinto L, Chirinda P, Acacio S, et al
    Impact of rotavirus vaccination on diarrheal hospitalizations in children younger than 5 years of age in a rural southern Mozambique.
    Vaccine. 2022 Sep 30. pii: S0264-410X(22)01158.
    >> Share

  1362. NAKASHIMA K, Suzuki K, Aoshima M, Murabata M, et al
    Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study
    Vaccine. 2022 Sep 29. pii: S0264-410X(22)01163.
    >> Share

  1363. SILVA-VALENCIA J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, et al
    Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study usi
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01189.
    >> Share

  1364. TRAKARNVANICH T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, et al
    Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01187.
    >> Share

  1365. MERDRIGNAC L, Acosta L, Habington A, Garcia Cenoz M, et al
    Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01160.
    >> Share

  1366. SPETZ M, Lundberg L, Nwaru C, Li H, et al
    An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01186.
    >> Share

  1367. HATHAWAY CA, Siegel EM, Gonzalez BD, Oswald LB, et al
    Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01184.
    >> Share

  1368. MARCHESE AM, Beyhaghi H, Orenstein WA
    With established safe and effective use, protein vaccines offer another choice against COVID-19.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01185.
    >> Share

  1369. CERVANTES-TORRES J, Rosales-Mendoza S, Cabello C, Montero L, et al
    Towards the development of an epitope-focused vaccine for SARS-CoV-2.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01168.
    >> Share

  1370. LLOYD PC, Hu M, Wong HL, Shoaibi A, et al
    Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01167.
    >> Share

  1371. ZHU H, Li X, Ren X, Chen H, et al
    Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01165.
    >> Share

  1372. OHTA M, Kambayashi Y, Mita H, Kuroda T, et al
    Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01155.
    >> Share

  1373. STOFFEL ST, Colaninno A, Bram R, Schwenkglenks M, et al
    Pneumococcal vaccination among adult risk patient with axial spondyloarthritis in Switzerland: Data from the survey of the ankylosing spondylitis association of Switzerland (SVMB).
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01164.
    >> Share

  1374. TOLSTRUP WESTER C, Lybecker Scheel-Hincke L, Bovil T, Andersen-Ranberg K, et al
    Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01153.
    >> Share

  1375. GATES DM, Cohen SA, Orr K, Caffrey AR, et al
    Pediatric influenza vaccination rates lower than previous estimates in the United States.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01162.
    >> Share

  1376. NOMURA Y, Noda K, Oohashi Y, Okuda S, et al
    Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01144.
    >> Share

  1377. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    >> Share

  1378. POLAND GA
    The human immune response to vaccines is symphonic, polyphonic, homophonic, and megaphonic.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01099.
    >> Share

  1379. MOHAMMED AH, Hassan BAR, Wayyes AM, Gadhban AQ, et al
    Parental health beliefs, intention, and strategies about covid-19 vaccine for their children: A cross-sectional analysis from five Arab countries in the Middle East.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01161.
    >> Share

  1380. KUIPER VP, van der Plas P, Hoogerwerf MA, Pieter R Koopman J, et al
    A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01100.
    >> Share

  1381. RUCKSTUHL L, Czock A, Haile SR, Lang P, et al
    Influence of cantonal health policy frameworks & activities on the influenza vaccination rate in patients with non-communicable diseases in Switzerland.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01148.
    >> Share

  1382. ROMER D, Winneg KM, Jamieson PE, Brensinger C, et al
    Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01154.
    >> Share

  1383. KIEFER MK, Mehl R, Rood KM, Germann K, et al
    Association between social vulnerability and COVID-19 vaccination hesitancy and vaccination in pregnant and postpartum individuals.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01152.
    >> Share

  1384. DYSON EH, Simpson AJH, Gwyther RJ, Cuthbertson H, et al
    Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01045.
    >> Share

  1385. LIU B, Gidding H, Stepien S, Cretikos M, et al
    Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01126.
    >> Share

  1386. FENG T, Li M, Zhang L, Li S, et al
    Immunity of two novel hepatitis C virus polyepitope vaccines.
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01115.
    >> Share

  1387. BANNIETTIS N, Wysocki J, Szenborn L, Phongsamart W, et al
    A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, c
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01086.
    >> Share

  1388. SHAPIRO JR, Privor-Dumm L, Rosser EN, Leng SX, et al
    The intersection of gender and race in older adults' decision to receive COVID-19 vaccines.
    Vaccine. 2022 Sep 20:S0264-410X(22)01151-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  1389. GRAAF A, Petric PP, Sehl-Ewert J, Henritzi D, et al
    Cold-passaged isolates and bat-swine influenza a chimeric viruses as modified live-attenuated vaccines against influenza a viruses in pigs.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01108.
    >> Share

  1390. SHI T, Meng L, Li D, Jin N, et al
    Effect of different vaccine strategies for the control of Japanese encephalitis in mainland China from 1961 to 2020: A quantitative analysis.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01127.
    >> Share

  1391. NTZIORA F, Georgia Kostaki E, Karapanou A, Mylona M, et al
    Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01150.
    >> Share

  1392. HUANG ST, Huang YC, Kuo E, Yang YM, et al
    Impacts of Catch-Up Immunization program with the 13-Valent pneumococcal Conjugate vaccine in Taiwan: Focus on age-stratified differences and high-risk population (2001-2015).
    Vaccine. 2022 Sep 17. pii: S0264-410X(22)01084.
    >> Share

  1393. LI L, Li Y, Bai Y, Li G, et al
    Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase b randomized, double-blind, parallel-controlled study.
    Vaccine. 2022 Sep 16. pii: S0264-410X(22)01114.
    >> Share

  1394. TILEY KS, White JM, Andrews N, Tessier E, et al
    Equity of the Meningitis B vaccination programme in England, 2016-2018.
    Vaccine. 2022 Sep 15. pii: S0264-410X(22)01111.
    >> Share

  1395. YU M, Chi X, Huang S, Wang Z, et al
    A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26.
    Vaccine. 2022 Sep 15. pii: S0264-410X(22)01103.
    >> Share

  1396. FRANKENTHAL D, Zatlawi M, Karni-Efrati Z, Keinan-Boker L, et al
    COVID-19 vaccine hesitancy among Israeli adults before and after vaccines' availability: A cross-sectional national survey.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01078.
    >> Share

  1397. CREVECOEUR J, Hens N, Neyens T, Lariviere Y, et al
    Change in COVID19 outbreak pattern following vaccination in long-term care facilities in Flanders, Belgium.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01124.
    >> Share

  1398. CARRENO JM, Singh G, Tcheou J, Srivastava K, et al
    mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01003.
    >> Share

  1399. ACEIL J, Paschall AV, Knoot CJ, Robinson LS, et al
    Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01112.
    >> Share

  1400. SUZUKI H, Noguchi T, Matsugu N, Suzuki A, et al
    Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01104.
    >> Share

  1401. STANFIELD BA, Bravo FJ, Dixon DA, Chouljenko VN, et al
    Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01119.
    >> Share

  1402. DIEMERT DJ, Zumer M, Campbell D, Grahek S, et al
    Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naive adults.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01113.
    >> Share

  1403. OSEI I, Sarwar G, Hossain I, Sonko K, et al
    Attendance and vaccination at immunization clinics in rural Gambia before and during the COVID-19 pandemic.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01125.
    >> Share

  1404. ZACE D, La Gatta E, Petrella L, Di Pietro ML, et al
    The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01118.
    >> Share

  1405. MONFARED IG
    The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01107.
    >> Share

  1406. FRIEDMAN-KLABANOFF DJ, Tjaden AH, Santacatterina M, Munawar I, et al
    Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01116.
    >> Share

  1407. YAMANAKA A, Rattanaamnuaychai P, Matsuda M, Suzuki R, et al
    Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01110.
    >> Share

  1408. HAO F, Bai Y, Xie X, Yuan T, et al
    Phenotypic characteristics and protective efficacy of an attenuated Mycoplasma hyopneumoniae vaccine by aerosol administration.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01080.
    >> Share

  1409. DAY ME, Klein M, Sucharew H, Carol Burkhardt M, et al
    Declining influenza vaccination rates in an underserved pediatric primary care center during the COVID-19 pandemic.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01121.
    >> Share

  1410. NAEIM A, Guerin RJ, Baxter-King R, Okun AH, et al
    Strategies to increase the intention to get vaccinated against COVID-19: Findings from a nationally representative survey of US adults, October 2020 to October 2021.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01117.
    >> Share

  1411. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Corrigendum to "Estimating the burden of adult hospitalized RSV infection including special populations". [Vaccine 40(31) (2022) 4121-4127].
    Vaccine. 2022 Sep 10. pii: S0264-410X(22)01123.
    >> Share

  1412. NIEMINEN H, Lahdenkari M, Syrjanen RK, Nohynek H, et al
    Lower incidence of hospital-treated infections in infants under 3 months of age vaccinated with BCG.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01087.
    >> Share

  1413. DEIFALLAH YOUSIF M, Felek A, Saydam M, Wilson S, et al
    Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01062.
    >> Share

  1414. ISHIGURO C, Mimura W, Murata F, Fukuda H, et al
    Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01077.
    >> Share

  1415. VANDEBRIEL RJ, Stalpers CAL, Vermeulen JP, Remkes M, et al
    Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation.
    Vaccine. 2022;40:5601-5607.
    >> Share

  1416. MOORE KA, Osterholm MT, Lackritz EM, Poland GA, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: Setting a path to address coronavirus threats.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01079.
    >> Share

  1417. TEPEROWSKI MONRAD J, Quaade S, Powell-Jackson T
    Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01041.
    >> Share

  1418. JOSE PRIYA TA, Kappalli S
    Modern biotechnological strategies for vaccine development in aquaculture - Prospects and challenges.
    Vaccine. 2022 Sep 7. pii: S0264-410X(22)01083.
    >> Share

  1419. CEANNT R, Vallieres F, Burns H, Murphy J, et al
    Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland.
    Vaccine. 2022 Sep 7. pii: S0264-410X(22)01082.
    >> Share

  1420. MOK CC, Chan KL, Tse SM
    Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01067.
    >> Share

  1421. LUBIS TA, Gunardi H, Herqutanto, Soedjatmiko S, et al
    Educational videos to address vaccine hesitancy in childhood immunization.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01035.
    >> Share

  1422. HABERSAAT KB, Narayan S, Malue Nielsen S, Scherzer M, et al
    How health workers can make a difference in the public COVID-19 vaccination response.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01081.
    >> Share

  1423. PERRIER Q, Lupo J, Gerster T, Augier C, et al
    SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01064.
    >> Share

  1424. NUORTI JP, Rinta-Kokko H, Toropainen M, Siira L, et al
    Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
    Vaccine. 2022 Sep 5. pii: S0264-410X(22)01037.
    >> Share

  1425. LUHATA LUNGAYO C, Burke RM, Cikomola A, Mukamba E, et al
    Epidemiology and pre-vaccine burden of rotavirus diarrhea in Democratic Republic of Congo (DRC): Results of sentinel surveillance, 2009-2019.
    Vaccine. 2022 Sep 3. pii: S0264-410X(22)01031.
    >> Share

  1426. ARORA AK, Chinsky K, Keller C, Mayers I, et al
    A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial.
    Vaccine. 2022 Sep 3. pii: S0264-410X(22)01042.
    >> Share

  1427. QI L, Sun Y, Juraska M, Moodie Z, et al
    Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.
    Vaccine. 2022 Sep 3. pii: S0264-410X(22)01043.
    >> Share

  1428. SALUJA T, Rai GK, Chaudhary S, Kanodia P, et al
    Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)01009.
    >> Share

  1429. MANOHAR MM, Campbell BE, Walduck AK, Moore RJ, et al
    Enhancement of live vaccines by co-delivery of immune modulating proteins.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)01049.
    >> Share

  1430. SAEZ-LLORENS X, Chan M, DeAntonio R, Petersen T, et al
    Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax(R), a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)00858.
    >> Share

  1431. LEWIN B, Qian L, Huang R, Sy LS, et al
    Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)01002.
    >> Share

  1432. VESGA JF, Metras R, Clark MHA, Ayazi E, et al
    Vaccine efficacy trials for Crimean-Congo haemorrhagic fever: Insights from modelling different epidemiological settings.
    Vaccine. 2022 Sep 1. pii: S0264-410X(22)01051.
    >> Share

  1433. BOLSEWICZ KT, Steffens MS, Karpish L, Bullivant B, et al
    "Every interaction you have ...should be an opportunity to discuss and offer influenza vaccination". Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families living in New South Wales, Australia.
    Vaccine. 2022 Sep 1. pii: S0264-410X(22)01047.
    >> Share

    August 2022
  1434. HRIN ML, Emmerich VK, Ip EH, Feldman SR, et al
    Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States.
    Vaccine. 2022 Aug 31. pii: S0264-410X(22)01052.
    >> Share

  1435. FRAIMAN J, Erviti J, Jones M, Greenland S, et al
    Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01028.
    >> Share

  1436. JACOBSON M, Chang TY, Shah M, Pramanik R, et al
    Can financial incentives and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A randomized trial.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01050.
    >> Share

  1437. SANCHEZ-SAEZ F, Peiro S, Cuenca L, Vanaclocha H, et al
    Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01007.
    >> Share

  1438. SARKAR P, Chandrasekaran V, Gunasekaran D, Chinnakali P, et al
    COVID-19 vaccine hesitancy among health care worker-parents (HCWP) in Puducherry, India and its implications on their children: A cross sectional descriptive study.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01040.
    >> Share

  1439. CAO X, Zai J, Zhao Q, Xie L, et al
    Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01044.
    >> Share

  1440. KAMAL HOSSAIN M, Hassanzadeganroudsari M, Feehan J, Deraos G, et al
    Development and characterization of a novel conjugated methamphetamine vaccine.
    Vaccine. 2022 Aug 27. pii: S0264-410X(22)01033.
    >> Share

  1441. DOYON-PLOURDE P, Fortin E, Quach C
    Evaluation of the 2018-2019 vaccine effectiveness against medically attended influenza-like illness using medical records and claims data.
    Vaccine. 2022 Aug 27. pii: S0264-410X(22)00976.
    >> Share

  1442. ROSHCHINA Y, Roshchin S, Rozhkova K
    Determinants of COVID-19 vaccine hesitancy and resistance in Russia.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01032.
    >> Share

  1443. TERESA VIETRI M, D'Elia G, Caliendo G, Passariello L, et al
    Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01034.
    >> Share

  1444. PHAM D, Shukla A, Welch K, Villa A, et al
    Assessing knowledge of human papillomavirus among men who have sex with men (MSM) using targeted dating applications.
    Vaccine. 2022;40:5376-5383.
    >> Share

  1445. CHUAN VOO T, Savulescu J, Schaefer O, Ho Zhi Ling A, et al
    COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications.
    Vaccine. 2022;40:5333-5337.
    >> Share

  1446. HEMMI T, Ainai A, Hashiguchi T, Tobiume M, et al
    Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01038.
    >> Share

  1447. KIKUT A, Clark D, Jesch E, Hornik R, et al
    Strengthened belief in vaccine effectiveness predicted increased COVID-19 vaccination intention and behaviour: Results from a nationally representative longitudinal survey of U.S. adults from July 2020 to April/May 2021.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01036.
    >> Share

  1448. OKUYAMA M, Morino S, Tanaka K, Nakamura-Miwa H, et al
    Vasovagal reactions after COVID-19 vaccination in Japan.
    Vaccine. 2022 Aug 25. pii: S0264-410X(22)01046.
    >> Share

  1449. CATHARINA DE BEER J, Goto D, Miller-Janson H, Holl R, et al
    Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)00817.
    >> Share

  1450. CALO WA, Lennon RP, Ruffin Iv MT, Keller C, et al
    Support for HPV vaccine school-entry requirements in the United States: The role of exemption policies.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)00983.
    >> Share

  1451. LIM AH, Ab Rahman N, Ong SM, Paraja J, et al
    Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)01005.
    >> Share

  1452. ESSON R, Rodrigues De Sousa E, Benair L, Devard N, et al
    Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate.
    Vaccine. 2022 Aug 23. pii: S0264-410X(22)00939.
    >> Share

  1453. KURUKULASURIYA S, Ahmed KA, Ojkic D, Gunawardana T, et al
    Evaluation of five circulating strains of variant infectious bursal disease virus (varIBDV) for their immunogenicity as broiler breeder vaccines and protective efficacy in neonatal broiler chicks.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01000.
    >> Share

  1454. ROMANO L, Tosti ME, Zanetti AR
    Beyond 30 years of universal anti-hepatitis B vaccination in Italy: Success and areas of improvement.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00966.
    >> Share

  1455. PRUDDEN HJ, Achilles SL, Schocken C, Broutet N, et al
    Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00999.
    >> Share

  1456. MACKLIN GR, Goel AK, Mach O, Tallis G, et al
    Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00962.
    >> Share

  1457. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    Views on COVID-19 vaccination of young children in Ireland, results from a cross-sectional survey of parents.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01013.
    >> Share

  1458. STIVANELLO E, Beghelli C, Cardoni F, Giansante C, et al
    Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01029.
    >> Share

  1459. WANG X, Deng Y, Zhao L, Wang L, et al
    Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01030.
    >> Share

  1460. KANOKUDOM S, Assawakosri S, Suntronwong N, Chansaenroj J, et al
    Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01011.
    >> Share

  1461. DOCHEZ C, Duclos P, MacDonald N, Steffen C, et al
    Advanced vaccinology training globally: Update and impact of the COVID-19 crisis.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01006.
    >> Share

  1462. KURASHIMA K, Numano T, Yoshino A, Osawa A, et al
    Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01027.
    >> Share

  1463. WILLIS GA, Bloomfield L, Berry M, Bulsara C, et al
    The impact of a vaccine mandate and the COVID-19 pandemic on influenza vaccination uptake in Western Australian health care students.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01026.
    >> Share

  1464. TOAPANTA-YANCHAPAXI L, Chiquete E, Avila-Rojo E, Lopez-Yanez S, et al
    Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01012.
    >> Share

  1465. CLEMENS SAC, Fortaleza CMCB, Crowe M, Pollard A, et al
    Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01010.
    >> Share

  1466. JAFFRY M, Mostafa F, Mandava K, Rosario S, et al
    No significant increase in Guillain-Barre syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01025.
    >> Share

  1467. PSARIDI L, Maltezou HC, Simonidou S, Lialliou I, et al
    Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection.
    Vaccine. 2022 Aug 19. pii: S0264-410X(22)01008.
    >> Share

  1468. MOHAMED TJ, Fong SM, Nadarajaw T, Choo CM, et al
    Burden of pertussis among young infants in Malaysia: A hospital-based surveillance study.
    Vaccine. 2022;40:5241-5247.
    >> Share

  1469. DEJONG MA, Wolf MA, Bitzer GJ, Hall JM, et al
    CpG 1018(R) adjuvant enhances Tdap immune responses against Bordetella pertussis in mice.
    Vaccine. 2022;40:5229-5240.
    >> Share

  1470. STOECKEL F, Stockli S, Phillips J, Lyons B, et al
    Stamping the vaccine passport? Public support for lifting COVID-19 related restrictions for vaccinated citizens in France, Germany, and Sweden.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00965.
    >> Share

  1471. LAFFAN MA, Rees S, Yadavalli M, Ferstenberg LB, et al
    Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00964.
    >> Share

  1472. PRINGLE W, Greyson D, Graham JE, Dube E, et al
    Suitable but requiring support: How the midwifery model of care offers opportunities to counsel the vaccine hesitant pregnant population.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00953.
    >> Share

  1473. AMANI A, Ngo Bama S, Dia M, Nguefack Lekelem S, et al
    Challenges, best practices, and lessons learned from oral cholera mass vaccination campaign in urban Cameroon during the COVID-19 era.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)01004.
    >> Share

  1474. ISHIDA M, Mulou N, Mahal A
    Travel time to health facilities in Papua New Guinea: Implications for coverage and equity in child vaccinations.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00958.
    >> Share

  1475. LINNANDER E, Ineza L, Mupeta Bobo P, Bechtold K, et al
    Improving management of vaccine supply chains: A multi-methods evaluation of vSTEP in Zambia.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00914.
    >> Share

  1476. WYMORE BRAND M, Anderson TK, Kitikoon P, Brian Kimble J, et al
    Bivalent hemagglutinin and neuraminidase influenza replicon particle vaccines protect pigs against influenza a virus without causing vaccine associated enhanced respiratory disease.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00937.
    >> Share

  1477. VISKUPIC F, Wiltse DL, Badahdah A
    Reminders of existing vaccine mandates increase support for a COVID-19 vaccine mandate: Evidence from a survey experiment.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00978.
    >> Share

  1478. ELLIOTT CBP, Chambers CS
    A historical analysis of vaccine mandates in the United States military and its application to the COVID-19 vaccine mandate.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00982.
    >> Share

  1479. ALKETBI LMB, Al Hosani F, Al Memari S, Al Mazrouei S, et al
    Parents' views on the acceptability of a COVID-19 vaccine for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00954.
    >> Share

  1480. MATSUURA T, Fukushima W, Nakagama Y, Kido Y, et al
    Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00984.
    >> Share

  1481. CASEROTTI M, Gavaruzzi T, Girardi P, Sellaro R, et al
    People's perspectives about COVID-19 vaccination certificate: Findings from a representative Italian sample.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00980.
    >> Share

  1482. SCHMIDTKE KA, Skrybant M, Kudrna L, Russell S, et al
    A workshop to co-design messages that may increase uptake of vaccines: A case study.
    Vaccine. 2022 Aug 12. pii: S0264-410X(22)00951.
    >> Share

  1483. XIROGIANNI A, Marmaras N, Georgakopoulou T, Papandreou A, et al
    Pneumococcal meningitis in Greece: A retrospective serotype surveillance study in the post-PCV13 era (2010-2020).
    Vaccine. 2022;40:5079-5087.
    >> Share

  1484. OMER SB, O'Leary ST, Bednarczyk RA, Ellingson MK, et al
    Multi-tiered intervention to increase maternal immunization coverage: A randomized, controlled trial.
    Vaccine. 2022;40:4955-4963.
    >> Share

  1485. HALASA N, Williams J, Faouri S, Shehabi A, et al
    Corrigendum to "Natural history and epidemiology of respiratory syncytial virus infection in the Middle East: Hospital surveillance for children under age two in Jordan" [Vaccine 33(47) (2015) 6479-6487].
    Vaccine. 2022 Aug 11. pii: S0264-410X(22)00959.
    >> Share

  1486. HOSHI SL, Okubo R, Tabuchi K, Seposo X, et al
    Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children.
    Vaccine. 2022 Aug 11. pii: S0264-410X(22)00960.
    >> Share

  1487. MARKOWITZ LE, Drolet M, Lewis RM, Lemieux-Mellouki P, et al
    Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs.
    Vaccine. 2022 Aug 11. pii: S0264-410X(22)00834.
    >> Share

  1488. MAEDA H, Gopal Dhoubhadel B, Sando E, Suzuki M, et al
    Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
    Vaccine. 2022 Aug 10. pii: S0264-410X(22)00938.
    >> Share

  1489. GUSMAO MR, Ostolin TLVDP, Carvalho LM, Costa AFP, et al
    Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
    Vaccine. 2022 Aug 10. pii: S0264-410X(22)00961.
    >> Share

  1490. YELVERTON V, Hair NL, Ghosh SH, Mfinanga SG, et al
    Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania.
    Vaccine. 2022 Aug 9. pii: S0264-410X(22)00907.
    >> Share

  1491. PROUT A, Rustandi RR, Tubbs C, Winters MA, et al
    Functional profiling of Covid 19 vaccine candidate by flow virometry.
    Vaccine. 2022 Aug 9. pii: S0264-410X(22)00963.
    >> Share

  1492. PERROUD JM, Soldano S, Avancena ALV, Wagner A, et al
    Adult vaccination uptake strategies in low- and middle-income countries: A systematic review.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00952.
    >> Share

  1493. HU S, Xiong C, Li Q, Wang Z, et al
    COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00947.
    >> Share

  1494. THOBANI RS, Yousafzai MT, Sultana S, Kazi AM, et al
    Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
    Vaccine. 2022 Aug 6. pii: S0264-410X(22)00840.
    >> Share

  1495. ESTRELA M, Magalhaes Silva T, Roque V, Rebelo Gomes E, et al
    Unravelling the drivers behind COVID-19 vaccination hesitancy and refusal among teachers: A nationwide study.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00955.
    >> Share

  1496. BURGER E, Baussano I, Kim JJ, Laprise JF, et al
    Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00910.
    >> Share

  1497. GAGNEUX-BRUNON A, Guyot E, Detoc M, Botelho-Nevers E, et al
    Midwives' attitudes toward participation of pregnant individuals in a preventive vaccine hypothetical clinical trial.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00945.
    >> Share

  1498. DE SWART RL, de Leeuw OS, Oreshkova N, Gerhards NM, et al
    Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    Vaccine. 2022;40:4676-4681.
    >> Share

  1499. HAO L, Kuttel MM, Ravenscroft N, Thompson A, et al
    Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.
    Vaccine. 2022;40:4872-4880.
    >> Share

  1500. LI YA, Sun Y, Zhang Y, Wang S, et al
    Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a virus-like particles induces a protective immune response against porcine circovirus type 2 in mice.
    Vaccine. 2022;40:4732-4741.
    >> Share

  1501. YEO J, Furr Gudmundsen C, Fazel S, Corrigan A, et al
    A behavior change model to address caregiver hesitancy around COVID-19 vaccination in pediatrics.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00949.
    >> Share

  1502. ULRICH AK, Pankratz GK, Bohn B, Yendell S, et al
    COVID-19 vaccine confidence and reasons for vaccination among health care workers and household members.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00956.
    >> Share

  1503. TOIZUMI M, Satoh C, Quilty BJ, Nguyen HAT, et al
    Effect of pneumococcal conjugate vaccine on prevalence of otitis media with effusion among children in Vietnam.
    Vaccine. 2022 Aug 4. pii: S0264-410X(22)00944.
    >> Share

  1504. SQUIRE JD, Joshi AY
    Response to mRNA COVID-19 vaccination in three XLA patients.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00941.
    >> Share

  1505. LOURENCO GUIMARAES E, Chissaque A, Pecenka C, Clark A, et al
    Cost-effectiveness of rotavirus vaccination in Mozambique.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00940.
    >> Share

  1506. QUIAMBAO BP, Lim JG, Bosch Castells V, Augard C, et al
    One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess im
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00923.
    >> Share

  1507. SINGH H, Chase AJ
    Measuring vaccine acceptance and knowledge within health professions education.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00926.
    >> Share

  1508. SNYDER J, Goldenberg M, Crooks VA, Katz R, et al
    Crowdfunding narratives and the valuation of vaccines for COVID-19.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00946.
    >> Share

  1509. CIMA MJ, McCormick D, Porter A 3rd, Zohoori N, et al
    COVID-19 vaccine uptake among Arkansas public K-12 school teachers and staff.
    Vaccine. 2022 Aug 2. pii: S0264-410X(22)00942.
    >> Share

  1510. DE MUNTER AC, Hautvast JLA, Ruijs WLM, Henri Spaan D, et al
    Deciding about maternal pertussis vaccination: associations between intention, and needs and values in a vaccine-hesitant religious group.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00924.
    >> Share

  1511. NARSINGAM S, Munson J, Drescher F
    Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00922.
    >> Share

  1512. BAUMER-MOURADIAN SH, Hart RJ, Bone JN, Seiler M, et al
    Should COVID-19 vaccines be mandated in schools? - an international caregiver perspective.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00921.
    >> Share

  1513. KORODI M, Horvath I, Rakosi K, Jenei Z, et al
    Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00936.
    >> Share

    July 2022
  1514. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    >> Share

  1515. DE BROUWER L, David D, Espitia Ballestas M, Sloots A, et al
    Prevalidation of the cAMP-PTx reporter assay for quantitative assessment of pertussis toxin activity.
    Vaccine. 2022;40:4513-4521.
    >> Share

  1516. COWLING BJ, Wong IOL, Shiu EYC, Lai AYT, et al
    Strength and durability of antibody responses to BNT162b2 and CoronaVac.
    Vaccine. 2022;40:4312-4317.
    >> Share

  1517. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    >> Share

  1518. LIU Z, Hosomi K, Kunisawa J
    Utilization of gut environment-mediated control system of host immunity in the development of vaccine adjuvants.
    Vaccine. 2022 Jul 30. pii: S0264-410X(22)00918.
    >> Share

  1519. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    >> Share

  1520. BOTTCHER J, Bauer BU, Ambros C, Alex M, et al
    Long-term control of Coxiellosis in sheep by annual primary vaccination of gimmers.
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00917.
    >> Share

  1521. CHEN H, Huang Z, Chang S, Hu M, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiorit
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00919.
    >> Share

  1522. ROSE O, Erzkamp S, Schobel W, Grajeda M, et al
    COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction.
    Vaccine. 2022 Jul 28. pii: S0264-410X(22)00925.
    >> Share

  1523. MARIN-LOPEZ A, Wang Y, Jiang J, Ledizet M, et al
    Erratum to "AgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection" [Vaccine 39(12) (2021) 1675-1679].
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00608.
    >> Share

  1524. BYRNE C, Coombs D, Gantt S
    Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00913.
    >> Share

  1525. RAMMAURO F, Carrion F, Olivero-Deibe N, Flo M, et al
    Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00911.
    >> Share

  1526. QUIAMBAO B, Montalban C, Minutello AM, Guinet-Morlot F, et al
    Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00830.
    >> Share

  1527. KRAUSE PR, Arora N, Dowling W, Munoz-Fontela C, et al
    Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00916.
    >> Share

  1528. SHENYU W, Xiaoqian D, Bo C, Xuan D, et al
    Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00908.
    >> Share

  1529. O'KENNEDY MM, Coetzee P, Koekemoer O, du Plessis L, et al
    Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR(-/-) mice.
    Vaccine. 2022 Jul 25. pii: S0264-410X(22)00848.
    >> Share

  1530. SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al
    EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice.
    Vaccine. 2022 Jul 22. pii: S0264-410X(22)00891.
    >> Share

  1531. CHANG MJ, Ollivault-Shiflett M, Schuman R, Ngoc Nguyen S, et al
    Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00886.
    >> Share

  1532. SIMSEK C, Bloemen M, Jansen D, Descheemaeker P, et al
    Rotavirus vaccine-derived cases in Belgium: Evidence for reversion of attenuating mutations and alternative causes of gastroenteritis.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00853.
    >> Share

  1533. PAWASKAR M, Gil-Rojas Y, Irene Parellada C, Rey-Velasco A, et al
    The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008-2019.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00889.
    >> Share

  1534. MCADAMS D, Estrada M, Holland D, Singh J, et al
    Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00892.
    >> Share

  1535. LORENZETTI L, Haydarov R, Namey E, Lawton A, et al
    Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria.
    Vaccine. 2022 Jul 20. pii: S0264-410X(22)00591.
    >> Share

  1536. DUGORD C, Franc C
    Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00855.
    >> Share

  1537. MCMILLAN CLD, Amarilla AA, Modhiran N, Choo JJY, et al
    Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00888.
    >> Share

  1538. SETHY G, Chisema M, Sharma L, Joshi K, et al
    COVID-19 vaccine express strategy in Malawi: An effort to reach the un-reach.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00887.
    >> Share

  1539. MIMURA W, Ishiguro C, Fukuda H
    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged>/=75years in Japan: The LIFE-VENUS Study.
    Vaccine. 2022 Jul 15. pii: S0264-410X(22)00852.
    >> Share

  1540. WALTON S, Cortina-Borja M, Dezateux C, Griffiths LJ, et al
    Linking cohort data and Welsh routine health records to investigate children at risk of delayed primary vaccination.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00849.
    >> Share

  1541. IMANISHI Y, Kinoshita T, Sakamoto M, Ichimiya M, et al
    Importance of human papillomavirus vaccination leaflets focusing on the safety profile targeted pediatricians in Japan.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00861.
    >> Share

  1542. VASUDEVAN L, Bruening R, Hung A, Woolson S, et al
    COVID-19 vaccination intention and activation among health care system employees: A mixed methods study.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00884.
    >> Share

  1543. ORTQVIST AK, Dahlqwist E, Magnus MC, Ljung R, et al
    COVID-19 vaccination in pregnant women in Sweden and Norway.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00859.
    >> Share

  1544. PRIDDY FH, Williams M, Carson S, Lavender B, et al
    Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00885.
    >> Share

  1545. GODDARD K, Lewis N, Fireman B, Weintraub E, et al
    Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00860.
    >> Share

  1546. CUFFEL A, Maylin S, Le Buanec H, Delaugerre C, et al
    Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00857.
    >> Share

  1547. PADRON-REGALADO E, Medina-Rivero E
    Perspectives for licensing vaccines in Mexico.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00854.
    >> Share

  1548. HATFALUDI T, Rezaee MS, Liebhart D, Bilic I, et al
    Experimental reproduction of histomonosis caused by Histomonas meleagridis genotype 2 in turkeys can be prevented by oral vaccination of day-old birds with a monoxenic genotype 1 vaccine candidate.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00851.
    >> Share

  1549. COURCIER EA, Collins SF, McCormick CM, Arnold ME, et al
    The impact of BCG strains and repeat vaccinations on immunodiagnostic tests in Eurasian badgers (Meles meles).
    Vaccine. 2022 Jul 9. pii: S0264-410X(22)00850.
    >> Share

  1550. WYPLOSZ B, Fernandes J, Sultan A, Roche N, et al
    Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00841.
    >> Share

  1551. MISCHLINGER J, Jaeger VK, Ciurea A, Gabay C, et al
    Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00760.
    >> Share

  1552. ZHANG Y, Wang Y, Jia C, Li G, et al
    Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects >/=3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00846.
    >> Share

  1553. BADRAN G, Angrand L, Masson JD, Crepeaux G, et al
    Physico-chemical properties of aluminum adjuvants in vaccines: Implications for toxicological evaluation.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00833.
    >> Share

  1554. REINHARDT A, Rossmann C, Engel E
    Radio public service announcements to promote vaccinations for older adults: Effects of framing and distraction.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00805.
    >> Share

  1555. CHADWICK C, Friede M, Moen A, Nannei C, et al
    Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00826.
    >> Share

  1556. OSTROPOLETS A, Shoener Dunham L, Johnson KD, Liu J, et al
    Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.
    Vaccine. 2022 Jul 5. pii: S0264-410X(22)00837.
    >> Share

  1557. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    >> Share

  1558. MCCORMICK DW, Konkle SL, Magleby R, Chakrabarti AK, et al
    SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge - Denver, Colorado, and San Diego, California, January-April 2021.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00835.
    >> Share

  1559. CASTILLO-CANO B, Martin-Perez M, Llorente-Garcia A, Montero-Corominas D, et al
    Assessment of thyroiditis risk associated with HPV vaccination among girls aged 9-18 years: A time-varying cohort study.
    Vaccine. 2022 Jul 2. pii: S0264-410X(22)00829.
    >> Share

  1560. BARNARD JG, Marsh R, Anderson-Mellies A, Williams JL, et al
    Pre-implementation evaluation for an HPV vaccine provider communication intervention among primary care clinics.
    Vaccine. 2022 Jul 2. pii: S0264-410X(22)00844.
    >> Share

  1561. HOU Z, Guo J, Lai X, Zhang H, et al
    Influenza vaccination hesitancy and its determinants among elderly in China: A national cross-sectional study.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00832.
    >> Share

  1562. SKIRROW H, Barnett S, Bell S, Mounier-Jack S, et al
    Women's views and experiences of accessing pertussis vaccination in pregnancy and infant vaccinations during the COVID-19 pandemic: A multi-methods study in the UK.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00845.
    >> Share

  1563. BARRALL AL, Hoff NA, Nkamba DM, Musene K, et al
    Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00842.
    >> Share

    June 2022
  1564. NASREEN S, Gebretekle GB, Lynch M, Kurdina A, et al
    Understanding predictors of pneumococcal vaccine uptake in older adults aged 65 years and older in high-income countries across the globe: A scoping review.
    Vaccine. 2022 Jun 30. pii: S0264-410X(22)00825.
    >> Share

  1565. HILLS T, Paterson A, Woodward R, Middleton F, et al
    The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.
    Vaccine. 2022 Jun 29. pii: S0264-410X(22)00839.
    >> Share

  1566. PICHON S, Moureau A, Petit C, Chu L, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00806.
    >> Share

  1567. BETTENCOURT C, Nogueira P, Paulo Gomes J, Joao Simoes M, et al
    Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00807.
    >> Share

  1568. MEDEIROS MZ, Soares PF, Fialho BC, Gauss L, et al
    Vaccine innovation model: A technology transfer perspective in pandemic contexts.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00823.
    >> Share

  1569. WONG SC, Chan VW, Lam GKM, Yuen LL, et al
    The impact of personal coaching on influenza vaccination among healthcare workers before and during COVID-19 pandemic.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00836.
    >> Share

  1570. LEE JT, Sean Hu S, Zhou T, Bonner KE, et al
    Employer requirements and COVID-19 vaccination and attitudes among healthcare personnel in the U.S.: Findings from National Immunization Survey Adult COVID Module, August - September 2021.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00838.
    >> Share

  1571. UFFMAN EA, Li SH, Chen JL, Allen N, et al
    Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00828.
    >> Share

  1572. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    >> Share

  1573. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    >> Share

  1574. HU G, Jin WP, Yang ZH, Lv SY, et al
    Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00768.
    >> Share

  1575. STRAUS W, Rubin H
    COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00822.
    >> Share

  1576. SHIVJI R, Conocchia R, Korakianiti E, Jekerle V, et al
    Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00827.
    >> Share

  1577. SEYRAN M
    Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00821.
    >> Share

  1578. AL-MUSTAPHA AI, Okechukwu O, Olayinka A, Muhammed OR, et al
    A national survey of COVID-19 vaccine acceptance in Nigeria.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00818.
    >> Share

  1579. LOHMANN S, Albarracin D
    Trust in the public health system as a source of information on vaccination matters most when environments are supportive.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00759.
    >> Share

  1580. HUANG L, Wasserman M, Grant L, Farkouh R, et al
    Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00773.
    >> Share

  1581. ZHAO Z, Liao Y, Li Y, Jiang G, et al
    Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00776.
    >> Share

  1582. CARTANYA-HUESO A, Martinez-Sanchez JM, Carlos Martin-Sanchez J, Lidon-Moyano C, et al
    Relationship between double COVID-19 vaccine uptake and trust in effectiveness and safety of vaccination in general in 23 Member states of the European Union: an ecological study.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00820.
    >> Share

  1583. MAERTENS K, Leuridan E, Munoz FM, Zimmermann P, et al
    Impact of vaccination during pregnancy on infants' immune responses to vaccinations- definitions and statistical approaches.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00811.
    >> Share

  1584. BRAZ HMB, Silva MF, Carvalho TP, Silva LAD, et al
    Pathogenesis of Brucella ovis in pregnant mice and protection induced by the candidate vaccine strain B. Ovis DeltaabcBA.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00812.
    >> Share

  1585. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    >> Share

  1586. SOARES GH, Sethi S, Hedges J, Jamieson L, et al
    Disparities in Human Papillomavirus vaccination coverage among adolescents in Australia: A geospatial analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00777.
    >> Share

  1587. WANG L, Zhang J, Meng S, Ge L, et al
    Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00784.
    >> Share

  1588. HONDA-OKUBO Y, Cartee RT, Thanawastien A, Seung Yang J, et al
    A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00809.
    >> Share

  1589. KORVES C, Izurieta HS, Smith J, Zwain GM, et al
    Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00816.
    >> Share

  1590. ULANOVA M, Huska B, Dubois S, McCready W, et al
    Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00810.
    >> Share

  1591. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    >> Share

  1592. KASAIJA PD, Contreras M, Kabi F, Mugerwa S, et al
    Oral vaccine formulation combining tick Subolesin with heat inactivated mycobacteria provides control of cross-species cattle tick infestations.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00804.
    >> Share

  1593. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    >> Share

  1594. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    >> Share

  1595. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    >> Share

  1596. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    >> Share

  1597. TAY S, Bowen AC, Blyth CC, Clifford P, et al
    A quality improvement study: Optimizing pneumococcal vaccination rates in children with cochlear implants.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00769.
    >> Share

  1598. MOUTA NUNES DE OLIVEIRA P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, et al
    Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00761.
    >> Share

  1599. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    >> Share

  1600. TSENG HF, Sy LS, Ackerson BK, Lee GS, et al
    Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00756.
    >> Share

  1601. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    >> Share

  1602. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    >> Share

  1603. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    >> Share

  1604. HERNANDEZ LM, Sumathy K, Sahastrabuddhe S, Excler JL, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00753.
    >> Share

  1605. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    >> Share

  1606. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    >> Share

  1607. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    >> Share

  1608. SHOOTS-REINHARD B, Lawrence ER, Schulkin J, Peters E, et al
    Excluding numeric side-effect information produces lower vaccine intentions.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00747.
    >> Share

  1609. ROLLIER CS, Dold C, Blackwell L, Linder A, et al
    Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00539.
    >> Share

  1610. HEININGER U
    Referring to: Wilkinson K, Righolt CH, Elliott LJ, Fanella S, Mahmud SM. Pertussis vaccine effectiveness and duration of protection - a systematic review and meta-analysis. Vaccine. 2021 May 27;39(23):3120-3130.
    Vaccine. 2022;40:3530.
    >> Share

  1611. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    In response to: JVAC-D-21-02863, detection of a potential error in the results of the manuscript, dementia risk following influenza vaccination in a large veteran cohort, that could call into question the main conclusion.
    Vaccine. 2022;40:3529.
    >> Share

  1612. VUICHARD-GYSIN D, Schoenenberger A
    Detection of a potential error in the results of the manuscript "Dementia risk following influenza vaccination in a large veteran cohort" that could eventually call into question the main conclusion.
    Vaccine. 2022;40:3528.
    >> Share

  1613. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    >> Share

  1614. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    >> Share

  1615. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    >> Share

  1616. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    >> Share

  1617. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    >> Share

  1618. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    >> Share

  1619. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    >> Share

  1620. LEAV B, Straus W, White P, Leav A, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00752.
    >> Share

  1621. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    >> Share

  1622. LIGHTOWLER MS, Manangazira P, Nackers F, Van Herp M, et al
    Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00552.
    >> Share

  1623. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00715.
    >> Share

  1624. OKUNO H, Satoh H, Morino S, Arai S, et al
    Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guerin vaccination: A national surveillance study in Japan from 2013 to 2017.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00672.
    >> Share

  1625. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    >> Share

  1626. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    >> Share

  1627. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    >> Share

  1628. BASS JR, Poland GA
    Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00750.
    >> Share

  1629. NIESSEN FA, Knol MJ, Hahne SJM, Bonten MJM, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: A test-negative case-control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00758.
    >> Share

  1630. SMITH WJ, Ahl PL, Wang B, Hamm M, et al
    Analytical technology development to monitor the stability of Polysaccharide-Protein conjugate vaccines.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00673.
    >> Share

  1631. SLOTTE P, Karlsson LC, Soveri A
    Attitudes towards mandatory vaccination and sanctions for vaccination refusal.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00697.
    >> Share

  1632. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    >> Share

  1633. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    >> Share

  1634. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    >> Share

  1635. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    >> Share

  1636. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    >> Share

  1637. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    >> Share

  1638. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    >> Share

  1639. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    >> Share

  1640. SLARVE M, Holznecht N, Reza H, Gilkes A, et al
    Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00674.
    >> Share

  1641. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    >> Share

  1642. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    >> Share

  1643. JANSSEN DF
    A familiar species of Crank: Anti-Vaccinationists in medical history.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00665.
    >> Share

  1644. BILGIN GM, Lokuge K, Glass K
    Modelling the impact of maternal pneumococcal vaccination on infant pneumococcal disease in low-income settings.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00684.
    >> Share

  1645. STEAD M, Ford A, Eadie D, Biggs H, et al
    A "step too far" or "perfect sense"? A qualitative study of British adults' views on mandating COVID-19 vaccination and vaccine passports.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00696.
    >> Share

    May 2022
  1646. AHMED S, Iqbal J, Sadiq K, Umrani F, et al
    Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants.
    Vaccine. 2022;40:3444-3451.
    >> Share

  1647. PILLSBURY M, Carias C, Samant S, Greenberg D, et al
    Comparison of performance of varicella vaccines via infectious disease modeling.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00574.
    >> Share

  1648. HISYAM BIN ISMAIL CMK, Raihan Mohammad Shabani N, Chuah C, Hassan Z, et al
    Shigella iron-binding proteins: An insight into molecular physiology, pathogenesis, and potential target vaccine development.
    Vaccine. 2022 May 31. pii: S0264-410X(22)00679.
    >> Share

  1649. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    >> Share

  1650. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    >> Share

  1651. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    >> Share

  1652. FISHMAN J, Salmon MK, Scheitrum D, Aleks Schaefer K, et al
    Comparative effectiveness of mandates and financial policies targeting COVID-19 vaccine hesitancy: A randomized, controlled survey experiment.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00702.
    >> Share

  1653. HEMMING-HARLO M, Gylling A, Herse F, Haavisto I, et al
    Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018).
    Vaccine. 2022 May 28. pii: S0264-410X(22)00584.
    >> Share

  1654. KLEINWAKS G, Schmit V, Morrison J
    Corrigendum to "Considering human challenge trials for tuberculosis vaccine development" [Vaccine 40(2) (2022) 173-174].
    Vaccine. 2022 May 28. pii: S0264-410X(22)00675.
    >> Share

  1655. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
    Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
    >> Share

  1656. SHIOHARA M, Suzuki S, Shichinohe S, Ishigaki H, et al
    Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00640.
    >> Share

  1657. RODES-SANCHEZ M, Spencer J, Tantri A, Mitrovich R, et al
    Working towards a sustainable, healthy market for vaccines: A framework to support evidence-based policymaking.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00671.
    >> Share

  1658. MACDONALD NE, Dube E, Comeau JL
    Have vaccine hesitancy models oversimplified a complex problem to our detriment? The Adapted Royal Society of Canada vaccine uptake framework.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00669.
    >> Share

  1659. SAVULESCU C, Krizova P, Valentiner-Branth P, Ladhani S, et al
    Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00581.
    >> Share

  1660. LAI X, Li M, Hou Z, Guo J, et al
    Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00606.
    >> Share

  1661. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    >> Share

  1662. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    >> Share

  1663. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    >> Share

  1664. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    >> Share

  1665. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    >> Share

  1666. MOUSSAOUI S, Combes S, Ibanez G, Gautier A, et al
    Are immigrants living in France more reluctant to receive vaccines than native-born French citizens? findings from the national health Barometer study.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00636.
    >> Share

  1667. ILESANMI MM, Adeyinka DA, Olakunde BO
    Sustainable Development Goals and childhood measles vaccination in Ekiti State, Nigeria: Results from spatial and interrupted time series analyses.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00632.
    >> Share

  1668. LARSEN L, Bistrup C, Sorensen SS, Boesby L, et al
    Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: A non-blinded, randomized clinical trial.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00635.
    >> Share

  1669. TAFURI S, Bianchi FP, Stefanizzi P
    The public health and the question of the "best vaccine".
    Vaccine. 2022 May 26. pii: S0264-410X(22)00639.
    >> Share

  1670. HOFFMAN BL, Batra Hershey T, Chu KH, Sidani JE, et al
    Moving vaccination beyond partisan politics.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00664.
    >> Share

  1671. ZHOU Y, Hu X, Chen R, Wu J, et al
    Impact of maternal and pre-existing antibodies on immunogenicity of inactivated rotavirus vaccines.
    Vaccine. 2022 May 26. pii: S0264-410X(22)00620.
    >> Share

  1672. JANKO MM, Joffe J, Michael D, Earl L, et al
    Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00637.
    >> Share

  1673. DUBE E, Gagnon D, MacDonald N
    Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
    >> Share

  1674. GAGHAN C, Adams D, Mohammed J, Crespo R, et al
    Characterization of vaccine-induced immune responses against coccidiosis in broiler chickens.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00638.
    >> Share

  1675. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    >> Share

  1676. BECK E, Biundo E, Devlin N, Doherty TM, et al
    Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
    >> Share

  1677. MALTER KB, Tugel ME, Gil-Rodriguez M, de la Guardia G, et al
    Corrigendum to "Variability in non-core vaccination rates of dogs and cats in veterinary clinics across the United States" [Vaccine 40(7) (2022) 1001-1009].
    Vaccine. 2022 May 23. pii: S0264-410X(22)00619.
    >> Share

  1678. QUINN MK, Edmond KM, Fawzi WW, Hurt L, et al
    Non-specific effects of BCG and DTP vaccination on infant mortality: An analysis of birth cohorts in Ghana and Tanzania.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00536.
    >> Share

  1679. CHANG CM, Awanye AM, Marsay L, Dold C, et al
    Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial.
    Vaccine. 2022 May 21. pii: S0264-410X(22)00616.
    >> Share

  1680. MOLLER A, Schwamborn K, Spillmann A, Hoogstraate J, et al
    Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?
    Vaccine. 2022 May 21. pii: S0264-410X(22)00611.
    >> Share

  1681. OSMAN S, Crowcroft N, McLachlan E, Hatchette T, et al
    Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2022;40:3228-3235.
    >> Share

  1682. LLAVE CL, Uy MEV, Lam HY, Aldaba JG, et al
    The cost-effectiveness of human papillomavirus vaccination in the Philippines.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00609.
    >> Share

  1683. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    >> Share

  1684. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    >> Share

  1685. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    >> Share

  1686. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    >> Share

  1687. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    >> Share

  1688. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    >> Share

  1689. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    >> Share

  1690. ZHANG Y, Lin L, Yang J, Lv Q, et al
    Two Bordetella bronchiseptica attenuated vaccine candidates confer protection against lethal challenge with B. Bronchiseptica and Pasteurella multocida toxin in mouse models.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00604.
    >> Share

  1691. POSTMA M, Biundo E, Chicoye A, Devlin N, et al
    Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts.
    Vaccine. 2022 May 18. pii: S0264-410X(22)00442.
    >> Share

  1692. VESIKARI T, Saez-Llorens X, Blazevic V, Lopez P, et al
    Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00550.
    >> Share

  1693. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    >> Share

  1694. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    >> Share

  1695. NAZURDINOV A, Azizov Z, Mullojonova M, Sadykova U, et al
    Impact and effectiveness of monovalent rotavirus vaccine in Tajik children.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00589.
    >> Share

  1696. SULIS G, Horn M, Borrow R, Basta NE, et al
    A comparison of national vaccination policies to prevent serogroup B meningococcal disease.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00568.
    >> Share

  1697. POLAND GA, van Dijk N
    John D. Bailey retiring after more than 20years of service to Vaccine.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00618.
    >> Share

  1698. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    >> Share

  1699. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    >> Share

  1700. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    >> Share

  1701. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    >> Share

  1702. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    >> Share

  1703. LI F, Freed D, Heidecker G, Galli J, et al
    A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00569.
    >> Share

  1704. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    >> Share

  1705. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    >> Share

  1706. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    >> Share

  1707. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.
    >> Share

  1708. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    >> Share

  1709. OSTER G, Bornheimer R, Ottino K, Stevenson C, et al
    Adult immunization against hepatitis B: Does the number of jabs matter?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00534.
    >> Share

  1710. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    >> Share

  1711. SHAUM A, Mujuru HA, Takamiya M, Ticklay I, et al
    Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00551.
    >> Share

  1712. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Corrigendum to "Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study" [Vaccine 40(2) (2022) 275-281].
    Vaccine. 2022 May 11. pii: S0264-410X(22)00537.
    >> Share

  1713. ISLAM N, Xu C, Lau CL, Mills DJ, et al
    Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00535.
    >> Share

  1714. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    >> Share

  1715. KITRO A, Sirikul W, Thongkum W, Soponpong S, et al
    Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Vaccine. 2022;40:2915-2924.
    >> Share

  1716. MARTIN J, Barrett ADT, Lei D, Minor P, et al
    WHO working group meeting to amend WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00548.
    >> Share

  1717. ZOLA MATUVANGA T, Lariviere Y, Lemey G, De Bie J, et al
    Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00544.
    >> Share

  1718. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    >> Share

  1719. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    >> Share

  1720. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus sero
    Vaccine. 2022 May 6. pii: S0264-410X(22)00571.
    >> Share

  1721. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    >> Share

  1722. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    >> Share

  1723. COLE JW, Chen AMH, McGuire K, Berman S, et al
    Erratum to "Motivational interviewing and vaccine acceptance in children: The MOTIVE study" [Vaccine 40(12) (2022) 1846-1854].
    Vaccine. 2022 May 5. pii: S0264-410X(22)00538.
    >> Share

  1724. VELICER C, Luxembourg A, Chen YT, Kohn M, et al
    Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00542.
    >> Share

  1725. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    >> Share

  1726. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    >> Share

  1727. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    >> Share

  1728. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    >> Share

  1729. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    >> Share

  1730. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    >> Share

  1731. GUTIERREZ-TOBAR IF, Londono-Ruiz JP, Marino-Drews C, Beltran-Higuera S, et al
    Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008-2019.
    Vaccine. 2022;40:2875-2883.
    >> Share

  1732. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    >> Share

  1733. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    >> Share

  1734. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    >> Share

    April 2022
  1735. TOLL M, Li A
    Vaccine mandates on childcare entry without conscientious objection exemptions: A quasi-experimental panel study.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00461.
    >> Share

  1736. GREYSON D, Carpiano RM, Bettinger JA
    Support for a vaccination documentation mandate in British Columbia, Canada.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00247.
    >> Share

  1737. TAMURA K, Kohnoe M, Takashino A, Kobayashi K, et al
    TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00518.
    >> Share

  1738. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    >> Share

  1739. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    >> Share

  1740. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    >> Share

  1741. TAMURA K, Chang B, Shimbashi R, Watanabe H, et al
    Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00502.
    >> Share

  1742. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    >> Share

  1743. LV H, Wang S, Liang Z, Yu W, et al
    Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00205.
    >> Share

  1744. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    >> Share

  1745. JAFFLIN K, Deml MJ, Schwendener CL, Kiener L, et al
    Parental and provider vaccine hesitancy and non-timely childhood vaccination in Switzerland.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00472.
    >> Share

  1746. KOULIDIATI JL, Kabore R, I Nebie E, Sidibe A, et al
    Timely completion of childhood vaccination and its predictors in Burkina Faso.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00497.
    >> Share

  1747. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    >> Share

  1748. KRUPP K, Galea J, Madhivanan P, Gerald L, et al
    Conversational artificial intelligence: A new approach for increasing influenza vaccination rates in children with asthma?
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00496.
    >> Share

  1749. YUKI Y, Nojima M, Kashima K, Sugiura K, et al
    Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00491.
    >> Share

  1750. ZHU FC, Zeng H, Li JX, Wang B, et al
    Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00462.
    >> Share

  1751. PERCIACCANTE A, Asensi V, Cucu AI, Charlier P, et al
    War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00465.
    >> Share

  1752. BEYER WEP, Palache AM, Boulfich M, Osterhaus ADME, et al
    Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00489.
    >> Share

  1753. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    >> Share

  1754. ONNIS V, Moriconi A, Paludi M, Giannini S, et al
    Clinically proven specification setting for a meningococcal serogroup a conjugate vaccine.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00493.
    >> Share

  1755. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.
    >> Share

  1756. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    >> Share

  1757. HAMID FA, Marker CL, Raleigh MD, Khaimraj A, et al
    Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00364.
    >> Share

  1758. SEPPALA E, Brathen Kristoffersen A, Boas H, Frimann Vestrheim D, et al
    Pertussis epidemiology including direct and indirect effects of the childhood pertussis booster vaccinations, Norway, 1998-2019.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00466.
    >> Share

  1759. BEULENS C, Raven SFH, van Jaarsveld CHM, van Loo I, et al
    Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00470.
    >> Share

  1760. STALPERS CAL, Retmana IA, Pennings JLA, Vandebriel RJ, et al
    Corrigendum to "Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines" [Vaccine 39(18) (2021) 2506-2516].
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00475.
    >> Share

  1761. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    >> Share

  1762. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    >> Share

  1763. ORTIZ JR, Spearman PW, Goepfert PA, Cross K, et al
    Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Vaccine. 2022 Apr 21. pii: S0264-410X(22)00366.
    >> Share

  1764. CAN G, Acar HC, Aydin SN, Balkan II, et al
    Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers.
    Vaccine. 2022;40:2574-2579.
    >> Share

  1765. LEBLANC JJ, ElSherif M, Ye L, MacKinnon-Cameron D, et al
    Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
    Vaccine. 2022;40:2635-2646.
    >> Share

  1766. THOMPSON D, Metz SW, Abad C, Beaty S, et al
    Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00435.
    >> Share

  1767. GARTNER BC, Weinke T, Wahle K, Kwetkat A, et al
    Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00440.
    >> Share

  1768. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    >> Share

  1769. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    >> Share

  1770. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    >> Share

  1771. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    >> Share

  1772. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    >> Share

  1773. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    >> Share

  1774. ANDERSON A
    Attitudes towards vaccination and knowledge about antibiotics: Analysis of Wellcome Monitor survey data.
    Vaccine. 2022 Apr 15. pii: S0264-410X(22)00429.
    >> Share

  1775. BAROUTSOU V, Wymann M, Zens K, Sinniger P, et al
    National and regional variations in timely adherence to recommended measles vaccination scheme in 2-years old in Switzerland, 2005-2019.
    Vaccine. 2022 Apr 15. pii: S0264-410X(22)00424.
    >> Share

  1776. KUSHNER T, Huang V, Janssen R
    Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review.
    Vaccine. 2022 Apr 13. pii: S0264-410X(22)00443.
    >> Share

  1777. FENOLLAR F, Thomas L, Raoult D, Gautret P, et al
    Screening for SARS-CoV-2 antibodies to save vaccine doses.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00444.
    >> Share

  1778. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    >> Share

  1779. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00441.
    >> Share

  1780. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    >> Share

  1781. ZHU XM, Yan W, Sun J, Liu L, et al
    Patterns and influencing factors of COVID-19 vaccination willingness among college students in China.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00433.
    >> Share

  1782. SHINJOH M, Furuichi M, Kobayashi H, Yamaguchi Y, et al
    Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00449.
    >> Share

  1783. SPRINGER S, Kaatz M, Zieger M
    Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00430.
    >> Share

  1784. CEYLAN ME, Onen Unsalver B, Donmez A, Kaya Yertutanol FD, et al
    A case of myocarditis and isolated hypopotassemia after Biontech-Pfizer vaccine for Covid-19.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00432.
    >> Share

  1785. LJUNG R, Feychting M, Burstrom B, Moller J, et al
    Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00431.
    >> Share

  1786. OKTARIA V, Bines JE, Murni IK, Dinari R, et al
    Timeliness of routine childhood vaccinations in Indonesian infants in the first year of life.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00420.
    >> Share

  1787. BENINGER P
    Need for a contingency dimension when planning vaccine development in a pandemic environment.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00401.
    >> Share

  1788. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Corrigendum to 'Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice' [Vaccine 39 (2021) 6213-6220].
    Vaccine. 2022 Apr 9. pii: S0264-410X(22)00221.
    >> Share

  1789. AINSLIE KEC, Riley S
    Is annual vaccination best? A modelling study of influenza vaccination strategies in children.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00384.
    >> Share

  1790. TIANSHUO Z, Hanyu L, Bingfeng H, Bei L, et al
    Evaluation of the reliability and validity of a vaccine hesitancy scale on knowledge, attitude, trust and vaccination environment (KATE-S) in Chinese parents.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00388.
    >> Share

  1791. MAYFIELD HJ, Lau CL, Sinclair JE, Brown SJ, et al
    Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00418.
    >> Share

  1792. BELDA F, Mora O, Lopez Martinez M, Torres N, et al
    Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00419.
    >> Share

  1793. ERFANI P, Sandoval RS, Rich KM, Ojo A, et al
    Ask Me Anything": Lessons learned in implementing a COVID-19 vaccine information initiative in Massachusetts jails.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00439.
    >> Share

  1794. KENIGSBERG TA, Hause AM, McNeil MM, Nelson JC, et al
    Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00426.
    >> Share

  1795. LINKINS LA, Iorio A, Little J, Lavis J, et al
    Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00422.
    >> Share

  1796. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    >> Share

  1797. SHAH S, Gui H, Chua PEY, Tan JB, et al
    Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
    Vaccine. 2022 Apr 5. pii: S0264-410X(22)00381.
    >> Share

  1798. HASSAN PM, Ali T, Saber E, Asghar A, et al
    Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00385.
    >> Share

  1799. LEWIS RM, Markowitz LE
    Disparities in human papillomavirus vaccination coverage in the United States, National Health and Nutrition Examination Survey, January 2017-March 2020.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00317.
    >> Share

  1800. WALTERS JN, Schouest B, Patel A, Reuschel EL, et al
    Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00368.
    >> Share

  1801. ENTRICAN G, Francis MJ
    Applications of platform technologies in veterinary vaccinology and the benefits for one health.
    Vaccine. 2022 Apr 2. pii: S0264-410X(22)00371.
    >> Share

  1802. FRISE R, Baillon L, Zhou J, Kugathasan R, et al
    A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00383.
    >> Share

  1803. MA C, Sun W, Tang T, Jia M, et al
    Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00386.
    >> Share

  1804. SUGHAYER MA, Souan L, Abu Alhowr MM, Al Rimawi D, et al
    Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00387.
    >> Share

    March 2022
  1805. GERTOSIO C, Licari A, De Silvestri A, Rebuffi C, et al
    Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis.
    Vaccine. 2022 Mar 31. pii: S0264-410X(22)00341.
    >> Share

  1806. TEJADA RA, Malagon T, Franco EL
    Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis.
    Vaccine. 2022 Mar 31. pii: S0264-410X(22)00357.
    >> Share

  1807. VANDOORN E, Parys A, Chepkwony S, Chiers K, et al
    Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00362.
    >> Share

  1808. BURNY W, Herve C, Caubet M, Yarzabal JP, et al
    Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00361.
    >> Share

  1809. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a rando
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00367.
    >> Share

  1810. EFUA SACKEY M, Markey K, Grealish A
    Healthcare professional's promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00365.
    >> Share

  1811. TADDIO A, Gudzak V, Jantzi M, Logeman C, et al
    Impact of the CARD (Comfort Ask Relax Distract) system on school-based vaccinations: A cluster randomized trial.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00224.
    >> Share

  1812. MCRAE J, Blyth CC, Cheng AC, Quinn HE, et al
    Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00353.
    >> Share

  1813. ESTIVARIZ CF, Kovacs SD, Mach O
    Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00304.
    >> Share

  1814. ISITT C, Sjoholm D, Hergens MP, Granath F, et al
    The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00372.
    >> Share

  1815. KATO H, Miyakawa K, Ohtake N, Yamaoka Y, et al
    Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00369.
    >> Share

  1816. LI K, Yu T, Seabury SA, Dor A, et al
    Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00370.
    >> Share

  1817. JUDDOO V, Juddoo S, Megarbane B
    Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00363.
    >> Share

  1818. BREAKWELL L, Marke D, Kaiser R, Tejada-Strop A, et al
    Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00360.
    >> Share

  1819. FUNK PR, Yogurtcu ON, Forshee RA, Anderson SA, et al
    Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00329.
    >> Share

  1820. WELLS K, Moore KL, Bednarczyk R
    Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00339.
    >> Share

  1821. RICKETSON LJ, Bettinger JA, Sadarangani M, Halperin SA, et al
    Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vaccine. 2022 Mar 26. pii: S0264-410X(22)00359.
    >> Share

  1822. SIMMONS LA, Whipps MDM, Phipps JE, Satish NS, et al
    Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00355.
    >> Share

  1823. FARAH W, Breeher L, Shah V, Hainy C, et al
    Disparities in COVID-19 vaccine uptake among health care workers.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00356.
    >> Share

  1824. NOMURA Y, Noda K, Oohashi Y, Okuda S, et al
    Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00354.
    >> Share

  1825. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    >> Share

  1826. ST JEAN DT, Rogawski McQuade ET, Edwards JK, Thompson P, et al
    Effect of early life antibiotic use on serologic responses to oral rotavirus vaccine in the MAL-ED birth cohort study.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00300.
    >> Share

  1827. LEACH K, Checchi F
    The utilisation of vaccines in humanitarian crises, 2015-2019: A review of practice.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00335.
    >> Share

  1828. VOORMAN A, Lyons H, Bennette C, Kovacs S, et al
    Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00277.
    >> Share

  1829. LIU X, Yu W, Yin Z, Rodewald L, et al
    Vaccine events raising public concern and associated immunization program policy and practice changes, China, 2005-2021.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00334.
    >> Share

  1830. ABDEL-QADER DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, et al
    IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00265.
    >> Share

  1831. SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
    Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
    >> Share

  1832. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Decreasing routine vaccination rates in children in the COVID-19 era.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00333.
    >> Share

  1833. FANO V, Crielesi A, Coviello E, Fabiani M, et al
    Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00208.
    >> Share

  1834. FERDINANDS JM, Patel M
    Influence of disease attenuation on relative influenza vaccine effectiveness by vaccine type.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00274.
    >> Share

  1835. JIAN-BIN L, Lau EYH, Chan DKC
    Why do Hong Kong parents have low intention to vaccinate their children against COVID-19? testing health belief model and theory of planned behavior in a large-scale survey.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00340.
    >> Share

  1836. YUEN WLP, Loh SYJ, Wang DB
    SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00337.
    >> Share

  1837. ZERBO O, Modaressi S, Goddard K, Lewis E, et al
    Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00331.
    >> Share

  1838. CALLAGHAN T, Washburn D, Goidel K, Nuzhath T, et al
    Imperfect messengers? An analysis of vaccine confidence among primary care physicians.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00302.
    >> Share

  1839. ESPOSITO S, Nauta J, Lapini G, Montomoli E, et al
    Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00263.
    >> Share

  1840. BILGIN H, Marku M, Yilmaz SS, Karahasan Yagci A, et al
    The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00264.
    >> Share

  1841. GRUHN S, Witte J, Greiner W, Damm O, et al
    Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Vaccine. 2022;40:1932-1947.
    >> Share

  1842. WANG H, Ypma E, Nicolay U
    Managing multiplicity in clinical vaccine studies - A case study using a gatekeeping testing strategy.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00244.
    >> Share

  1843. GRAFFIGNA G, Palamenghi L, Barello S, Boccia S, et al
    Erratum to ""Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy" [Vaccine 38(48) (2020) 7585-7586].
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00295.
    >> Share

  1844. BATOOL R, Yousafzai MT, Qureshi S, Ali M, et al
    Corrigendum to "Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study". [Vaccine 39 (2021) 5858-5865].
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00294.
    >> Share

  1845. MACKLIN G, Peak C, Eisenhawer M, Kurji F, et al
    Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00195.
    >> Share

  1846. SADIGH K, Fox G, Khetsuriani N, Gao H, et al
    Policy and practice of checking vaccination status at school in 2018, a global overview.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00266.
    >> Share

  1847. GAO Z, Chen L, Song T, Pan X, et al
    A candidate multi-epitope vaccine against porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae induces robust humoral and cellular response in mice.
    Vaccine. 2022 Mar 17. pii: S0264-410X(22)00296.
    >> Share

  1848. GUL A, Doskaya M, Can H, Karakavuk M, et al
    Immunogenicity of a xenogeneic multi-epitope HER2(+) breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205.
    Vaccine. 2022 Mar 16. pii: S0264-410X(22)00279.
    >> Share

  1849. BEESLAAR J, Mather S, Absalon J, Eiden JJ, et al
    Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
    Vaccine. 2022;40:1872-1878.
    >> Share

  1850. KHETSURIANI N, Zaika O, Slobodianyk L, Scobie HM, et al
    Diphtheria and tetanus seroepidemiology among children in Ukraine, 2017.
    Vaccine. 2022;40:1810-1820.
    >> Share

  1851. CAMARA J, Gonzalez-Diaz A, Barrabeig I, Fernandez-Huerta M, et al
    SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00303.
    >> Share

  1852. ROTOLO B, Dube E, Vivion M, MacDonald SE, et al
    Hesitancy towards COVID-19 vaccines on social media in Canada.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00301.
    >> Share

  1853. MOSCARDINO U, Musso P, Inguglia C, Ceccon C, et al
    Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.
    Vaccine. 2022 Mar 14. pii: S0264-410X(22)00293.
    >> Share

  1854. MORGA A, Kimura T, Feng Q, Rozario N, et al
    Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination.
    Vaccine. 2022 Mar 12. pii: S0264-410X(22)00269.
    >> Share

  1855. LAMORI J, Feng X, Pericone CD, Mesa-Frias M, et al
    Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    Vaccine. 2022 Mar 12. pii: S0264-410X(22)00268.
    >> Share

  1856. HUANG HJ, Yang M, Chen HW, Wang S, et al
    A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.
    Vaccine. 2022 Mar 11. pii: S0264-410X(22)00225.
    >> Share

  1857. GU YOON J, Jang AY, Ja Kim M, Bin Seo Y, et al
    Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era: Serotype-dependent difference in ceftriaxone susceptibility.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00267.
    >> Share

  1858. KAKATSAKI I, Vergadi E, Paraskakis E, Galanakis E, et al
    Attitudes of junior healthcare professionals towards mandatory vaccination.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00275.
    >> Share

  1859. HARUTYUNYAN V, Quddus A, Pallansch M, Zipursky S, et al
    Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.
    Vaccine. 2022 Mar 10. pii: S0264-410X(22)00204.
    >> Share

  1860. VAN DEN HOOGEN LL, Smits G, van Hagen CCE, Wong D, et al
    Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00272.
    >> Share

  1861. THOMAS CM, Searle K, Galvan A, Liebman AK, et al
    Healthcare worker perspectives on COVID-19 vaccines: Implications for increasing vaccine acceptance among healthcare workers and patients.
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00276.
    >> Share

  1862. WILKINSON K, Righolt CH, Kwong JC, Schwartz KL, et al
    Corrigendum to "A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study" [Vaccine 37(48) (2019) 7132-7137].
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00240.
    >> Share

  1863. YUEN VWH
    Political attitudes and efficacy of health expert communication on the support for COVID-19 vaccination program: Findings from a survey in Hong Kong.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00261.
    >> Share

  1864. BANSAL P, Raj A, Mani Shukla D, Sunder N, et al
    COVID-19 vaccine preferences in India.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00241.
    >> Share

  1865. ULRICH AK, Sundaram ME, Basta NE
    Supporting individual vaccine decision-making: A role for vaccination counselors.
    Vaccine. 2022 Mar 4. pii: S0264-410X(22)00135.
    >> Share

  1866. MASCHERINI M, Nivakoski S
    Social media use and vaccine hesitancy in the European Union.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00206.
    >> Share

  1867. KLUMPP M, Monfared IG, Vollmer S
    Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00259.
    >> Share

  1868. COULAUD PJ, Ablona A, Bolduc N, Fast D, et al
    COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00260.
    >> Share

  1869. ROBERTSON LJ, Price R, Moore JS, Curry G, et al
    IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00262.
    >> Share

  1870. KREPS SE, Kriner DL
    How do COVID-19 vaccine mandates affect attitudes toward the vaccine and participation in mandate-affected activities? Evidence from the United States.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00258.
    >> Share

  1871. WONDIMU A, Postma MJ, van Hulst M
    Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00245.
    >> Share

  1872. YU M, Yao X, Liu G, Wu J, et al
    Barriers and facilitators to uptake and promotion of influenza vaccination among health care workers in the community in Beijing, China: A qualitative study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00207.
    >> Share

  1873. POINTON L, Howe AS, Hobbs M, Paynter J, et al
    Evidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00243.
    >> Share

  1874. LAI FTT, Leung MTY, Chan EWW, Huang L, et al
    Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Vaccine. 2022;40:1390-1396.
    >> Share

  1875. DENNY L
    HPV vaccine introduction and implementation in LMICs.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00227.
    >> Share

  1876. GU J, Dor A, Li K, Broniatowski DA, et al
    The impact of Facebook's vaccine misinformation policy on user endorsements of vaccine content: An interrupted time series analysis.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00209.
    >> Share

  1877. SEXSON TEJTEL SK, Munoz FM, Al-Ammouri I, Savorgnan F, et al
    Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:1499-1511.
    >> Share

  1878. MOURA C, Truche P, Sousa Salgado L, Meireles T, et al
    The impact of COVID-19 on routine pediatric vaccination delivery in Brazil.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00242.
    >> Share

    February 2022
  1879. SINGH JA, Kochhar S, Wolff J, Atuire C, et al
    WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00175.
    >> Share

  1880. MCANDREW T, Cambeiro J, Besiroglu T
    Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00200.
    >> Share

  1881. LAU YL, Fan Leung T, Sirvan Cetin B, Cagri Dinleyici E, et al
    Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00218.
    >> Share

  1882. SALIOU P, Duteil Q, Plotkin SA, Gentilini M, et al
    The scourge of vaccine falsification.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00119.
    >> Share

  1883. SCHAFER W, Reinders T, Schink T
    Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00222.
    >> Share

  1884. DANIELS V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, et al
    Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00220.
    >> Share

  1885. KAGEYAMA T, Tanaka S, Etori K, Hattori K, et al
    Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00192.
    >> Share

  1886. MULLER KE, Dohos D, Sipos Z, Kiss S, et al
    Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00163.
    >> Share

  1887. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    Vaccine. 2022;40:1223-1230.
    >> Share

  1888. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    Vaccine. 2022;40:1215-1222.
    >> Share

  1889. DIXON MG, Tapia MD, Wannemuehler K, Luce R, et al
    Measles susceptibility in maternal-infant dyads-Bamako, Mali.
    Vaccine. 2022;40:1316-1322.
    >> Share

  1890. HAO F, Shao W
    Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00219.
    >> Share

  1891. NIE J, Sun Y, Feng K, Huang L, et al
    The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00159.
    >> Share

  1892. EL-HENEIDY A, Grimwood K, Lambert SB, Sarna M, et al
    Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00198.
    >> Share

  1893. ABBATECOLA AM, Incalzi RA, Malara A, Palmieri A, et al
    Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00217.
    >> Share

  1894. CHOOI WH, Ng PW, Hussain Z, Ming LC, et al
    Vaccine contamination: Causes and control.
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00169.
    >> Share

  1895. TAWINPRAI K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, et al
    Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00143.
    >> Share

  1896. ISMAIL ALHOSANI F, Eduardo Stanciole A, Aden B, Timoshkin A, et al
    Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00174.
    >> Share

  1897. FILIA A, Rota MC, Grossi A, Martinelli D, et al
    Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination.
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00187.
    >> Share

  1898. WINTER T, Riordan BC, Scarf D, Jose PE, et al
    Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00074.
    >> Share

  1899. STANDAERT B, Strens D, Raes M, Benninghoff B, et al
    Explaining the formation of a plateau in rotavirus vaccine impact on rotavirus hospitalisations in Belgium.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00199.
    >> Share

  1900. LEE GY, Inthasorn P, Laowahutanont P, Lawpoolsri S, et al
    Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00188.
    >> Share

  1901. SCHMALING KB
    Couples and COVID-19 vaccination: Frequency and reasons for discordance.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00202.
    >> Share

  1902. TRUMP BD, Golan MS, Keisler JM, Cegan JC, et al
    Vaccine supply chain: Resilience-by-design and resilience-by-intervention.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00172.
    >> Share

  1903. HENSCHKE N, Bergman H, Hungerford D, Cunliffe NA, et al
    The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00125.
    >> Share

  1904. KASSTAN B, Mounier-Jack S, Letley L, Gaskell KM, et al
    Localising vaccination services: Qualitative insights on public health and minority group collaborations to co-deliver coronavirus vaccines.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00201.
    >> Share

  1905. MERKLEY E, Loewen PJ
    The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00168.
    >> Share

  1906. LAZO L, Bequet-Romero M, Lemos G, Musacchio A, et al
    A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Vaccine. 2022;40:1162-1169.
    >> Share

  1907. JOG P, Memon IA, Thisyakorn U, Hozbor D, et al
    Pertussis in Asia: Recent country-specific data and recommendations.
    Vaccine. 2022;40:1170-1179.
    >> Share

  1908. STEFANIZZI P, Larocca AMV, Martinelli A, Soldano S, et al
    Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00124.
    >> Share

  1909. KALASKA B, Miklosz J, Swieton J, Jakimczuk A, et al
    The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00173.
    >> Share

  1910. BUCKLEY A, Lager K
    Efficacy of an inactivated Senecavirus A vaccine in weaned pigs and mature sows.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00142.
    >> Share

  1911. ANUGULRUENGKITT S, Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, et al
    Seroprevalence of mumps among children and adolescents in Thailand, 2020.
    Vaccine. 2022;40:1061-1064.
    >> Share

  1912. HUSKA B, Kubinec C, Sadarangani M, Ulanova M, et al
    Seroprevalence of IgG and IgM antibodies to Haemophilus influenzae type a in Canadian children.
    Vaccine. 2022;40:1128-1134.
    >> Share

  1913. ARAKELIAN T, Oosterhuis K, Tondini E, Los M, et al
    Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00162.
    >> Share

  1914. SALEH OA, Halperin O
    Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00160.
    >> Share

  1915. HIDLE A, Brennan T, Garon J, An Q, et al
    Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00047.
    >> Share

  1916. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    >> Share

  1917. TANI N, Chong Y, Kurata Y, Gondo K, et al
    Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00158.
    >> Share

  1918. AMMETER T, Lang P, Czock A
    Overview of the influenza vaccination activities and legal frameworks in 26 Swiss cantons during the influenza season 2019/20.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00132.
    >> Share

  1919. MUCHIRI SK, Muthee R, Kiarie H, Sitienei J, et al
    Unmet need for COVID-19 vaccination coverage in Kenya.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00167.
    >> Share

  1920. GAFFNEY KK, Jana Broadhurst M, Brett-Major DM
    Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00193.
    >> Share

  1921. YAMAMOTO S, Fukunaga A, Tanaka A, Takeuchi JS, et al
    Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00196.
    >> Share

  1922. UWAMINO Y, Yokoyama T, Shimura T, Nishimura T, et al
    The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00191.
    >> Share

  1923. GAO F, An C, Bian L, Wang Y, et al
    Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00194.
    >> Share

  1924. CHAN IL, Mowson R, Alonso JP, Roberti J, et al
    Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00197.
    >> Share

  1925. CHRYSI P, Stella M, Marios K, Despo C, et al
    Exploring vaccination coverage and attitudes of health care workers towards influenza vaccine in Cyprus.
    Vaccine. 2022 Feb 12. pii: S0264-410X(22)00141.
    >> Share

  1926. HELLER O, Chun Y, Shlomo Y, Gewirtz-Meydan A, et al
    Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00165.
    >> Share

  1927. KOCHHAR S, Barreira D, Beattie P, Cavaleri M, et al
    Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
    Vaccine. 2022 Feb 11. pii: S0264-410X(21)01395.
    >> Share

  1928. DIETRICH LG, Luthy A, Lucas Ramanathan P, Baldesberger N, et al
    Healthcare professional and professional stakeholders' perspectives on vaccine mandates in Switzerland: A mixed-methods study.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00007.
    >> Share

  1929. TIBBELS NJ, Dosso A, Fordham C, Benie W, et al
    "On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00166.
    >> Share

  1930. KAPLONEK P, Yao L, Reppe K, Voss F, et al
    A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae.
    Vaccine. 2022;40:1038-1046.
    >> Share

  1931. ABHILASH KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, et al
    Impact of prior vaccination with Covishield(TM) and Covaxin(R) on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00157.
    >> Share

  1932. DEBELLUT F, Mkisi R, Masoo V, Chisema M, et al
    Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00139.
    >> Share

  1933. COLE JW, M H Chen A, McGuire K, Berman S, et al
    Motivational interviewing and vaccine acceptance in children: The MOTIVE study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00114.
    >> Share

  1934. PAOLINO KM, Regules JA, Moon JE, Ruck RC, et al
    Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00093.
    >> Share

  1935. BERGMANN ESTEVES S, Moreira Santos C, Ferreira Salgado F, Paldes Goncales A, et al
    Efficacy of commercially available vaccines against canine leptospirosis: A systematic review and meta-analysis.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00144.
    >> Share

  1936. DREYER N, Reynolds MW, Albert L, Brinkley E, et al
    How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00103.
    >> Share

  1937. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    >> Share

  1938. DE LUCA C, Schachner A, Heidl S, Hess M, et al
    Vaccination with a fowl adenovirus chimeric fiber protein (crecFib-4/11) simultaneously protects chickens against hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH).
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00116.
    >> Share

  1939. SCHALTZ-BUCHHOLZER F, Toldi G
    The association between parental and neonatal BCG vaccination and neonatal T helper 17 cell expansion.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00128.
    >> Share

  1940. CARLOW DA, Lai JCY, Kollmann TR, Sadarangani M, et al
    Cutaneous CpG adjuvant conditioning to enhance vaccine responses.
    Vaccine. 2022 Feb 8. pii: S0264-410X(21)01668.
    >> Share

  1941. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00164.
    >> Share

  1942. PEREZ-RODRIGUEZ S, de la Caridad Rodriguez-Gonzalez M, Ochoa-Azze R, Climent-Ruiz Y, et al
    A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00161.
    >> Share

  1943. LADHANI SN, Campbell H, Amin-Chowdhury Z, Lucidarme J, et al
    Timing of meningococcal vaccination with 4CMenB (Bexsero(R)) in children with invasive meningococcal group B (MenB) disease in England.
    Vaccine. 2022 Feb 8. pii: S0264-410X(21)01618.
    >> Share

  1944. CORNISH MJ, Hedrick JA, Gabrielsen AA, Johnson AD, et al
    Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00096.
    >> Share

  1945. DENG JZ, Lancaster C, Winters MA, Phillips KM, et al
    Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00076.
    >> Share

  1946. WALKER B, Anderson A, Stoecker C, Shao Y, et al
    COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid.
    Vaccine. 2022;40:837-840.
    >> Share

  1947. CRUVINEL E, P Richter K, S Scheuermann T, M Machado N, et al
    The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00120.
    >> Share

  1948. MEWHIRTER J, Sagir M, Sanders R
    Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00134.
    >> Share

  1949. DOMNICH A, Orsi A, Sticchi L, Panatto D, et al
    Effect of the 2020/21 season influenza vaccine on SARS-CoV-2 infection in a cohort of Italian healthcare workers.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00137.
    >> Share

  1950. BELLOS I, Karageorgiou V, Viskin D
    Myocarditis following mRNA Covid-19 vaccination: A pooled analysis.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00140.
    >> Share

  1951. SPRENGHOLZ P, Korn L, Eitze S, Felgendreff L, et al
    Attitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00130.
    >> Share

  1952. WONODI C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, et al
    Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00126.
    >> Share

  1953. WALKER J, Paul P, Dooling K, Oliver S, et al
    Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00136.
    >> Share

  1954. HU S, Logan N, Puenpa J, Wanlapakorn N, et al
    Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants.
    Vaccine. 2022 Feb 5. pii: S0264-410X(22)00095.
    >> Share

  1955. AKGUN O, Kayaalp GK, Demirkan FG, Cakmak F, et al
    Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00117.
    >> Share

  1956. NONVIGNON J, Owusu R, Asare B, Adjagba A, et al
    Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00070.
    >> Share

  1957. OLIANI F, Savoia A, Gallo G, Tiwana N, et al
    Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00115.
    >> Share

  1958. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00059.
    >> Share

  1959. IRVING SA, Groom HC, Dandamudi P, Daley MF, et al
    A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00091.
    >> Share

  1960. TAKESHITA K, Ishiwada N, Takeuchi N, Ohkusu M, et al
    Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00102.
    >> Share

  1961. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00058.
    >> Share

  1962. ELLITHORPE ME, Alade F, Adams RB, Nowak GJ, et al
    Looking ahead: Caregivers' COVID-19 vaccination intention for children 5 years old and younger using the health belief model.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00097.
    >> Share

  1963. HEYERDAHL LW, Vray M, Lana B, Tvardik N, et al
    Conditionality of COVID-19 vaccine acceptance in European countries.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00099.
    >> Share

  1964. SHAW J, Anderson KB, Fabi RE, Thompson CA, et al
    COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00100.
    >> Share

  1965. YOUSAF M, Hassan Raza S, Mahmood N, Core R, et al
    Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00101.
    >> Share

    January 2022
  1966. YANG YL, Kim J, Jeong Y, Jang YS, et al
    Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection.
    Vaccine. 2022;40:714-725.
    >> Share

  1967. JANSSEN YF, Feitsma EA, Boersma HH, Alleva DG, et al
    Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00077.
    >> Share

  1968. PANWAR K, Godi A, Cocuzza CE, Andrews N, et al
    Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix(R) or Gardasil(R) vaccine.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00075.
    >> Share

  1969. SANDMANN FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, et al
    Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00039.
    >> Share

  1970. PITTET LF, Cox L, Freyne B, Germano S, et al
    Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
    Vaccine. 2022 Jan 29. pii: S0264-410X(22)00020.
    >> Share

  1971. MORGAN C, Giattas MR, Holroyd T, Pfitzer A, et al
    Integration of other services with human papillomavirus vaccination; lessons from earlier in the life course highlight the need for new policy and implementation evidence.
    Vaccine. 2022 Jan 29. pii: S0264-410X(21)01674.
    >> Share

  1972. SHERIDAN S, McIntyre P, Liu B, Fathima P, et al
    Pertussis burden and acellular pertussis vaccine effectiveness in high risk children.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01322.
    >> Share

  1973. MSUSA KP, Rogalski-Salter T, Mandi H, Clemens R, et al
    Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00072.
    >> Share

  1974. KANTELE A, Rombo L, Vene S, Kundi M, et al
    Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50 years or older: A single-centre, open-label, randomized controlled trial.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00048.
    >> Share

  1975. KALNIN KV, Plitnik T, Kishko M, Huang D, et al
    Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00045.
    >> Share

  1976. WHITE AA, Neelon B, Martin RH, Cartmell KB, et al
    Spatial patterns of HPV and Tdap vaccine dose administration and the association of health department clinic access in Georgia counties.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01647.
    >> Share

  1977. DING H, Huang J, Ngai CH, Sun Q, et al
    The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00057.
    >> Share

  1978. STEPPERT P, Mosor M, Stanek L, Burgstaller D, et al
    A scalable, integrated downstream process for production of a recombinant measles virus-vectored vaccine.
    Vaccine. 2022 Jan 27. pii: S0264-410X(22)00019.
    >> Share

  1979. HE Q, Xiao J, Liu M, Li Z, et al
    Immunogenicity of meningococcal polysaccharide conjugate vaccine as a replacement for meningococcal polysaccharide vaccine in children in Guangzhou, China.
    Vaccine. 2022 Jan 27. pii: S0264-410X(21)01200.
    >> Share

  1980. JAFFE AE, Graupensperger S, Blayney JA, Duckworth JC, et al
    The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies.
    Vaccine. 2022 Jan 26. pii: S0264-410X(22)00073.
    >> Share

  1981. KARAFILLAKIS E, Peretti-Watel P, Verger P, Chantler T, et al
    'I trust them because my mum trusts them': Exploring the role of trust in HPV vaccination decision-making among adolescent girls and their mothers in France.
    Vaccine. 2022 Jan 25. pii: S0264-410X(22)00046.
    >> Share

  1982. IANNINO F, Uriza PJ, Duarte CM, Pepe MV, et al
    Development of a Salmonella-based oral vaccine to control intestinal colonization of Shiga-toxin-producing Escherichia coli (STEC) in animals.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00056.
    >> Share

  1983. OGUTI B, Ali A, Andrews N, Barug D, et al
    The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.
    Vaccine. 2022;40:450-458.
    >> Share

  1984. ZINTGRAFF J, Gagetti P, Napoli D, Sanchez Eluchans N, et al
    Invasive Streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006-2019. Temporal progression of serotypes distribution and antibiotic resistance.
    Vaccine. 2022;40:459-470.
    >> Share

  1985. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Vaccine. 2022;40:536-543.
    >> Share

  1986. KIMOTO T
    Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant.
    Vaccine. 2022;40:544-553.
    >> Share

  1987. TANGUAY M, Boutin M, Laumaea A, Salaciak M, et al
    B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00071.
    >> Share

  1988. TRICOU V, Gottardo R, Egan MA, Clement F, et al
    Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00040.
    >> Share

  1989. HIDALGO-RUIZ M, Mejia-Lopez S, Perez-Serrano RM, Zaldivar-Lelo de Larrea G, et al
    Babesia bovis AMA-1, MSA-2c and RAP-1 contain conserved B and T-cell epitopes, which generate neutralizing antibodies and a long-lasting Th1 immune response in vaccinated cattle.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00049.
    >> Share

  1990. GHASWALLA PK, Bengtson LGS, Marshall GS, Buikema AR, et al
    Corrigendum to 'Meningococcal vaccination in patients with newly diagnosed asplenia in the United States' [Vaccine 39 (2021) 272-281].
    Vaccine. 2022 Jan 22. pii: S0264-410X(21)00994.
    >> Share

  1991. TRENT MJ, Salmon DA, MacIntyre CR
    Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00026.
    >> Share

  1992. STEBBINGS R, Armour G, Pettis V, Goodman J, et al
    AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice.
    Vaccine. 2022;40:192-195.
    >> Share

  1993. DRAZAN D, Czajka H, Maguire JD, Pregaldien JL, et al
    A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Vaccine. 2022;40:351-358.
    >> Share

  1994. RUSTANDI RR, Xu Q
    Reactivity characterization of bromoacetyl derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB(R) by NMR spectroscopy.
    Vaccine. 2022;40:187-191.
    >> Share

  1995. TUN ZM, Ring Z, Tam CC
    Factors associated with maternal tetanus vaccination in Myanmar: An analysis of demographic and health survey data.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00042.
    >> Share

  1996. LIU F, Feng C, Xu S, Wu Q, et al
    An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00054.
    >> Share

  1997. LIAO Q, Cowling BJ, Xiao J, Yuan J, et al
    Priming with social benefit information of vaccination to increase acceptance of COVID-19 vaccines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00055.
    >> Share

  1998. LI LL, Zheng C, La J, Do NV, et al
    Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00051.
    >> Share

  1999. PITCOVSKI J, Gruzdev N, Abzach A, Katz C, et al
    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00050.
    >> Share

  2000. ZHU D, Lv M, Bai Y, Wu J, et al
    Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00024.
    >> Share

  2001. PASSARETTI CL, Priem JS, Agner TG, McCurdy L, et al
    Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00044.
    >> Share

  2002. TUSE D, Malm M, Tamminen K, Diessner A, et al
    Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants.
    Vaccine. 2022 Jan 18. pii: S0264-410X(22)00022.
    >> Share

  2003. ROLFES L, Harmark L, Kant A, van Balveren L, et al
    COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00028.
    >> Share

  2004. OHFUJI S, Tanaka T, Nakano T, Kase T, et al
    Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00023.
    >> Share

  2005. BEDSTON S, Akbari A, Jarvis CI, Lowthian E, et al
    COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
    Vaccine. 2022 Jan 15. pii: S0264-410X(21)01535.
    >> Share

  2006. TANAKA M, Okubo R, Hoshi SL, Ishikawa N, et al
    Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Vaccine. 2022 Jan 13. pii: S0264-410X(22)00003.
    >> Share

  2007. SIMON JK, Staerke NB, Hemming-Harlo M, Layle S, et al
    Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged >/=50 years: A randomized phase 3 trial (PNEU-TRUE).
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01675.
    >> Share

  2008. MALTER KB, Tugel ME, Gil-Rodriguez M, Guardia G, et al
    Variability in non-core vaccination rates of dogs and cats in veterinary clinics across the United States.
    Vaccine. 2022 Jan 13. pii: S0264-410X(22)00006.
    >> Share

  2009. WARNER EL, Barbati JL, Duncan KL, Yan K, et al
    Vaccine misinformation types and properties in Russian troll tweets.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01648.
    >> Share

  2010. MOYO P, Bosco E, Bardenheier BH, Rivera-Hernandez M, et al
    Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01688.
    >> Share

  2011. WONG WHS, Leung D, Chua GT, Duque JSR, et al
    Adolescents' attitudes to the COVID-19 vaccination.
    Vaccine. 2022 Jan 12. pii: S0264-410X(22)00025.
    >> Share

  2012. WOO EJ, Moro PL
    Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Vaccine. 2022 Jan 11. pii: S0264-410X(22)00001.
    >> Share

  2013. SHIMIZU S, Tanaka R, Itoh E, Maekawa-Matsuura M, et al
    Performance and usability evaluation of novel intradermal injection device Immucise and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01669.
    >> Share

  2014. BLYTH DM, Liang Z, Williams M, Murray CK, et al
    Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01637.
    >> Share

  2015. DANIEL CL, Williams J, Legg R, McGowen C, et al
    Factors associated with COVID-19 vaccination intentions among adults in the deep South.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01667.
    >> Share

  2016. PENG KW, Carey T, Lech P, Vandergaast R, et al
    Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01671.
    >> Share

  2017. OMER I, Rosenberg A, Sefty H, Pando R, et al
    Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Vaccine. 2022 Jan 8. pii: S0264-410X(21)01664.
    >> Share

  2018. VADLAMUDI NK, Patrick DM, Rose C, Sadatsafavi M, et al
    A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01673.
    >> Share

  2019. FOO D, Sarna M, Pereira G, Moore HC, et al
    Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhood.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01556.
    >> Share

  2020. UWAMINO Y, Kurafuji T, Sato Y, Tomita Y, et al
    Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and universit
    Vaccine. 2022 Jan 7. pii: S0264-410X(22)00002.
    >> Share

  2021. HSIAO A, Hansen J, Nunley KV, Lewis N, et al
    Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
    Vaccine. 2022 Jan 6. pii: S0264-410X(21)01641.
    >> Share

  2022. EUSER S, Kroese FM, Derks M, de Bruin M, et al
    Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands.
    Vaccine. 2022 Jan 5. pii: S0264-410X(21)01670.
    >> Share

  2023. HUANG Z, Ji M, Ren J, Sun X, et al
    Effect of the framing of HPV vaccination on parents' willingness to accept an HPV vaccine.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01659.
    >> Share

  2024. GLADSTONE RA, Siira L, Brynildsrud OB, Vestrheim DF, et al
    International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01377.
    >> Share

  2025. LEDLIE S, Ricci C, Pan C, Rojas A, et al
    Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01655.
    >> Share

  2026. VILLENA R, Valenzuela MT, Bastias M, Santolaya ME, et al
    Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01549.
    >> Share

  2027. PENLINGTON M, Goulet P, Metcalfe B
    Improving knowledge and trust in vaccines: A survey-based assessment of the potential of the European Union Clinical Trial Regulation No 536/2014 plain language summary to increase health literacy.
    Vaccine. 2022 Jan 4. pii: S0264-410X(21)01653.
    >> Share

  2028. ZHANG J, Ji Y, Wang Z, Jia Y, et al
    Effective improvements to the live-attenuated Newcastle disease virus vaccine by polyethylenimine-based biomimetic silicification.
    Vaccine. 2022 Jan 3. pii: S0264-410X(21)01662.
    >> Share

  2029. KUZNETSOVA A, Ceregido MA, Jourquin A, Campora L, et al
    Fourteen years of the Pregnancy Registry on maternal immunisation with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine.
    Vaccine. 2022 Jan 3. pii: S0264-410X(21)01658.
    >> Share

  2030. OHM M, Knol MJ, Vos ERA, Bogaard MJM, et al
    Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016/17 and 2020.
    Vaccine. 2022;40:59-66.
    >> Share

  2031. KUJAWSKI SA, Yao L, Wang HE, Carias C, et al
    Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis.
    Vaccine. 2022 Jan 1. pii: S0264-410X(21)01672.
    >> Share

    December 2021
  2032. PASCHALL AV, Ozdilek A, Briner SL, Brindley MA, et al
    Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01666.
    >> Share

  2033. GROOM HC, Crane B, Naleway AL, Weintraub E, et al
    Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01656.
    >> Share

  2034. LUBLIN A, Katz C, Gruzdev N, Yadid I, et al
    Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins.
    Vaccine. 2021 Dec 30. pii: S0264-410X(21)01661.
    >> Share

  2035. SAELAND E, van der Fits L, Bolder R, Heemskerk-van der Meer M, et al
    Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01651.
    >> Share

  2036. FAINGELERNT Y, Dagan R, Givon-Lavi N, van der Beek BA, et al
    The impact of the pneumococcal conjugate vaccines on the incidence of community-acquired alveolar pneumonia in premature compared with in term-born infants.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01636.
    >> Share

  2037. ASOGWA OA, de Hoog MLA, Bruijning-Verhagen PCJI
    Impact of 7-valent versus 10-valent pneumococcal conjugate vaccines on primary care consultations across various age groups in the Netherlands, 5 years after the switch: A time-series analysis.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01533.
    >> Share

  2038. REIS LR, Costa-Rocha IAD, Campi-Azevedo AC, Peruhype-Magalhaes V, et al
    Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01638.
    >> Share

  2039. KUSI KA, Ofori EA, Akyea-Mensah K, Kyei-Baafour E, et al
    Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01650.
    >> Share

  2040. CHOWDHURY F, Akter A, Bhuiyan TR, Tauheed I, et al
    A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01623.
    >> Share

  2041. SHUKLA S, Fressin F, Un M, Coetzer H, et al
    Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01657.
    >> Share

  2042. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    >> Share

  2043. DE KOFF EM, van Houten MA, de Heij F, Berbers GAM, et al
    Salivary antibody responses to ten-valent pneumococcal conjugate vaccination following two different immunization schedules in a healthy birth cohort.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01622.
    >> Share

  2044. FREEMAN RE, Thaker J, Daley MF, Glanz JM, et al
    Vaccine timeliness and prevalence of undervaccination patterns in children ages 0-19 months, U.S., National immunization Survey-Child 2017.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01645.
    >> Share

  2045. JUNE CHOE Y, Yi S, Hwang I, Kim J, et al
    Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01654.
    >> Share

  2046. THOMAS SJ, Perez JL, Lockhart SP, Hariharan S, et al
    Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01652.
    >> Share

  2047. LACY J, Tessier E, Andrews N, White J, et al
    Impact of an accelerated measles-mumps-rubella (MMR) vaccine schedule on vaccine coverage: An ecological study among London children, 2012-2018.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01619.
    >> Share

  2048. BRENNAN T, Hidle A, Doshi RH, An Q, et al
    Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01531.
    >> Share

  2049. RAHIM S, Ahmad Z, Abdul-Ghafar J
    The polio vaccination story of Pakistan.
    Vaccine. 2021 Dec 23. pii: S0264-410X(21)01595.
    >> Share

  2050. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01544.
    >> Share

  2051. KIM HJ, Yun HJ, Kim J, Kym S, et al
    Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01620.
    >> Share

  2052. ROMAIN-SCELLE N, Elias C, Vanhems P
    COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhone-Alpes region (France): An ecological study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01644.
    >> Share

  2053. MANOMAIPIBOON A, Phumisantiphong U, Maneerit J, Chalearmchai Y, et al
    Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01632.
    >> Share

  2054. KENNEDY RB, Ovsyannikova IG, Haralambieva IH, Grill DE, et al
    Proteomic assessment of humoral immune responses in smallpox vaccine recipients.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01642.
    >> Share

  2055. PORTH JM, Wagner AL, Treleaven E, Fleischer NL, et al
    Childhood vaccination timeliness following maternal migration to an informal urban settlement in Kenya.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01625.
    >> Share

  2056. TADAKUMA K, Maruyama T, Mori K, Fujiki N, et al
    Effectiveness of seasonal influenza vaccine in adult Japanese workers, 2017-2020.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01624.
    >> Share

  2057. ERBER W, Khan F, Zavadska D, Freimane Z, et al
    Effectiveness of TBE vaccination in southern Germany and Latvia.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01639.
    >> Share

  2058. PETERSEN MB, Jorgensen F, Lindholt MF
    Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01631.
    >> Share

  2059. WILLIAMS KV, Zhai B, Alcorn JF, Patricia Nowalk M, et al
    A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01643.
    >> Share

  2060. SHAPIRO GK, Gottfredson N, Leask J, Wiley K, et al
    COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01649.
    >> Share

  2061. BLANCO S, Salome Konigheim B, Diaz A, Spinsanti L, et al
    Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Vaccine. 2021 Dec 20. pii: S0264-410X(21)01634.
    >> Share

  2062. NASREEN S, Wang J, Kwong JC, Crowcroft NS, et al
    Population-based incidence of invasive pneumococcal disease in children and adults in Ontario and British Columbia, 2002-2018: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2021;39:7545-7553.
    >> Share

  2063. IVANOVA-MARKOVA Y, Gonzalez-Dominguez A, Hidalgo A, Sanchez R, et al
    Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
    Vaccine. 2021;39:7646-7654.
    >> Share

  2064. RANADE D, Jena R, Sancheti S, Deore V, et al
    Rapid, high throughput protein estimation method for saponin and alhydrogel adjuvanted R21 VLP Malaria vaccine based on intrinsic fluorescence.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01627.
    >> Share

  2065. HERRING WL, Zhang Y, Shinde V, Stoddard J, et al
    Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01609.
    >> Share

  2066. POUKKA E, Baum U, Palmu AA, Lehtonen TO, et al
    Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01640.
    >> Share

  2067. WIDGREN K, Tomba GS, Leung KY, Giesecke J, et al
    Modelling varicella vaccination - What does a lack of surge in herpes zoster incidence tell us about exogenous boosting?
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01537.
    >> Share

  2068. CHUNG NH, Chen YC, Yang SJ, Lin YC, et al
    Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein.
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01635.
    >> Share

  2069. CARLSON SJ, McKenzie L, Roberts L, Blyth CC, et al
    Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
    Vaccine. 2021 Dec 16. pii: S0264-410X(21)01629.
    >> Share

  2070. GOLDBLATT D, Fiore-Gartland A, Johnson M, Hunt A, et al
    Towards a population-based threshold of protection for COVID-19 vaccines.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01615.
    >> Share

  2071. YU Y, Jia W, Lau MMC, Lau JTF, et al
    Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01628.
    >> Share

  2072. CHEN X, Wang H
    On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine.
    Vaccine. 2021 Dec 14. pii: S0264-410X(21)01596.
    >> Share

  2073. ALMOHAYA AM, Alsubie H, Alqarni B, Alzayad B, et al
    Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01610.
    >> Share

  2074. KURANI S, MacLaughlin KL, Jacobson RM, St Sauver JL, et al
    Socioeconomic disadvantage and human papillomavirus (HPV) vaccination uptake.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01611.
    >> Share

  2075. BOTTON J, Dray-Spira R, Baricault B, Drouin J, et al
    Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01617.
    >> Share

  2076. COSSU D, Ruberto S, Yokoyama K, Hattori N, et al
    Efficacy of BCG vaccine in animal models of neurological disorders.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01613.
    >> Share

  2077. LUTRICK K, Groom H, Fowlkes AL, Groover KD, et al
    COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01593.
    >> Share

  2078. HSIEH YL, Rak S, SteelFisher GK, Bauhoff S, et al
    Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01559.
    >> Share

  2079. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01621.
    >> Share

  2080. ZHAO AR, Bishai DM
    Public health spending, primary care, and perceived risk promoted vaccination against H1N1.
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01538.
    >> Share

  2081. KATZ MA, Harlev EB, Chazan B, Chowers M, et al
    Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01580.
    >> Share

  2082. AVILA-AGUERO ML, Camacho-Badilla K, Ulloa-Gutierrez R, Espinal-Tejada C, et al
    Epidemiology of pertussis in Costa Rica and the impact of vaccination: A 58-year experience (1961-2018).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01552.
    >> Share

  2083. KADKHODA K
    Post RNA-based COVID vaccines myocarditis: Proposed mechanisms.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01594.
    >> Share

  2084. ZHAO H, Li Y, Wang Z
    Adverse event of Sinovac Coronavirus vaccine: Deafness.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01576.
    >> Share

  2085. HOOK SA, Hansen AP, Niesobecki SA, Meek JI, et al
    Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States.
    Vaccine. 2021 Dec 8. pii: S0264-410X(21)01540.
    >> Share

  2086. PEPIN J, Labbe AC, Carignan A, Parent ME, et al
    Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
    Vaccine. 2021;39:7300-7307.
    >> Share

  2087. VON REYN CF
    BCG versus rBCG: What is the way forward?
    Vaccine. 2021;39:7319-7320.
    >> Share

  2088. VAN HOOIJ A, van den Eeden SJF, Khatun M, Soren S, et al
    BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease.
    Vaccine. 2021;39:7230-7237.
    >> Share

  2089. HEIJMENBERG I, Husain A, Sathkumara HD, Muruganandah V, et al
    ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence.
    Vaccine. 2021;39:7265-7276.
    >> Share

  2090. KOWALEWICZ-KULBAT M, Locht C
    BCG for the prevention and treatment of allergic asthma.
    Vaccine. 2021;39:7341-7352.
    >> Share

  2091. LENNON RP, Block R Jr, Schneider EC, Zephrin L, et al
    Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01597.
    >> Share

  2092. MA J, Casadei E, Bruce TJ, Sepahi A, et al
    Long-term efficacy of nasal vaccination against enteric red mouth (ERM) disease and infectious hematopoietic necrosis (IHN) in juvenile rainbow trout (Oncorhynchus mykiss).
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01551.
    >> Share

  2093. MARGOLIS MA, Brewer NT, Boynton MH, Lafata JE, et al
    Provider response and follow-up to parental declination of HPV vaccination.
    Vaccine. 2021 Dec 6. pii: S0264-410X(21)01529.
    >> Share

  2094. PEREZ-VILAR S, Dores GM, Marquez PL, Ng CS, et al
    Safety surveillance of meningococcal group B vaccine (Bexsero(R)), Vaccine Adverse Event Reporting System, 2015-2018.
    Vaccine. 2021 Dec 6. pii: S0264-410X(21)01545.
    >> Share

  2095. SULIS G, Basta NE, Wolfson C, Kirkland SA, et al
    Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01579.
    >> Share

  2096. RAW RK, Rees J, Kelly CA, Wroe C, et al
    Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01577.
    >> Share

  2097. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01553.
    >> Share

  2098. FACK C, Wood R, Hatherill M, Cobelens F, et al
    The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01488.
    >> Share

  2099. NGUYEN AT, Arnold BF, Kennedy CJ, Mishra K, et al
    Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01547.
    >> Share

  2100. IZAK M, Stoyanov E, Dezuraev K, Shinar E, et al
    Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01557.
    >> Share

  2101. HERZBERG J, Vollmer T, Fischer B, Becher H, et al
    SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01555.
    >> Share

  2102. YORSAENG R, Suntronwong N, Phowatthanasathian H, Assawakosri S, et al
    Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01560.
    >> Share

  2103. HELLE F, Moyet J, Demey B, Francois C, et al
    Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01558.
    >> Share

  2104. LI S, Chen W, Shen Y, Xia J, et al
    Molecular characterization of infectious bronchitis virus in Southwestern China for the protective efficacy evaluation of four live vaccine strains.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01546.
    >> Share

  2105. DUONG CH, Mueller JE, Tubert-Bitter P, Escolano S, et al
    Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01502.
    >> Share

  2106. WANG CH, Kung WJ, Lee CH, Lee CF, et al
    High rates of colonization and antimicrobial resistance of group B streptococcus highlight the need for vaccination even after implementation of guidelines for intrapartum antibiotic prophylaxis.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01543.
    >> Share

  2107. MUNOZ-QUILES C, Lopez-Lacort M, Diez-Domingo J, Rodrigo-Casares V, et al
    Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01536.
    >> Share

  2108. NEWALL AT, Beutels P, Tuffaha HW, Hall PS, et al
    How can early stage economic evaluation help guide research for future vaccines?
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01462.
    >> Share

  2109. PRICE J, Mooney J, Bain C, Bawa JT, et al
    National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.
    Vaccine. 2021 Dec 2. pii: S0264-410X(21)01443.
    >> Share

  2110. VALCKX S, Crevecoeur J, Verelst F, Vranckx M, et al
    Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01414.
    >> Share

  2111. EZE P, Aniebo CL, Agu UJ, Agu SA, et al
    Validity of maternal recall for estimating childhood vaccination coverage - Evidence from Nigeria.
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01534.
    >> Share

  2112. WIRTZ C, Mohamed Y, Engel D, Sidibe A, et al
    Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01447.
    >> Share

    November 2021
  2113. ATTWELL K, Rizzi M, McKenzie L, Carlson SJ, et al
    COVID-19 vaccine Mandates: An Australian attitudinal study.
    Vaccine. 2021 Nov 30. pii: S0264-410X(21)01530.
    >> Share

  2114. SUGISHITA Y, Sugawara T
    Effectiveness and cost-effectiveness of influenza vaccination for elderly people.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01257.
    >> Share

  2115. PORRAS C, Sampson JN, Herrero R, Gail MH, et al
    Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01486.
    >> Share

  2116. ZOU X, He J, Zheng J, Liang M, et al
    Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01532.
    >> Share

  2117. LAURENZ M, von Eiff C, Borchert K, Jacob C, et al
    Vaccination rates and adherence in premature infants before and after pneumococcal conjugate vaccine schedule change for term infants - A claims database analysis in Germany.
    Vaccine. 2021 Nov 28. pii: S0264-410X(21)01437.
    >> Share

  2118. LI H, Monslow MA, Freed DC, Chang D, et al
    Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates.
    Vaccine. 2021 Nov 28. pii: S0264-410X(21)01416.
    >> Share

  2119. MALTEZOU HC, Anastassopoulou C, Hatziantoniou S, Poland GA, et al
    Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01539.
    >> Share

  2120. CASTRO F, Pascale JM, Slocum Hewitt I, Calvo A, et al
    Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01504.
    >> Share

  2121. SCHMITZ M, Luminet O, Klein O, Morbee S, et al
    Predicting vaccine uptake during COVID-19 crisis: A motivational approach.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01542.
    >> Share

  2122. JIN P, Sun F, Liu Q, Wang Q, et al
    An oral vaccine based on chitosan/aluminum adjuvant induces both local and systemic immune responses in turbot (Scophthalmus maximus).
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01396.
    >> Share

  2123. GULPINAR G, Uzun MB
    Examining community pharmacists' intention to provide pharmacist-driven vaccination services: A structural equation modelling.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01499.
    >> Share

  2124. ROBERTSON JS, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, et al
    International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01528.
    >> Share

  2125. ENGEL D, Afeli ADJ, Morgan C, Zeck W, et al
    Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01466.
    >> Share

  2126. AHMED S, Dorin F, Satter SM, Sarker AR, et al
    The economic burden of rotavirus hospitalization among children < 5 years of age in selected hospitals in Bangladesh.
    Vaccine. 2021;39:7082-7090.
    >> Share

  2127. CANNON K, Elder C, Young M, Scott DA, et al
    A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults >/=65 years of age with different prior pneumococcal vaccination.
    Vaccine. 2021 Nov 25. pii: S0264-410X(21)01352.
    >> Share

  2128. KLEINWAKS G, Schmit V, Morrison J
    Considering human challenge trials for tuberculosis vaccine development.
    Vaccine. 2021 Nov 25. pii: S0264-410X(21)01469.
    >> Share

  2129. URUENA A, Badano MN, Bare P, Gonzalez J, et al
    Humoral and cellular immune memory response 12 years following single dose vaccination against hepatitis A in Argentinian children.
    Vaccine. 2021 Nov 24. pii: S0264-410X(21)01482.
    >> Share

  2130. BUCHMAN TG, Simpson SQ, Sciarretta KL, Finne KP, et al
    Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries().
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01461.
    >> Share

  2131. BETTENCOURT PJG, Joosten SA, Lindestam Arlehamn CS, Behr MA, et al
    100 years of the Bacillus Calmette-Guerin vaccine.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01483.
    >> Share

  2132. SUN P, Jani V, Johnson A, Cheng Y, et al
    T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01325.
    >> Share

  2133. DINC HO, Saltoglu N, Can G, Balkan II, et al
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01507.
    >> Share

  2134. LENTZEN MP, Huebenthal V, Kaiser R, Kreppel M, et al
    A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01526.
    >> Share

  2135. AREGA SM, Knobel DL, Toka FN, Conan A, et al
    Non-specific effects of veterinary vaccines: a systematic review.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01479.
    >> Share

  2136. HARA M, Koshida R, Nakano T
    Parents' views on mumps, mumps vaccine, and the factors associated with vaccination in Japan.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01449.
    >> Share

  2137. YE K, Shi D, Zhang Z, Bian L, et al
    A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01393.
    >> Share

  2138. LIN C, Tu P, Terry TC
    Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01444.
    >> Share

  2139. CHEN T, Dai M, Xia S
    Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01484.
    >> Share

  2140. CAMBON L, Schwarzinger M, Alla F
    Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01467.
    >> Share

  2141. MUSCATELLO DJ, Nazareno AL, Turner RM, Newall AT, et al
    Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01464.
    >> Share

  2142. BELLIZZI S, Aidyralieva C, Al-Shaikh A, Muthu N, et al
    Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01468.
    >> Share

  2143. ORTEGA-SANCHEZ IR, Mott JA, Kittikraisak W, Khanthamaly V, et al
    Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01445.
    >> Share

  2144. IRVING SA, Ball SW, Booth SM, Regan AK, et al
    A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01463.
    >> Share

  2145. HAFNER-GIESSAUF H, Horn S, Schwantzer G, Sprenger-Mahr H, et al
    Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01474.
    >> Share

  2146. BLAIN AE, Reese HE, Marjuki H, Topaz N, et al
    Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01480.
    >> Share

  2147. WANG W, Wang Y, Wang Y, Yan F, et al
    Vaccine bidding, procurement and distribution management practices in mainland China: A nationwide study.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01465.
    >> Share

  2148. NGUYEN KH, Anneser E, Toppo A, Allen JD, et al
    Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults >/= 18 years, United States.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01485.
    >> Share

  2149. KITRO A, Sirikul W, Piankusol C, Rirermsoonthorn P, et al
    Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand.
    Vaccine. 2021 Nov 17. pii: S0264-410X(21)01476.
    >> Share

  2150. JEAN BAPTISTE AE, Bawa S, Oteri AJ, Dieng B, et al
    Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria.
    Vaccine. 2021;39 Suppl 3:C1-C2.
    >> Share

  2151. KORAVE J, Bawa S, Ageda B, Ucho A, et al
    Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State.
    Vaccine. 2021;39 Suppl 3:C76-C81.
    >> Share

  2152. HOFF NA, Bratcher A, Mukadi P, Ahuka S, et al
    Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01404.
    >> Share

  2153. VOSS G, Jacquet JM, Tornieporth N, Kampmann B, et al
    Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01382.
    >> Share

  2154. VOHRA P, Chintoan-Uta C, Bremner A, Mauri M, et al
    Evaluation of a Campylobacter jejuni N-glycan-ExoA glycoconjugate vaccine to reduce C. jejuni colonisation in chickens.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01434.
    >> Share

  2155. LIANG Q, Li H, Chang X, Zhang H, et al
    A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.
    Vaccine. 2021;39:6947-6955.
    >> Share

  2156. BRAKEL KA, Binjawadagi B, French-Kim K, Watts M, et al
    Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Vaccine. 2021;39:6817-6828.
    >> Share

  2157. BOBO FT, Asante A, Woldie M, Dawson A, et al
    Child vaccination in sub-Saharan Africa: Increasing coverage addresses inequalities.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01439.
    >> Share

  2158. ESPARZA J, Damaso CR
    Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01441.
    >> Share

  2159. AMEND KL, Turnbull B, Zhou L, Marks MA, et al
    Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01403.
    >> Share

  2160. SILAS J, Jones A, Weiss-Cohen L, Ayton P, et al
    The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01472.
    >> Share

  2161. MURPHY RP, Taaffe C, Ahern E, McMahon G, et al
    A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01470.
    >> Share

  2162. ROGERS JH, Cox SN, Hughes JP, Link AC, et al
    Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01471.
    >> Share

  2163. CHOKEPHAIBULKIT K, Puthanakit T, Bhat N, Mansouri S, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
    Vaccine. 2021 Nov 14. pii: S0264-410X(21)01425.
    >> Share

  2164. BURKE RM, Shih S, Hsiung CA, Yen C, et al
    Impact of rotavirus vaccination on rotavirus hospitalizations in Taiwanese children.
    Vaccine. 2021 Nov 14. pii: S0264-410X(21)01397.
    >> Share

  2165. REESE HE, McNamara LA, Vianzon V, Blain A, et al
    Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01438.
    >> Share

  2166. ROSENTHAL S, Cummings CL
    Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01448.
    >> Share

  2167. HARMON SHE, Faour DE, MacDonald NE
    Mandatory immunization and vaccine injury support programs: A survey of 28 GNN countries.
    Vaccine. 2021 Nov 12. pii: S0264-410X(21)01390.
    >> Share

  2168. CHHABRIA S, Stanford FC
    A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01442.
    >> Share

  2169. VIZCARRA P, Haemmerle J, Velasco H, Velasco T, et al
    BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01417.
    >> Share

  2170. AW R, Ashik MR, Islam AAZM, Khan I, et al
    Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01432.
    >> Share

  2171. COLOMBATTI OLIVIERI MA, Moyano RD, Mon ML, Gravisaco MJ, et al
    Evaluation of a virulent strain of Mycobacterium avium subsp. Paratuberculosis used as a heat-killed vaccine.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01433.
    >> Share

  2172. MCLEAN HQ, Levine MZ, King JP, Flannery B, et al
    Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01415.
    >> Share

  2173. BABUADZE GG, Echanove J, Lamarre C, deLaVega MA, et al
    A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01315.
    >> Share

  2174. RODRIGUES CMC, Plotkin SA
    The influence of interval between doses on response to vaccines.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01381.
    >> Share

  2175. RADWAN NF, Abu-Sheasha GA, Bedwani RN, Yassine OG, et al
    Vaccine wastage and cost saving after multi-dose vial policy implementation in Egypt: A success story.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01400.
    >> Share

  2176. SHAH SFA, Ginossar T, Bentley JM, Zimet G, et al
    Using the Theory of Planned behavior to identify correlates of HPV vaccination uptake among college students attending a rural university in Alabama.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01431.
    >> Share

  2177. SVENNERHOLM AM, Qadri F, Lundgren A, Kaim J, et al
    Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
    Vaccine. 2021 Nov 9. pii: S0264-410X(21)01389.
    >> Share

  2178. THULUVA S, Matur R, Tsa K, Gv SR, et al
    A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV(TM)) in 1-15 years-old healthy hepatitis A vaccine-naive children.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01326.
    >> Share

  2179. HOSANGADI D, Martin EK, Watson M, Bruns R, et al
    Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01398.
    >> Share

  2180. MCKINNON B, Quach C, Dube E, Tuong Nguyen C, et al
    Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01426.
    >> Share

  2181. WU K, Choi A, Koch M, Elbashir S, et al
    Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01435.
    >> Share

  2182. VILLANUEVA-UY MET, Lam HY, Aldaba JG, Uy TMZ, et al
    Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01290.
    >> Share

  2183. CUEVAS-JUAREZ E, Pando-Robles V, Palomares LA
    Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01383.
    >> Share

  2184. SHARUN K, Tiwari R, Saied AA, Dhama K, et al
    SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01386.
    >> Share

  2185. GOODE JR, Cook P, Cuttino S, Gatewood SBS, et al
    Early experience with COVID-19 vaccine in a Federally-Qualified Healthcare Center for the homeless.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01388.
    >> Share

  2186. DE HAAS TDJ, Yeung KHT, Hutubessy R, van der Putten IM, et al
    Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong.
    Vaccine. 2021;39:6762-6780.
    >> Share

  2187. LAU CL, Mayfield HJ, Sinclair JE, Brown SJ, et al
    Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
    Vaccine. 2021 Nov 4. pii: S0264-410X(21)01428.
    >> Share

  2188. SANZ-ROJO S, Jimenez-Garcia R, Lopez-de-Andres A, de Miguel-Diez J, et al
    Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01392.
    >> Share

  2189. VASUDEVAN L, Ostermann J, Wang Y, Harrison SE, et al
    Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01356.
    >> Share

  2190. RIBERA-CANO A, Dupont M, Houze-Cerfon CH, Houze-Cerfon V, et al
    Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01429.
    >> Share

  2191. MIYA TV, Groome MJ, de Assis Rosa D
    TLR genetic variation is associated with Rotavirus-specific IgA seroconversion in South African Black infants after two doses of Rotarix vaccine.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01384.
    >> Share

  2192. PIERRON A, Bozon F, Berceanu A, Fontan J, et al
    Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01369.
    >> Share

  2193. MALTEZOU HC
    Vaccination of healthcare personnel in the COVID-19 era: A call for actions.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01427.
    >> Share

  2194. CASSONE A, Cauda R
    Multicomponent vaccines to fight SARS-CoV-2 variants of concern.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01402.
    >> Share

  2195. WAGNER A, Jasinska J, Tomosel E, Zielinski CC, et al
    Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01401.
    >> Share

    October 2021
  2196. LIU H, Zhou C, An J, Song Y, et al
    Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01399.
    >> Share

  2197. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    >> Share

  2198. KHOURY J, Najjar-Debbiny R, Hanna A, Jabbour A, et al
    COVID-19 vaccine - Long term immune decline and breakthrough infections.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01370.
    >> Share

  2199. GORDON SF, Clothier HJ, Morgan H, Buttery JP, et al
    Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01350.
    >> Share

  2200. GARCIA-GRIMSHAW M, Ceballos-Liceaga SE, Michel-Chavez A, Garcia-Alanis M, et al
    Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01391.
    >> Share

  2201. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.
    >> Share

  2202. MARTIN S, Vanderslott S
    "Any idea how fast 'It's just a mask!' can turn into 'It's just a vaccine!'": From mask mandates to vaccine mandates during the COVID-19 pandemic.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01351.
    >> Share

  2203. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    >> Share

  2204. JEON S, Kelly M, Yun J, Lee B, et al
    Scalable production and immunogenicity of a cholera conjugate vaccine.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01312.
    >> Share

  2205. CAPPOZZO F, Dal Zotto A, Scollo M, Bernardini D, et al
    dTap vaccination uptake during pregnancy: Pregnant women-focused and health professionals-focused predictors in the Veneto Region (Italy).
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01321.
    >> Share

  2206. HUANG J, Bai Y, Ding H, Wang B, et al
    Acceptance of pneumococcal vaccination in older adults: A general population-based survey.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01344.
    >> Share

  2207. CHANTHAVANICH P, Versage E, Van Twuijver E, Hohenboken M, et al
    Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01317.
    >> Share

  2208. OLANIPEKUN T, Abe T, Effoe V, Westney G, et al
    Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01324.
    >> Share

  2209. OPRIESSNIG T, Rawal G, McKeen L, Filippsen Favaro P, et al
    Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination.
    Vaccine. 2021 Oct 24. pii: S0264-410X(21)01353.
    >> Share

  2210. LOEB M, Russell ML, Kelly-Stradiotto C, Fuller N, et al
    Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01355.
    >> Share

  2211. MYAT TW, Thu HM, Tate JE, Burnett E, et al
    Rotavirus infection among children under five years of age hospitalized with acute gastroenteritis in Myanmar during 2018-2020 - Multicentre surveillance before rotavirus vaccine introduction.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01323.
    >> Share

  2212. FAN X, Li X, Wan K, Zhao X, et al
    Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01354.
    >> Share

  2213. SHACHOR-MEYOUHAS Y, Hussein K, Szwarcwort-Cohen M, Weissman A, et al
    Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01327.
    >> Share

  2214. TRAN VN, Nguyen HA, Le TTA, Truong TT, et al
    Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Vaccine. 2021;39:6485-6491.
    >> Share

  2215. ANDRADE G
    Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01371.
    >> Share

  2216. SHUBITZ LF, Robb EJ, Powell DA, Bowen RA, et al
    Deltacps1 vaccine protects dogs against experimentally induced coccidioidomycosis.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01349.
    >> Share

  2217. VAN BEEK LF, Langereis JD, van den Berg van Saparoea HB, Gillard J, et al
    Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01313.
    >> Share

  2218. DAR SA, Kole S, Shin SM, Jeong HJ, et al
    Comparative study on antigen persistence and immunoprotective efficacy of intramuscular and intraperitoneal injections of squalene - aluminium hydroxide (Sq + Al) adjuvanted viral hemorrhagic septicaemia virus vaccine in olive flounder (Paralichthys o
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01345.
    >> Share

  2219. ABU-RAYA B, Maertens K, Munoz FM, Zimmermann P, et al
    Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis.
    Vaccine. 2021;39:6545-6552.
    >> Share

  2220. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    >> Share

  2221. MAKOVITZKI A, Lerer E, Kafri Y, Adar Y, et al
    Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01376.
    >> Share

  2222. WANG J, Wagner AL, Chen Y, Jaime E, et al
    Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01340.
    >> Share

  2223. JAMES EK, Bokemper SE, Gerber AS, Omer SB, et al
    Persuasive messaging to increase COVID-19 vaccine uptake intentions.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01368.
    >> Share

  2224. NETANEL C, Ben-Aharon O, Ben-Ari Z, Chodick G, et al
    Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016.
    Vaccine. 2021 Oct 20. pii: S0264-410X(21)01287.
    >> Share

  2225. DANKWA EA, Donnelly CA, Brouwer AF, Zhao R, et al
    Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United states.
    Vaccine. 2021 Oct 19. pii: S0264-410X(21)01308.
    >> Share

  2226. KIM D, Pekgun P, Yildirim I, Keskinocak P, et al
    Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01346.
    >> Share

  2227. DANG TKNS, Rivero Cabrera R, Yeung KHT, van der Putten IM, et al
    Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months - 2 years and pregnant women.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01291.
    >> Share

  2228. CHEN AT, Stacey HD, Marzok A, Singh P, et al
    Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01341.
    >> Share

  2229. MAKI Y, Kashiwagi S, Kimizuka Y
    Laser vaccine adjuvants: Light-augmented immune responses.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01233.
    >> Share

  2230. CHAPIN-BARDALES J, Myers T, Gee J, Shay DK, et al
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01339.
    >> Share

  2231. ALI SAHRAIAN M, Ghadiri F, Azimi A, Naser Moghadasi A, et al
    Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Vaccine. 2021;39:6347-6350.
    >> Share

  2232. AYAZ S, Dibben O, Chapman D
    Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness.
    Vaccine. 2021 Oct 15. pii: S0264-410X(21)01320.
    >> Share

  2233. SILVER MC, Neumann PJ, Ma S, Kim DD, et al
    Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01285.
    >> Share

  2234. MOGHNIEH R, Mekdashi R, El-Hassan S, Abdallah D, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01314.
    >> Share

  2235. LALWANI SK, Ramanan PV, Sapru A, Sundaram B, et al
    Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01208.
    >> Share

  2236. BUUS M, da Silva I, Nielsen S, Thysen SM, et al
    Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau.
    Vaccine. 2021 Oct 12. pii: S0264-410X(21)01150.
    >> Share

  2237. PARK WJ, Yoon YK, Kim Y, Park JS, et al
    Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to DeltaVP8* protein from rotavirus.
    Vaccine. 2021 Oct 9. pii: S0264-410X(21)01282.
    >> Share

  2238. MCNAY LA, Arnoczy G, Martell M, Mock P, et al
    Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies.
    Vaccine. 2021;39:6183-6185.
    >> Share

  2239. HART P, Farrar J
    The influenza vaccines roadmap - A better future through improved influenza vaccines.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01286.
    >> Share

  2240. VERBERK JDM, van Dongen JAP, van de Kassteele J, Andrews NJ, et al
    Impact analysis of rotavirus vaccination in various geographic regions in Western Europe.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01262.
    >> Share

  2241. BRYDEN GM, Rockloff M, Browne M, Unsworth C, et al
    Effect of contamination and purity priming on attitudes to vaccination and other health interventions: A randomised controlled experiment.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01278.
    >> Share

  2242. VANDERMEULEN C, Leroux-Roels I, Vandeleur J, Staniscia T, et al
    A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01283.
    >> Share

  2243. FU LY, Torres R, Caleb S, Cheng YI, et al
    Vaccination coverage among young homeless children compared to US national immunization survey data.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01288.
    >> Share

  2244. MOTTELSON A, Vandeweerdt C, Atchapero M, Luong T, et al
    A self-administered virtual reality intervention increases COVID-19 vaccination intention.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01311.
    >> Share

  2245. HUMBLE RM, Sell H, Dube E, MacDonald NE, et al
    Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01309.
    >> Share

  2246. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    >> Share

  2247. CLEMENTS JD, Gorman GH, Waters CN, Lane HC, et al
    Tackling the burden of mumps in the military: A report of the Defense Health Board.
    Vaccine. 2021;39:6186-6188.
    >> Share

  2248. MAHAPATRA SR, Dey J, Kaur T, Sarangi R, et al
    Immunoinformatics and molecular docking studies reveal a novel Multi-Epitope peptide vaccine against pneumonia infection.
    Vaccine. 2021;39:6221-6237.
    >> Share

  2249. SCHNEIDER JC, Chen HC, Bautista E, Retallack D, et al
    Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults.
    Vaccine. 2021;39:6333-6339.
    >> Share

  2250. WANG J, Wu QS, Lu J, Ni YH, et al
    Low vaccination coverage of pneumococcal conjugate vaccines (PCVs) in Shanghai, China: A database analysis based on birth cohorts from 2012 to 2020.
    Vaccine. 2021;39:6189-6194.
    >> Share

  2251. ABAYNEH T, Getachew B, Gelaye E, Traxler R, et al
    Viability evaluation of freeze dried and suspension anthrax spore vaccine formulations stored at different temperatures.
    Vaccine. 2021;39:6245-6249.
    >> Share

  2252. MULLER-PEBODY B, Sinnathamby MA, Warburton F, Rooney G, et al
    Impact of the childhood influenza vaccine programme on antibiotic prescribing rates in primary care in England.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01284.
    >> Share

  2253. GIERSING B, Shah N, Kristensen D, Amorij JP, et al
    Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)00996.
    >> Share

  2254. REIDENBERG BE, Hirsch K, Costello CM, Russo M, et al
    Drive through COVID19 vaccination for developmentally disabled persons.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01279.
    >> Share

  2255. MUKHERJEE N, Julian E, Torrelles JB, Svatek RS, et al
    Effects of Mycobacterium bovis Calmette et Guerin (BCG) in oncotherapy: Bladder cancer and beyond.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01256.
    >> Share

  2256. ALLEVA DG, Delpero AR, Scully MM, Murikipudi S, et al
    Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01294.
    >> Share

  2257. LAZAROS G, Anastassopoulou C, Hatziantoniou S, Kalos T, et al
    A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01295.
    >> Share

  2258. DRAPER M, Stergiopoulos S
    Shingles vaccination uptake in Massachusetts adults aged 50 years and older.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01223.
    >> Share

  2259. BRUCE YU Y, Taraban MB, Briggs KT
    All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01280.
    >> Share

  2260. VADREVU KM, Raju D, Rani S, Reddy S, et al
    Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV(R)) vaccine up to 7years following primary vaccination of children<2years of age with, or without, a booster vaccination.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)00966.
    >> Share

  2261. CORCORAN KE, Scheitle CP, DiGregorio BD
    Christian nationalism and COVID-19 vaccine hesitancy and uptake.
    Vaccine. 2021 Oct 2. pii: S0264-410X(21)01289.
    >> Share

  2262. SRICHAN P, Thohinung U, Kodyee S, Apidechkul T, et al
    Vaccine serocoverage under the expanded program on immunization among hill tribe children in Thailand: A cross-sectional study.
    Vaccine. 2021 Oct 1. pii: S0264-410X(21)01264.
    >> Share

  2263. RANE MS, Rohani P, Halloran ME
    Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington.
    Vaccine. 2021;39:6144-6150.
    >> Share

  2264. BHAT S, Caldera F, Farraye FA
    Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients.
    Vaccine. 2021;39:6015-6016.
    >> Share

  2265. KNUF M, Haas H, Garcia-Corbeira P, Turriani E, et al
    Hexavalent vaccines: What can we learn from head-to-head studies?
    Vaccine. 2021;39:6025-6036.
    >> Share

  2266. YOSHIKAWA T
    Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
    Vaccine. 2021;39:6174-6181.
    >> Share

  2267. PARADOWSKA-STANKIEWICZ I, Rumik A, Bogusz J, Zbrzezniak J, et al
    Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents.
    Vaccine. 2021;39:6067-6073.
    >> Share

  2268. FUJISAWA S, Murata S, Takehara M, Aoyama J, et al
    In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickens.
    Vaccine. 2021;39:6057-6066.
    >> Share

  2269. KUNITOKI K, Funato M, Mitsunami M, Kinoshita T, et al
    Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence.
    Vaccine. 2021;39:6104-6110.
    >> Share

  2270. SISNOWSKI J, Vujovich-Dunn C, Gidding H, Brotherton J, et al
    Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states.
    Vaccine. 2021;39:6117-6126.
    >> Share

  2271. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021;39:6166-6173.
    >> Share

  2272. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021;39:6157-6165.
    >> Share

  2273. MALTEZOU HC, Effraimidou E, Cassimos DC, Medic S, et al
    Vaccination programs for pregnant women in Europe, 2021.
    Vaccine. 2021;39:6137-6143.
    >> Share

    September 2021
  2274. NIEUWENHUIZEN NE, Zyla J, Zedler U, Bandermann S, et al
    Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females.
    Vaccine. 2021 Sep 30. pii: S0264-410X(21)01230.
    >> Share

  2275. LEWIS G, Lazzaro T, Crawford NW
    Recurrent lipoatrophy following multiple vaccinations: A case study.
    Vaccine. 2021 Sep 30. pii: S0264-410X(21)01237.
    >> Share

  2276. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    >> Share

  2277. FRANCIS-OLIVIERO F, Bozoki S, Micsik A, Kieny MP, et al
    Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01224.
    >> Share

  2278. YACOUB MR, Cucca V, Asperti C, Ramirez GA, et al
    Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01239.
    >> Share

  2279. ROMANO CJ, Hall C, Khodr ZG, Bukowinski AT, et al
    History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01171.
    >> Share

  2280. HOFMEISTER MG, Weng MK, Thoroughman D, Thomasson ED, et al
    Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016-2019.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01254.
    >> Share

  2281. MOON JE, Greenleaf ME, Regules JA, Debois M, et al
    A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01203.
    >> Share

  2282. CASEY RM, Adrien N, Badiane O, Diallo A, et al
    National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01075.
    >> Share

  2283. SINGH AK, Srikrishna G, Bivalacqua TJ, Bishai WR, et al
    Recombinant BCGs for tuberculosis and bladder cancer.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01231.
    >> Share

  2284. VIEIRA REZENDE RP, Braz AS, Guimaraes MFB, Ribeiro SLE, et al
    Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01260.
    >> Share

  2285. BLEICHER I, Kadour-Peero E, Sagi-Dain L, Sagi S, et al
    Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01234.
    >> Share

  2286. SHEVZOV-ZEBRUN N, Caplan A
    Parental consent for vaccination of minors against COVID-19.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01250.
    >> Share

  2287. FISHER KA, Nguyen N, Crawford S, Fouayzi H, et al
    Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01261.
    >> Share

  2288. MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
    Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
    >> Share

  2289. ZENG W, Cui Y, Jarawan E, Avila C, et al
    Optimizing immunization schedules in endemic cholera regions: cost-effectiveness assessment of vaccination strategies for cholera control in Bangladesh.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01235.
    >> Share

  2290. AKSNES BN, Walldorf JA, Nkwenkeu SF, Zoma RL, et al
    Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01229.
    >> Share

  2291. FADLYANA E, Rusmil K, Tarigan R, Rahmadi AR, et al
    A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01255.
    >> Share

  2292. SINGH AK, Phatak SR, Singh R, Bhattacharjee K, et al
    Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)(R)) and BBV-152 (Covaxin(TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01258.
    >> Share

  2293. FOWLER A, Sampson M, Remaley AT, Chackerian B, et al
    A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice.
    Vaccine. 2021;39:5780-5786.
    >> Share

  2294. NOWAK SA, Gidengil CA, Parker AM, Matthews LJ, et al
    Association among trust in health care providers, friends, and family, and vaccine hesitancy.
    Vaccine. 2021;39:5737-5740.
    >> Share

  2295. MALO JA, Ware RS, Lambert SB
    Estimating the risk of recurrent invasive pneumococcal disease in Australia, 1991-2016.
    Vaccine. 2021;39:5748-5756.
    >> Share

  2296. KARAFILLAKIS E, Peretti-Watel P, Verger P, Chantler T, et al
    The role of maturity in adolescent decision-making around HPV vaccination in France.
    Vaccine. 2021;39:5741-5747.
    >> Share

  2297. LAWRENCE J, Kitchin N, Anderson AS, Pride MW, et al
    Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years.
    Vaccine. 2021;39:5991-6003.
    >> Share

  2298. KOTLER L, Greenberg D, Givon-Lavi N, van der Beek BA, et al
    Decline in pneumococcal nasopharyngeal carriage in children 6-23 months with respiratory illnesses following pneumococcal conjugate vaccine implementation.
    Vaccine. 2021;39:5757-5761.
    >> Share

  2299. AZAM JM, Saitta B, Bonner K, Ferrari MJ, et al
    Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response.
    Vaccine. 2021;39:5845-5853.
    >> Share

  2300. YUN KW, Rhie K, Kang JH, Kim KH, et al
    Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014-2019.
    Vaccine. 2021;39:5787-5793.
    >> Share

  2301. CAMPBELL JD, Pasetti MF, Oot L, Adam Z, et al
    Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach.
    Vaccine. 2021;39:5802-5813.
    >> Share

  2302. BAQUI AH, Koffi AK, McCollum ED, Roy AD, et al
    Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies.
    Vaccine. 2021;39:5794-5801.
    >> Share

  2303. PRELOG M, Almanzar G, Stern R, Robrade K, et al
    Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA).
    Vaccine. 2021;39:5918-5927.
    >> Share

  2304. SILCOCK R, Moghimi A, Perrett K, Crawford N, et al
    Subcutaneous nodule at the vaccine injection site - A case of mistaken identity.
    Vaccine. 2021;39:6013-6014.
    >> Share

  2305. MARCHI S, Remarque EJ, Viviani S, Rizzo C, et al
    Measles immunity over two decades in two large Italian Regions: How far is the elimination goal?
    Vaccine. 2021;39:5928-5933.
    >> Share

  2306. HUANG XX, Bose AS, Gupta BP, Rai P, et al
    Vaccine preventable diseases surveillance in Nepal: How much does it cost?
    Vaccine. 2021;39:5982-5990.
    >> Share

  2307. BEDFORD H, Firman N, Waller J, Marlow L, et al
    Which young women are not being vaccinated against HPV? Cross-sectional analysis of a UK national cohort study.
    Vaccine. 2021;39:5934-5939.
    >> Share

  2308. YAMAZAKI Y, Ikeda M, Imada T, Furuno K, et al
    A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased ris
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01168.
    >> Share

  2309. MOORE KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, et al
    A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future.
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01028.
    >> Share

  2310. CHOWDHURY F, Akter A, Rahman Bhuiyan T, Tauheed I, et al
    A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01222.
    >> Share

  2311. MELGAARD A, Krogsgaard LW, Randrup T, Plana-Ripoll O, et al
    Pre-vaccination vulnerability and suspected adverse events following HPV vaccination. A case-control study nested in the Danish national birth cohort.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01232.
    >> Share

  2312. LIU CH, Huang WT, Chie WC, Arnold Chan K, et al
    Safety surveillance of varicella vaccine using tree-temporal scan analysis.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01226.
    >> Share

  2313. GIESE H, Neth H, Gaissmaier W
    Determinants of information diffusion in online communication on vaccination: The benefits of visual displays.
    Vaccine. 2021 Sep 21. pii: S0264-410X(21)01195.
    >> Share

  2314. ANGSUWATCHARAKON P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, et al
    High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01127.
    >> Share

  2315. MANSUY JM, Sagna AS, Laurent M, Izopet J, et al
    COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination?
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01227.
    >> Share

  2316. ELBASHA EH, Choi Y, Daniels V, Goveia MG, et al
    Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study.
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01147.
    >> Share

  2317. MOSINA L, Kulper-Schiek W, Jacques-Carroll L, Earnshaw A, et al
    Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01225.
    >> Share

  2318. PRESTON KB, Wong TAS, To A, Tashiro TE, et al
    Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.
    Vaccine. 2021;39:5650-5657.
    >> Share

  2319. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021;39:5607-5614.
    >> Share

  2320. DECKER MD, Garman PM, Hughes H, Yacovone MA, et al
    Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members.
    Vaccine. 2021;39:5541-5547.
    >> Share

  2321. KUROKAWA N, Robinson MK, Bernard C, Kawaguchi Y, et al
    Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.
    Vaccine. 2021;39:5513-5523.
    >> Share

  2322. GOLDEN AR, Adam HJ, Baxter M, Martin I, et al
    Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018.
    Vaccine. 2021;39:5474-5483.
    >> Share

  2323. MORAIS E, El Mouaddin N, Schuurman S, De A, et al
    Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data.
    Vaccine. 2021;39:5461-5473.
    >> Share

  2324. MORIKAWA Y, Sakakibara H, Kimiya T, Obonai T, et al
    Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease.
    Vaccine. 2021;39:5680-5687.
    >> Share

  2325. ODUWOLE EO, Mahomed H, Laurenzi CA, Larson HJ, et al
    Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.
    Vaccine. 2021;39:5506-5512.
    >> Share

  2326. YSEBAERT C, Castado C, Mortier MC, Rioux S, et al
    UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen.
    Vaccine. 2021;39:5641-5649.
    >> Share

  2327. NIKOLAY B, Ribeiro Dos Santos G, Lipsitch M, Rahman M, et al
    Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh.
    Vaccine. 2021;39:5600-5606.
    >> Share

  2328. JUNG Y, Min JY, Kim HJ, Min KB, et al
    Disparities in infant mortality from all-infectious, vaccine-preventable, and non-vaccine preventable diseases in relation to parental education.
    Vaccine. 2021;39:5658-5665.
    >> Share

  2329. VENEGAS-VARGAS C, Taylor LP, Foss DL, Godbee TK, et al
    Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d.
    Vaccine. 2021;39:5615-5625.
    >> Share

  2330. ZHANG N, Zheng T, Chen Y, Zhu H, et al
    Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice.
    Vaccine. 2021;39:5699-5705.
    >> Share

  2331. KARAFILLAKIS E, Paterson P, Larson HJ
    'My primary purpose is to protect the unborn child': Understanding pregnant women's perceptions of maternal vaccination and vaccine trials in Europe.
    Vaccine. 2021;39:5673-5679.
    >> Share

  2332. KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
    Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
    Vaccine. 2021;39:5635-5640.
    >> Share

  2333. NACIUTE M, Kiwitt T, Kemp RA, Hook S, et al
    Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration.
    Vaccine. 2021;39:5589-5599.
    >> Share

  2334. JIANG Y, Li X, Yu L, Tong W, et al
    Immune efficacy of a candidate porcine reproductive and respiratory syndrome vaccine rHN-NP49 administered by a Needle-free intradermal delivery system in comparison with intramuscular injection.
    Vaccine. 2021;39:5557-5562.
    >> Share

  2335. HASSAN AS, Perera DJ, Ward BJ, Ndao M, et al
    Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection.
    Vaccine. 2021;39:5580-5588.
    >> Share

  2336. RODRIGUES DE OLIVEIRA N, Jorge S, Andrade Colares Maia M, Thurow Bunde T, et al
    Protective efficacy of whole-cell inactivated Leptospira vaccines made using virulent or avirulent strains in a hamster model.
    Vaccine. 2021;39:5626-5634.
    >> Share

  2337. KIM DY, Kang YM, Cho HK, Park SJ, et al
    Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01149.
    >> Share

  2338. SULIMAN DM, Nawaz FA, Mohanan P, Modber MAKA, et al
    UAE efforts in promoting COVID-19 vaccination and building vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01194.
    >> Share

  2339. SCHLEISS MR, John CC, Permar SR
    Children are the key to the Endgame: A case for routine pediatric COVID vaccination.
    Vaccine. 2021;39:5333-5336.
    >> Share

  2340. WEBSTER H, Valencia S, Kumar A, Chan C, et al
    Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Vaccine. 2021;39:5358-5367.
    >> Share

  2341. IWAMOTO M, Hickman CJ, Colley H, Arciuolo RJ, et al
    Measles infection in persons with secondary vaccine failure, New York City, 2018-19.
    Vaccine. 2021;39:5346-5350.
    >> Share

  2342. STAPLES JN, Nelamangala SL, Morris S, Wells K, et al
    Exploring socio-demographic and geospatial variation in human papillomavirus vaccination uptake in Virginia.
    Vaccine. 2021;39:5385-5390.
    >> Share

  2343. GOUD R, Thompson D, Welsh K, Lu M, et al
    ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare.
    Vaccine. 2021;39:5368-5375.
    >> Share

  2344. KRISTINSDOTTIR I, Haraldsson A, Love A, Asgeirsdottir TL, et al
    Burden of rotavirus disease in young children in Iceland - Time to vaccinate?
    Vaccine. 2021;39:5422-5427.
    >> Share

  2345. BRITTON KJ, Pickering JL, Pomat WS, de Gier C, et al
    Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants.
    Vaccine. 2021;39:5401-5409.
    >> Share

  2346. BORGHI L, Riva E
    Was Aldo Castellani the inventor of combined and polyvalent vaccines?
    Vaccine. 2021;39:5442-5446.
    >> Share

  2347. ELDRIDGE JH, Egan MA, Matassov D, Hamm S, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
    Vaccine. 2021;39:5436-5441.
    >> Share

  2348. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    >> Share

    August 2021
  2349. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    >> Share

  2350. YLADE M, Agrupis KA, Daag JV, Crisostomo MV, et al
    Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: A case-control study.
    Vaccine. 2021;39:5318-5325.
    >> Share

  2351. MILLER CN, Kemp TJ, Abrahamsen M, Isaacs-Soriano K, et al
    Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine.
    Vaccine. 2021;39:5295-5301.
    >> Share

  2352. WILSON R
    HPV vaccine acceptance in West Africa: A systematic literature review.
    Vaccine. 2021;39:5277-5284.
    >> Share

  2353. CHHATWAL J, Sapru A, Sundaram B, Shenoy B, et al
    A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India.
    Vaccine. 2021;39:5313-5317.
    >> Share

  2354. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    >> Share

  2355. GORANDER S, Honda-Okubo Y, Backstrom M, Baldwin J, et al
    A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection.
    Vaccine. 2021 Aug 26. pii: S0264-410X(21)01098.
    >> Share

  2356. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    >> Share

  2357. LAMM DL, Morales A
    A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01046.
    >> Share

  2358. WANG R, Chen K, Wang Y, Liu C, et al
    Booster immunization improves the generation of T follicular helper (Tfh) cells specific to hepatitis B surface antigen (HBsAg) after prenatal HBsAg exposure.
    Vaccine. 2021 Aug 16. pii: S0264-410X(21)01040.
    >> Share

  2359. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016